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Summary and Conclusions 
 
Usage of antibiotics 
The use of veterinary medicines may lead to risks concerning human health, environment, food safety, 
animal health and animal welfare. For example the use of antibiotics leads to the development of 
resistance in bacteria. The policy of the Dutch government, c.q. the Ministry of Agriculture, Nature 
and Food Quality, is aimed at a reduction of antibiotic resistance levels in bacteria, for instance by 
implementing policies to achieve a reduction of the use of antibiotics by farmers. A clear insight in the 
use of veterinary medicines is needed to be able to deal with this matter properly. 
 The Ministry of Agriculture, Nature and Food Quality (LNV) requested LEI to study the use 
of antibiotics on Dutch livestock farms in 2007. The objective of this study was to determine the use 
of antibiotics in 2007 and compare the use with that in previous years. In addition, the study searched 
for reasons for the extent to which farms make use of antibiotics. 
 The analyses in this report are based on the information collected in LEI’s Farm Accountancy 
Data Network, as well as data from FIDIN and antibiotic use figures from other countries.  
 The analysis of the FIDIN figures reveals that the therapeutic veterinary antibiotic use 
(including antimicrobial growth promoters) has increased in the period 1999-2007 by 83% and the 
growth promoters have been banned, first partly and as from 2006 entirely. The use increased by 8.9% 
in 2007 as compared to 2006. The therapeutic antibiotic use per kg live weight in 2007 was twice as 
high as in 1999. A part of this increase may be accounted for by a substitution of growth promoters.  
In comparison with other countries for which veterinary antibiotic consumption figures are available, 
the antibiotic use per average food-producing animal is greatest in the Netherlands. However, it is not 
yet clear whether this is applicable to all or a number of sectors. Antibiotic use is increasing in the 
Netherlands, Denmark and Germany, while the use is stable in the other five countries examined 
during this study. 
Figure 1 shows the antibiotic use at a sample of 159 farms in 2007. The four vertical lines in the figure 
indicate the confidence interval, i.e. on the basis of this sample the average antibiotic use in the 
Netherlands can be stated to lie within the upper and lower limits with 95% confidence. 
Figure 2 shows the changes in the use at all farm categories in the sentinel farms during the years 
2004-2007. The antibiotic use for fattening pigs and, in particular, broilers, exhibits an evident 
increase. The increase for fattening pigs is statistically significant and numbers 3.5 daily dosages per 
animal year and will lie within an increase of 2.0 to 11.5 daily dosages per animal year with 95% 
confidence. Also the increase for broilers is statistically significant and numbers 13.8 daily dosages 
per animal year and will lie within an increase of 4.1 to 27.0 daily dosages per animal year with 95% 
confidence1.  
 
                                                     
1 The confidence limits for the increase 2004-2007 were calculated based on unweighted data. 
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Figure S1 Average number of daily dosages per animal year in 2007, with the corresponding 95% 
confidence intervals. 
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Figure S2 Trend in antibiotic usage from 2004 to 2007, expressed as daily dosages per animal year 
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 Antibiotic use has remained virtually unchanged at the dairy cattle farms. The proportion of 
antibiotics administered via the udder (intramammary) fell from 3.5 daily dosages per animal year 
(dd/ay) in 2006 to 2.9 dd/ay in 2007, whereby the use of cloxacillin decreased and the use of 
amoxicillin-clavulanic acid increased. 
 At the fattening pig farms the total use of antibiotics has increased. The use of tetracyclines 
decreased (–1.3 dd/ay) whilst the use of other antibiotics increased (in particular, colistin sulphate, +3 
dd/ay) and macrolides (+1 dd/ay).  
The antibiotic use at the farms with sows/piglets in 2007 was comparable to that in 2006, both in terms 
of the total use and the use of the various groups of antibiotics. A further analysis of sow farms 
revealed that: a) in general, antibiotic use is higher at farms with more sows; b) farms that occasionally 
make preventive use of antibiotics have the lowest average antibiotic use, whilst farms that routinely 
give preventive treatments have the highest average use and the use at farms that never give preventive 
treatments lies in between the two; c) the sow holders’ assessment of the health of their animals is 
related to their use of antibiotics: antibiotic use was lower at farms where the holders were of the 
opinion that their animals were in good health. 
 The total antibiotic use increased at broiler farms, largely due to the increased use of 
penicillins (+3.9 dd/ay; amoxicillin and phenoxymethylpenicillin). Fluoroquinolones and 
aminoglycosides are primarily used in the broiler sector, although the use of fluoroquinolones has 
decreased (-1.8 dd/ay). Antibiotic use varies greatly between farms: the 25% of the farms that use 
most antibiotics account for 49% of the total antibiotic use.  
 Farms in all sectors that have used a large amount of antibiotics in a given year in many cases 
also used large amounts of antibiotics in the previous year. Consequently, antibiotic use at many farms 
is relatively stable. 
 
Trends in resistance 
In 2006/2007 S. Typhimurium and S. Enteritidis were the most prevalent serovars in humans, 
third was the antigenic variant S. enterica subspecies enterica 1,4,5,12:i:-, a monophasic variant of S. 
Typhimurium which is emerging internationally since 2004. Pigs and cattle were the most important 
animal sources of S. Typhimurium. Layers (eggs) and foreign travel were the most important sources 
for S. Enteritidis. In broilers S. Java was isolated most frequently. In broilers S. Enteritidis and S. 
Typhimurium constituted only a small fraction of all salmonella’s. 
In 2006/2007, 81 cefotaxime resistant, ESBL suspected strains were found, which was substantially 
more than in 2004/2005 (n = 21). These isolates belonged predominantly to the serovar S. Java (63%), 
of which only 1 strain was isolated from a human source, the others all from poultry sources. 
Resistance to cefotaxime is increasing at an alarming rate. The isolates from humans originate partly 
from exotic sources, but also from poultry. In animals poultry is up to now the only reservoir for 
ESBL-producing salmonella’s.  
In C. jejuni resistance levels for ciprofloxacin and nalidixic acid were substantially higher than 
in previous years, in particular in broilers. At the same time in human isolates a substantial increase in 
resistance to fluoroquinolones was observed as well. In 2007 for the first time an erythromycin 
resistant C. jejuni strain was isolated from a cow. Erythromycin resistance is however a regular 
finding in humans to some extent travel related, or related to consumption of contaminated imported 
products, or due to human therapeutic use of macrolides. In C. coli resistance to macrolides occurred 
frequently. In 2006/2007 for the first time next to erythromycin, the related antibiotics clarithromycin 
and tulathromycin were included in the tests. The resistance levels were slightly different from 
erythromycin, which is probably due to the cut-off values used.  
Resistance in E. coli O157 was traditionally rarely present. In human isolates resistance levels 
were low. In isolates from calves however, resistance was quite commonly present, with levels 
varying from 0.7 – 20.7 %. In calves one ESBL suspected isolate was detected.  
Overall, the resistance levels of food-borne commensal E. coli were highest in broilers and 
poultry raw meat products, followed by veal calves, slaughter pigs and dairy cattle, in which resistance 
is rare. In broilers and slaughter pigs, for most antibiotics the resistance levels show a tendency to 
increase. This increase is also obvious for multi-drug resistance. In broilers and poultry raw meat 
products resistance to cefotaxime indicative of extended spectrum beta-lactamases (ESBLs), has 
increased from 9.7% in 2004 to almost 17% in 2006/2007. 
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For the enterococci as indicator organisms, highest resistance levels were observed for 
tetracycline and erythromycin in both bacterial species. In broiler chickens the resistance levels show a 
tendency to decrease, while in the other animals the levels seem to be stable. Resistance to 
vancomycin remains present but is rare. Multi drug resistance is very common in veal calves, pigs and 
broilers, but not in dairy cows  
In bovine respiratory disease pathogens the resistance levels were higher in Mannheimia 
haemolytica. Tetracycline resistance occurred most frequently in both species, although substantially 
more frequently in M. haemolytica, in which species also resistance to amoxicilline, flumequine and 
chloramphenicol occurred frequently. Resistance to aminoglycosides was present in single isolates in 
Pasteurella multocida only. Single isolates resistant to tilmicosin and florfenicol were detected. For 
florfenicol this was the first time a resistant PMU is reported in The Netherlands. 
The resistance levels for E. coli strains isolated from milk samples from cows suffering from 
mastitis were low except for ampicillin. In 2006/2007 the first ESBL-producing E. coli’s were isolated 
from mastitis. The coliform bacteria showed a high level of resistance to ampicillin and to the 
combination with clavulanic acid. All isolates were susceptible to cefoperazone and cefquinome.  
The S. aureus isolates tested were susceptible to most antibiotics. 9.2% were penicillin resistant. In 
2006/2007 one S. aureus was identified to be MRSA. The strain belonged to the animal associated 
clonal complex 398. The coagulase negative staphylococci were more resistant than S. aureus. 56% 
were resistant to penicillin and 1.5% to oxacillin (mecA-positive).  
 
Conclusions  
It can be concluded that therapeutic usage of antibiotics in food animals in The Netherlands has almost 
doubled in the past decade. Likely determinants for the increase are the ban of the growth promoters 
and the up scaling of farm sizes. The quality of animal feed is under stress because of high prices on 
the global market and the ban of animal protein in feed, which may affect the digestibility in the GI-
tract which is compensated by oral antibiotics. The continuous increase in antibiotic usage is striking 
because currently there is an intense debate about the negative effects and public health risks of 
antibiotic usage in intensive animal husbandry. The resistance levels in animal bacteria show a 
simultaneous tendency to increase, both for individual drugs and multi-drug resistance.  
 
Next to the frequent occurrence of MRSA in Dutch food-animals, of particular concern is the rapid 
increase in the occurrence in ESBL-producing organisms in predominantly poultry and poultry meat 
products. This increase is both observed to occur frequently in the commensal GI-tract flora of broiler 
chickens, in Salmonella serovars from broilers and to a lesser extend in Salmonella from humans.  
Compared to the animal derived MRSA the risks of acquiring ESBLs by humans are different. MRSA 
is mainly transmitted by direct contact, while for the ESBLs food borne transmission is likely to 
contribute to the dissemination, since the genes are located on mobile genetic element and therefore 
transferable within and between bacterial species. 
 
As a result of the concerns for public health related to antibiotic usage in intensive animal husbandry, 
the animal production sectors have signed a convenant in 2008 with the purpose to minimize 
resistance by responsible use of antibiotics. Each sector has developed a detailed plan to implement 
this. The major aspects of the plans are: 
- To define the responsibilities for prescribing, selling and administration of antibiotics 
- To increase the transparency by: 
? implementing a control system on these agreements 
? monitoring of antibiotic usage at different levels 
- To implement research and communication strategies for responsible antibiotic usage 
 
These are important developments; however, these plans will only be effective for prevention of 
current and future resistance development if the result will be a substantial reduction in the exposure 
of animals to antibiotics. 
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Samenvatting en Conclusies 
 
Gebruik van antibiotica 
Het LEI heeft in opdracht van het ministerie van LNV onderzoek gedaan naar het gebruik van 
antibiotica in de Nederlandse veehouderij in 2007. Het doel van dit onderzoek is het bepalen van het 
antibioticagebruik in 2007 en de vergelijking met voorgaande jaren. Daarnaast is gezocht naar 
oorzaken van de mate waarin antibiotica werd gebruikt op de bedrijven. 
 Voor de analyses in dit rapport is gebruik gemaakt van informatie verzameld binnen het 
Bedrijven Informatienet van het LEI. Daarnaast is gebruik gemaakt van gegevens van FIDIN en van 
antibiotica gebruikscijfers van andere landen.  
 Uit de analyse van de FIDIN cijfers blijkt dat het totale therapeutisch veterinaire 
antibioticagebruik in Nederland sinds 1999 met 83% is toegenomen, dat is een toename van 
gemiddeld 7,9% per jaar. In 2007 blijkt het gebruik ten opzichte van 2006 met 8,9% te zijn 
toegenomen. Het therapeutisch antibioticagebruik per kg levend gewicht is ten opzichte van 1999 
verdubbeld. 
Nederland past vergeleken met de andere landen waarvan verbruikscijfers bekend zijn, veterinair per 
gemiddeld aanwezig dier het meeste antibiotica toe. Echter, voor specifieke diersectoren kan deze 
vergelijking anders liggen. Tevens stijgt het antibioticagebruik van Nederland momenteel elk jaar, 
terwijl van de andere vergeleken landen alleen Denemarken en Duitsland een stijging laten zien en de 
overige vijf landen een stabiel gebruik hebben. 
Figuur S1 (zie blz. .7) laat het antibioticagebruik in dagdoseringen van 2007 zien met het bijbehorende 
95% betrouwbaarheidsinterval, op de 159 steekproefbedrijven. 
  Figuur S2 (zie blz. 7) laat het verloop zien van alle bedrijven uit de steekproef van 
2004 tot en met 2007. Alleen de vleesvarkens en vooral de vleeskuikens laten een duidelijk stijgende 
lijn zien. De toename voor vleesvarkens in deze periode is statistisch significant en bedraagt 3,5 
dagdoseringen per dierjaar en zal met 95% zekerheid liggen tussen een toename van 2,0 tot 11,5 
dagdoseringen per dierjaar. Ook de toename voor vleeskuikens is statistisch significant, bedraagt 13,8 
dagdoseringen per dierjaar en zal met 95% zekerheid liggen tussen een toename van 4,1 en 27,0 
dagdoseringen per dierjaar. Per achtereenvolgend jaar bekeken zijn de stijgingen niet significant. 
 Het percentage antibiotica dat bij melkvee intramammair wordt toegediend is afgenomen van 
64% in 2006 naar 53% in 2007. Binnen de intramammair toegediende antibiotica is een afname te zien 
in het gebruik van cloxacilline en een toename in het gebruik van amoxicilline-clavulaanzuur. 
 Opvallend bij het antibioticagebruik op vleesvarkensbedrijven is de afname van het gebruik 
van tetracyclines (-1,3) en de toename van het gebruik van overige antibiotica (colistinesulfaat) (+3) 
en macroliden (+1).  
Het antibioticagebruik bij zeugen /biggen laat over 2007 eenzelfde beeld zien als over 2006, zowel in 
totaal gebruik, als het gebruik verdeeld over de verschillende antibioticagroepen. Uit de nadere analyse 
op zeugenbedrijven is gebleken dat: a) op zeugenbedrijven een sterk verband is tussen bedrijfsomvang 
en antibioticagebruik, hoe groter het bedrijf, des te meer antibiotica-gebruik,  waarbij het gemiddelde 
antibioticagebruik per bedrijf het laagst is bij bedrijven die soms preventief antibiotica gebruiken en 
het hoogst bij bedrijven die altijd preventief antibiotica gebruiken; b) er een significant verschil bestaat 
tussen het gemiddelde antibioticagebruik van de groepen van bedrijven die altijd, soms of nooit 
preventief antibiotica gebruiken; c) de inschatting van zeugenhouders over de gezondheidstoestand 
van hun dieren een voorspeller kan zijn voor de mate van het antibioticagebruik; d) een betere 
schatting wordt verkregen van het werkelijk antibioticagebruik als per middel het gebruik kan worden 
toegewezen aan het juiste varken (zeugen of biggen). 
 In de steekproef is de vleeskuikensector de enige sector die quinolonen en aminoglycosiden 
gebruikt. Het totale antibioticagebruik in deze sector is toegenomen. De toename is vooral terug te 
vinden bij het gebruik van penicillines (+3,9). Het gebruik van quinolonen is afgenomen (-1,8). Er zijn 
grote verschillen in antibioticagebruik tussen bedrijven. 25% van de bedrijven, is verantwoordelijk 
voor 49% van het antibioticagebruik.  
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In alle sectoren geldt dat bedrijven die in een jaar veel antibiotica hebben gebruikt, dat vaak in het 
voorgaande jaar ook al deden. Veel bedrijven zijn dus vrij stabiel in de mate waarin ze antibiotica 
toepassen. 
 
Trends in resistentie 
In 2006/2007 S. Typhimurium and S. Enteritidis waren de meest prevalente serotypen in 
humane infecties en op de derde plaats kwam de antigene variant S. enterica subspecies enterica 
1,4,5,12:i:-, een monofasische variant van S. Typhimurium die in toenemende mate voorkomt sinds 
2004. Varkens en rundvee waren de belangrijkste dierlijke bronnen van S. Typhimurium. Legkippen 
(eieren) en reizen naar het buitenland waren de belangrijkste bronnen voor S. Enteritidis. In 
vleeskuikens kwam S. Java het meest voor en vormen S. Enteritidis en S. Typhimurium slechts een 
kleine fractie van alle salmonella’s. 
In 2006/2007 werden 81 cefotaxim resistente, ESBL verdachte salmonella’s gevonden, wat een 
beduidende toename is ten opzichte van 2004/2005 (n = 21). Deze isolaten behoorden vooral tot het 
serotype S. Java (63%), van welke slechts 1 stam afkomstig was van een humane bron. De overige 
werden allen in pluimvee geïsoleerd. Resistentie tegen cefotaxim neemt alarmerend toe. De isolaten 
uit mensen stamden deels van exotische bronnen door reizen naar het verre Oosten of Afrika, maar 
deels ook van pluimvee. In dieren is tot nu toe pluimvee het enige reservoir voor ESBL-producerende 
salmonella’s.  
In C. jejuni waren de resistentie niveaus voor ciprofloxacin en nalidixinezuur beduidend hoger 
dan in voorgaande jaren, en vooral in vleeskuikens. Tegelijkertijd werd ook in humane isolaten een 
beduidende toename in resistentie tegen fluoroquinolonen gezien. In 2007 werd voor de eerste keer 
een erythromycine resistente C. jejuni geïsoleerd uit een rund. Erythromycine resistentie is echter een 
regelmatige bevinding in mensen, wat deels wordt veroorzaakt door reizen, door consumptie van 
gecontamineerde geïmporteerde producten, of als gevolg van humane therapeutisch gebruik van 
macroliden. In C. coli kwam resistentie tegen de macroliden vaak voor. In 2006/2007 werden voor de 
eerste keer naast erythromycine, de verwante antibiotica clarithromycine en tulathromycine meegetest. 
The resistentieniveaus verschillen licht van erythromycine, wat waarschijnlijk komt door de gebruikte 
afkapwaarden.  
In E. coli O157 komt resistentie slechts zelden voor. In humane isolaten waren de 
resistentieniveaus laag. Echter, in kalverisolaten kwam resistentie relatief vaak voor, met waarden 
variërend van 0.7 – 20.7 %. In kalveren werd ook één ESBL-verdacht isolaat gevonden.  
Over het geheel genomen waren de resistentieniveaus van commensale E. coli als 
indicatororganisme het hoogst in vleeskuikens en rauw vlees van pluimvee, gevolgd door 
vleeskalveren, vleesvarkens en melkvee. In vleeskuikens en vleesvarkens, vertonen de 
resistentieniveaus toenemende tendensen voor de meeste antibiotica. Dit gebeurt ook voor 
multiresistentie. In vleeskuikens (en pluimveevlees) is het voorkomen van resistentie tegen cefotaxim, 
wat indicatief is voor de aanwezigheid van extended spectrum beta-lactamasen (ESBL’s), toegenomen 
van 9.7% in 2004 tot bijna 17% in 2006/2007. 
Voor de enterokokken als indicatororganismen, werden de hoogste resistentieniveaus gezien 
voor tetracycline en erythromycine. In vleeskuikens vertonen de resistentieniveaus een toenemende 
trend terwijl ze in de andere diersoorten stabiel lijken. Resistentie tegen vancomycine komt nog steeds 
incidenteel voor. Multiresistentie komt algemeen voor in vleeskalveren, vleesvarkens en vleeskuikens, 
maar niet n melkkoeien.  
In bovine luchtwegpathogenen waren de resistentieniveaus hoger in Mannheimia haemolytica 
dan in Pasteurella multocida. Tetracycline resistentie kwam het vaakst voor in beide species, maar 
beduidend vaker in M. haemolytica, in welke species ook resistentie tegen amoxicilline, flumequine 
and chloramphenicol vaak voorkwam. Resistentie tegen aminoglycosiden kwam alleen voor in enkele 
P. multocida isolaten. Enkele isolaten die resistent waren tegen tilmicosin en florfenicol werden 
gedetecteerd. Voor florfenicol was dit de eerste keer dat er een resistente P. multocida is gerapporteerd 
in Nederland. 
De resistentieniveaus van E. coli isolaten uit melkmonsters van mastitiskoeien waren laag met 
uitzondering van ampicillin. In 2006/2007 werd ook uit een mastitismonster de eerste ESBL-
producerende E. coli’s geïsoleerd.  
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De coliforme bacteriën uit mastitismelk vertoonden hoge resistentieniveaus voor ampicilline en de 
combinatie met clavulaanzuur. Alle isolaten waren gevoelig voor cefoperazone en cefquinome.  
De S. aureus isolaten uit mastitismelk waren gevoelig voor de meeste antibiotica. 9.2% was penicilline 
resistent. In 2006/2007werd één S. aureus uit mastitismelk geïdentificeerd als MRSA. De stam 
behoorde tot het diergeassocieerde clonal complex 398, wat ook bij varkens en kalveren veel 
voorkomt. De coagulase negatieve stafylokokken waren resistenter dan S. aureus. 56% was resistent 
tegen penicilline en 1.5% tegen oxacilline (mecA-positief).  
 
Conclusies  
Er kan worden geconcludeerd dat het therapeutisch antibioticumgebruik in voedselproducerende 
dieren in Nederland in het afgelopen decennium bijna verdubbeld is. Waarschijnlijke determinanten 
voor deze toename zijn het verbod van de groeibevorderaars en de schaalvergroting van de bedrijven. 
De kwaliteit van het diervoeder staat bovendien onder druk door hoge prijzen van grondstoffen op de 
wereldmarkt en het verbod van dierlijk eiwit in diervoeders. Dit kan de verteerbaarheid van het 
voedsel in de darm negatief beïnvloeden, wat gecompenseerd wordt door gebruik van antibiotica. De 
continue toename van gebruik is des te opvallender omdat er momenteel een intensief debat 
plaatsvindt over de negatieve effecten en volksgezondheidsrisico’s van het gebruik inde dierlijke 
productie. De resistentieniveaus nemen tegelijkertijd toe, zowel voor individuele antibiotica als 
multiresistentie. 
  
Naast het veelvuldig voorkomen van MRSA in Nederlandse voedselproducerende dieren, is vooral de 
snelle toename van ESBL-producerende organismen, vooral in pluimvee en pluimveevlees een reden 
voor zorg. Deze toename wordt zowel gezien bij de commensale flora van het darmkanaal van 
vleeskuikens, in Salmonella uit vleeskuikens en worden in mindere mate ook in Salmonella uit de 
mens geïsoleerd. In vergelijking met de diergerelateerde MRSA is er een verschil in het risico van het 
verkrijgen van ESBLs. MRSA wordt voornamelijk overgedragen naar de mens via direct contact, 
terwijl voor de ESBLs de voedselketen waarschijnlijk een rol speelt in de verspreiding omdat de genen 
op mobiele genetische elementen liggen die overdraagbaar zijn binnen en tussen bacteriespecies.  
 
Als gevolg van de aan het antibioticumgebruik in de intensieve veehouderij gebonden risico’s voor de 
volksgezondheid hebben de dierhouderij sectoren in 2008 een convenant getekend met als doel het 
verminderen van resistentie door een verantwoord gebruik van antibiotica. Iedere sector heeft hiervoor 
een plan ontwikkeld, waarvan de hoofdpunten bestaan uit: 
- Het afspreken van de verantwoordelijkheden voor het voorschrijven, leveren en toedienen van 
antibiotica tussen dierenarts, veehouder en dierlijke productie industrie. 
- Dit moet een transparant proces worden door: 
? het invoeren van een controlesysteem op deze afspraken 
? monitoren van antibioticumgebruik op verschillende niveaus 
- Het ontwikkelen van een onderzoeks-, en communicatiestrategie voor verantwoord gebruik 
 
Dit zijn belangrijke ontwikkelingen, echter deze plannen zullen alleen effectief zijn in het voorkómen 
van huidige en toekomstige resistentieontwikkeling in de veehouderij indien ze leiden tot een 
substantiële reductie van de blootstelling van dieren aan antibiotica.  
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I  Usage of antibiotics in animal husbandry in the  Netherlands 
 
1. Introduction 
 
Problem definition 
The extent to which antibiotics are used for veterinary purposes on food producing animals can 
contribute to public and animal health risks. It is an important determinant for the development of 
antibiotic resistance within the treated animal populations. This is also recognised by the European 
commission: the member states are required to monitor antimicrobial resistance in relation to public 
health. Within this context, the monitoring of antibiotic use is also important. This report contains 
information about the monitoring results in the Netherlands. 
 
Recent developments 
Various developments in the Netherlands may have had an impact on the veterinary use of antibiotics 
during the last decade. An increase in antibiotic use could be caused by the prohibition of the use of 
growth promoters as from 1 January 2006. In addition, a new Animal Medicines Act implemented on 
the basis of Directive 2004/28/EC lays down a new structure for channeling animal medicines. 
Putative causes for the increased antibiotic use are the lower feed quality in the Netherlands (in 
comparison to other countries) due to the prohibition on animal protein in feed, and the increases in 
scale in the livestock farming sector. New active antimicrobial ingredients have also been introduced 
for use in food producing animals. 
 Developments that should result in lower antibiotic use and an awareness of the need to limit 
the use of antibiotics, include the discovery of human patients infected with MRSA originating from 
livestock, the increasing concerns about the high and increasing use of antibiotics both inside and 
outside the agricultural sector and the response of the sector and the authorities to those concerns in 
the form of convenants designed to reduce antibiotic use. 
 
Monitoring by FIDIN 
In the Netherlands, FIDIN - the veterinary pharmaceutical industry - provides continuous reporting of 
antibiotic use (FIDIN, 2008). These reports are produced on a voluntary basis. The figures stated in 
the reports give an impression of the total number of kilograms of antibiotics (active ingredients) used 
in the Netherlands at the level of pharmacotherapeutic groups (the groups of active ingredients, such 
as tetracyclines and quinolones). The figures do not provide an insight into the use per type of animal, 
but for all types of animal. 
 
Necessity of constant and detailed monitoring 
The MARAN reports (Mevius et al., 2006) published over a number of years reveal that although the 
total number of animals produced in the Netherlands is decreasing, the therapeutic use of antibiotics is 
increasing. It was decided to monitor antibiotic use in the various sectors continuously and in great 
detail to obtain an improved insight into the underlying factors that could explain this increase. This is 
achieved by the detailed monitoring of a stratified sample of Dutch farms. This study reviewed farms 
that supply data to LEI´s FADN (Farm Accountancy Data Network). In recent years, this Farm 
Accountancy Data Network has proven very useful in recording and reporting data about antibiotic use 
(and other animal medication). 
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Objective and result 
The objective of this study is to obtain an insight into the use and trends in antibiotic use in livestock 
farming. To this end, the number and types of antibiotics used on pigs, broilers and dairy cattle each 
year is determined at a group of sample farms in the Netherlands. These annual reports provide a good 
insight into trends in antibiotic use per type of livestock farming. In 2010, the types of animals that are 
monitored will be expanded to include data about veal farms. 
 This study provides information about antibiotic use in the different types of animals in Dutch 
livestock farming, the various active ingredients, and the amounts that are used. Further research into 
the risk factors influencing antibiotic use is promoted improving the insights into antibiotic use. This 
study examined the relationship between antibiotic use at individual farms and a number of technical 
and economic key figures. Our report also includes a further analysis of a number of segments, and an 
analysis of FIDIN’s overall-use figures. 
 The VANTURES Working Party will combine the results from this study with data about 
resistance per pathogen per type of animal and publish the information in the MARAN reports. This is 
in accordance with the mandate the Working Party received from the national coordinative Antibiotic 
Resistance Platform. 
 
Effect 
The collected figures give an insight into the Dutch livestock-farming sector’s use of antibiotics. The 
Ministry of Agriculture, Nature and Food Quality will use the results from the study to provide the 
European Commission information about antibiotic use at the type of animal level. In addition, the 
usage data can play an important role in explaining trends in resistance that have become apparent. 
Trends in antibiotic use can also be used to measure the effect of policy. Moreover, the government’s 
policy can take account of the underlying risk factors that have resulted in the use of antibiotics.  
 
 
2. Materials and methods 
 
The analyses in this report are based on the information collected in LEI’s Farm Accountancy Data 
Network, as well as data from FIDIN and antibiotic use figures from other countries.  
 
2.1 FIDIN antibiotic use figures and country comparisons 
 
The FIDIN reports state the total number of kilograms of antibiotics (active ingredient) used in the 
Netherlands at the level of pharmacotherapeutic groups. The figures give insight into the use for all 
types of animals, but not for the individual animal species. 
 This LEI study relates the total antibiotic use published by FIDIN to the number of animals in 
the Dutch livestock farming sector (pigs, broilers, veal calves, cattle, and sheep). In total, the numbers 
of these animals result in an estimated number of kilograms of animal in a country. The national 
antibiotic use is then divided between the numbers of animal kilograms. This yields information about 
trends in the antibiotic use per kilogram of live animal weight over the years, and corrects for yearly 
fluctuations in the number of animals produced. 
 The country comparisons are based on Eurostat figures on animal numbers for different 
European countries2. The other data were obtained from Utrecht University’s Faculty of Animal 
Health (Van Geijlswijk et al., 2009). The analysis for the Netherlands based on the method used for 
the calculations using the data for 2006 is enclosed in Annex 4.  
 
                                                     
2 The Dutch data used last year (2006) were obtained from LEI /Statistics Netherlands (CBS), agricultural and 
horticultural figures. Consequently, the absolute figures from previous reports can no longer be  
compared directly with the figures in this report. These have been included in the calculation to provide for a 
realistic comparison with countries with a large number of sheep. 
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2.2 Farms in the Farm Accountancy Data Network 
 
The results in this study are based on data from a number of farms in LEI’s Farm Accountancy Data 
Network. The Data Network contains a representative sample of around 1,500 agricultural and 
horticultural farms in the Netherlands (Vrolijk and Van der Veen, 2008). Records are made of the 
economic data and technical key figures of these farms. Every year a number of farms are replaced by 
other farms to ensure that the database of the Data Network remains representative for Dutch livestock 
farming. Extremely detailed records have been kept of the animal-medicine data at some of the farms 
since 1999. Records are kept of each individual animal medication and every veterinary service.  
 This report reviews the use in 2007, and is based on 159 farms in the Farm Accountancy Data 
Network, of which 36 were dairy farms, 52 fattening pig farms, 42 sow farms, and 29 broiler farms. 
Separate records are kept of the usage figures for sows and fattening pigs at closed pig farms. Annex 3 
lists the precise figures for the farms and animals in the sample over the course of the years. 
 This study made use of data about technical and economic key figures and antibiotic use at the 
farms contained in the Farm Accountancy Data Network, supplemented with data from a brief 
questionnaire with questions on accommodation, feed and health (Annex 5). Since not all additional 
data was available for all farms, a number of analyses have been carried out on a smaller group of 
farms. When this is the case, the analysis is accompanied by a statement of the number of farms 
involved. 
 In some instances, the results are applicable to all farms in the sample for 2007, and reference is 
then made to the total group (159 farms). Reliable statements about an increase or decrease in use can 
be made only when the monitoring of the antibiotic use is based on the same farms that took part in 
both 2006 and 2007. Reference is then made to the comparison group (123 farms). The comparison 
group is used for comparisons of the antibiotic use in 2006 and 2007. Table 2.1 specifies the total 
group for 2007. 
 
Table 2.1 Characteristics of the 159 farms in the sample for 2007 (total group) 
 
2007 Number of farms 
Average number 
of 
animals on each 
farm 
Number of 
animals on 
smallest farm 
Number of 
animals on 
largest farm 
Dairy cattle 36 84 22 241 
Pigs 
-fattening pigs 
-sows(/piglets) 
 
52 
42 
 
2,477 
473 
 
177 
98 
 
7,182 
1,155 
Broilers 29 67,000 11,000 244,000 
 
 
2.3 Antibiotic use: use in grams and daily dosages per animal year 
 
The antibiotic use was analysed using two methods: 1) an analysis of the quantities of active 
ingredients in grams; and 2) an analysis of the number of daily dosages per animal year. 
 In addition to the use figures in daily dosages, this report also includes figures for the use in 
grams since this information can be used for comparisons with other studies, where relevant. 
However, a comparison on the basis of daily dosages is a much better method, because it more 
accurately predicts the exposure of animals of different weights to antibiotics. 
 
Quantity of active ingredient in grams 
This is based on the quantities of active ingredients in the antibiotics used on the farms. The total 
amounts of active ingredients were determined for each farm, and were expressed in terms of grams of 
active ingredient per average animal present per year (per animal year). Expressing the use per animal 
year provides for comparisons of farms with different vacancy periods. All the grams are then totalled. 
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This is often the sole method available for reporting information about use, since no better data is 
available. The FIDIN reports are one example. (FIDIN, 2008) 
 
Daily dosages 
Antibiotics vary in their potency and pharmacokinetic properties3, and this is manifested in the form of 
the varying dosages per kilogram of body weight. The unit daily dosage is suitable for calculating the 
total exposure to different antibiotics and, for example, making comparisons per group. Adopting this 
approach offers an opportunity to obtain an improved insight into the relationship with the existence of 
or trends in the development of resistance. Moreover, this unit conforms to international developments 
in this field and developments in the human sector. The broader implementation of records of this 
nature will also improve the feasibility of comparing the resultant data, for example antibiotic use in 
different EU member states in similar livestock systems. 
 The number of daily dosages per animal year was determined by calculating the total number of 
kilograms of animal (the treatable weight) that can be treated with each active ingredient. This was 
then divided by the total weight of the number of livestock in the country4. This assumes that the 
average treatment is administered to animals with an average weight. Adopting this approach provides 
for calculations and comparisons of the total antibiotic use on farms, even when different active 
ingredients are involved. More information is given in the daily dosages box, which also includes an 
example of a calculation. 
 This information can then be used to obtain an insight into the total antibiotic use for a specific 
category of animal (for example, fattening pigs) on a group of farms (for example, all pig farms with 
fattening pigs). This is also expressed in terms of an average number of daily dosages per animal year 
for fattening pigs. 
 
Daily dosages 
The amounts of different active ingredients cannot simply be totalled since the effectiveness and 
kinetics (and, consequently, the dosage prescription) varies between active ingredients. However, 
active ingredients can be compared and totalled once the active ingredient in each antibiotic 
preparation is expressed in terms of the daily dosage. The daily dosage is a measure of the number of 
milligrams of a specific active ingredient required to treat one kilogram of animal in one day with that 
antibiotic preparation, and is based on the recorded average dosage of a medicine for a specific type of 
animal. These daily dosages can be totalled to determine the total exposure to antibiotics. The daily 
dosages are specific to the type of animal, and have been defined for cattle, pigs and chicken. 
Consequently, antibiotic preparations used to treat several types of animal can be administered using a 
range of daily dosages, i.e. the daily dosage for each type of animal. 
 
Example of a calculation of the daily dosage 
For example, a farm with 150 fattening pigs with an average weight of 70.2 kg used 2 litres of 
antibiotic preparation X during the course of one year (40% of which consists of active ingredient a  
and the remainder of solvent and supplements) and 20 kg of antibiotic preparation Y (25% of which 
consists of active ingredient b). Antibiotic preparation X contains active ingredient a: the specified 
dose is 10 mg a day per kg animal weight. Antibiotic preparation Y contains active ingredient b: the 
specified dose is 50 mg a day per kg animal weight. 
 Antibiotic preparation X can be used to treat (2,000 * 40% * 1000)/10 = 80,000 kg animal 
weight. Antibiotic preparation Y can be used to treat (20,000 * 25% * 1,000)/50 = 100,000 kg animal 
weight. Consequently, the farm has used antibiotics for a total of 180,000 kg animal weight. The farm 
has an average of 150 fattening pigs per year, with a total weight of 10,530 kg. 180,000 kg were 
                                                     
3 Differences in dosage are determined by differences in potency as well as differences in assimilation and 
differences in distribution throughout the body. 
4 This is the average weight of the treated animals (in kilograms per animal) multiplied by the average number of 
animals present on the farm per year. 
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treated in that year, equivalent to 180,000/10,530 = 17.1 daily dosages. Consequently, an average 
fattening pig5 on the farm in that year was administered a prescribed dosage of antibiotics on 17.1 
days. In this example the farm uses 17.1 daily dosages per animal year of antibiotic preparation X plus 
Y. 
 
 
 
Animal weights 
In an ideal situation, the number of daily dosages should be determined on the basis of the treated 
weight of the treated animals. However, the information that is available is insufficient for the 
determination of the exact weight of the animals at the time of the administration of the medicine, and 
for this reason the calculations use the average weight per animal during the period the animal is on 
the farm. The following average weights have been used: dairy cow 600 kg, broiler 1kg, fattening pig 
70.2 kg, sow 220 kg, maiden gilt 107.5 kg, piglet 12.5 kg, breeding boar 350 kg (ASG, 2007). For sow 
farms, the weight of the average number of sows, gilts, piglets and breeding boars is totalled. 
 
 
2.4  Statistical analysis 
 
Analyses at the level of individual farms are required to obtain an insight into the risk factors for 
antibiotic use. The data collected in the Data Network offers an opportunity for these analyses.  
Beforehand correlation tables were made followed by appropriate (multiple) linear regressions6 to 
examine the relationship between the size of the farm, the level of the technical results, and the 
antibiotic use (in number of daily dosages). These analyses were carried out using the software 
packages SPSS and Genstat. 
 
 
3. Trends in antibiotic usage 
 
3.1 Trends in the total antibiotic use in the Netherlands 
 
Figure 3.1 shows the trends in the total therapeutic antibiotic use in the Netherlands. The figure was 
prepared from usage figures collated by FIDIN (FIDIN, 2008). 
 
                                                     
5 This refers to a pig on the farm throughout the year: however, there is no such pig. This is a method which can 
be used to provide for comparisons of farms with different vacancy rates. For example, a farm has 2 herds of 
animals a year, both of which comprise 200 animals that remain on the farm for 5.5 months. The farm is vacant 
during the first and last week of the year, and for 2 weeks between the two herds. The calculations for this farm 
are based on an average of 183 animals present on the farm. When a farm is vacant for six months and has a herd 
of 200 animals for six months then the calculations are based on an average of 100 animals on the farm.  
6 In the event of two or more quantitative variables taking the nominal ordinal or linear character of the variables 
into consideration. 
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Figure 3.1 Veterinary therapeutic antibiotic use from 1999-2007 (FIDIN, 2008) 
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Figure 3.2 Total antibiotic use in the Netherlands, 1999 – 2007.  
 
0
100
200
300
400
500
600
700
1999 2000 2001 2002 2003 2004 2005 2006 2007
kg
 a
ct
iv
e 
in
gr
ed
ie
nt
 x
 1
.0
00
AMGPs (growth promoters)
Antibiotics (therapeutic use)
Total
 
 
 
 Figure 3.1 reveals that the total amount of antibiotics sold by the pharmaceutical industry in the 
Netherlands for therapeutic veterinary use has increased by 83% since 1998, equivalent to an average 
increase of 7.9% per year. The use increased by 8.9% in 2007 as compared to 2006. 
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 The use of antimicrobial growth promoters (AMGP) was prohibited at the beginning of 2006. 
Figure 3.2 shows the trend in total antibiotic use including growth promoters. The total use increased 
by over 3% during the period from 1999 to 2007. The figures reveal an increase in total use during the 
period from 2003 through 2005 and a decline in the use of AMGPs. The total use (in kilograms) 
actually fell slightly in 2005 and 2006. In 2007, the use of antibiotics once again increased sharply as 
compared to 2006. A part of this increase may be accounted for by a substitution of growth promoters. 
  Over the years, the number of the livestock has also changed. The best possible insight into the 
trends in therapeutic antibiotic use is obtained by relating the total data in Figure 3.1 to the trends in 
the number of animals in the Netherlands. Figure 3.3 shows the trends in the numbers of animals. 
 
Figure 3.3 Trends in livestock production in the Netherlands. Numbers of animals, 1999-2007 (x 1,000 
animals). The modified scale on the right-hand axis indicates the numbers of broilers (solid 
squares).  
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Source: Eurostat 2008. 
 
 
 These yearly production numbers of animals are converted into live weight in Figure 3.4.. 
Although the number of broilers has fluctuated over the years, the resultant variation in the total 
animal weight (on average, 1 kg per broiler) is minimal. The other types of animal do not exhibit any 
significant differences. The higher live weights in 1999 and 2000 were due to the relatively larger 
number of pigs in those years. 
 In conclusion, the total antibiotic use is divided by the live weight present (in kg) to obtain the 
best possible insight into the actual trends in antibiotic use (see Figure 3.5. 7) 
 
  
                                                     
7 The analysis of the data for 2006 presented last year was based on a different method of calculation. The effects 
of this are shown in Annex 4.  
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Figure 3.4 Trends in livestock in the Netherlands. Live weight, 1999-2007 (in millions of kg) 
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Figure 3.5 Total therapeutic antibiotic use 1999-2007, in mg per kg live weight 
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 Figure 3.5 reveals that therapeutic antibiotic use expressed in terms of mg per kg live weight has 
doubled in the eight years since records began in 1999. 
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3.2  Usage outside the Netherlands8 
 
Figures for the quantities of purchased or prescribed veterinary antibiotics have been published for a 
number of European countries. These countries also present the figures in terms of kg active 
ingredients. An insight into the volume and composition of antibiotic use in these countries can be 
obtained by collecting all the available data and converting the weight of active ingredients in each 
group of medicines into the treatable weight of animal (see Table 3.1). The total of these figures is 
related to the number of livestock in the relevant country. 
 
Table 3.1 Conversion factors for kg antibiotic to treatable kg to daily dosage 
 
Group of medicines average dosage (mg/kg) 
conversion factor, kg
antibiotic to
treatable kg
tetracyclines 8.22 121543
trim /sulfa combinations 23.0 43435
β-Lactams 7.09 141131
aminoglycosides 6.84 146196
macrolides 5.77 173441
fluoroquinolones 4.48 223012
other 5.00 199886
 
Figure 3.6. Daily dosages of antibiotics (calculated from the sold/delivered kg of active ingredient) per 
average animal per year in the various countries. 
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Figure 3.6 shows the calculated daily dosages of antibiotics that an average animal is administered per 
year in the various countries. The average animal in the Netherlands is administered a daily dosage of 
antibiotics on approximately 20 days (2001) to 30 days (2007) a year. The number of daily dosages is 
significantly lower in other countries, although the situation can differ for specific types of animals. 
                                                     
8 This Subsection is, bar a few minor changes, reproduced from Van Geijlswijk et al. (2009). 
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The Dutch antibiotic use is currently increasing each year (cf. figures 3.1 and 3.5): use is also 
increasing in Germany and Denmark, whereas use in the other countries is relatively stable. 
These differences are in part due to the major differences in the national animal populations 
(denominator data). France and the UK, for example, have large numbers of beef cattle and sheep that 
are always outdoors and receive very limited amounts of antibiotics. In the Netherlands, the use 
reflects the larger proportion of intensive livestock farming operations. Reports previously published 
in countries such as Denmark, where livestock farming exhibits more similarities with the 
Netherlands, indicate that antibiotic use is actually lower. Direct comparisons are complicated by the 
differences in the level at which records are kept: at a national sales level (Netherlands, France, 
Germany, UK, Finland, Norway) or at farm level (prescription level) (Denmark, Sweden [as from 
2003]).  
 
An overview of European antibiotic use by group of medicines gives an insight into the veterinary 
antibiotics policy pursued in the various countries. (see Figure 3.7) 
 
Figure 3.7. Percentages (%) of the total antibiotic use (expressed as calculated daily dosages) of the six 
main groups of antimicrobial preparations in each country in 2005. 
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The following remarks can be made about the groups of medicines used in the various countries: 
• A distinction can be made between three general treatment strategies in Europe 
– Scandinavian countries: a strategy primarily based on beta-lactam antibiotics  
– Denmark: a strategy based on tetracyclines + macrolides + betalactams 
– Other European countries: a strategy primarily based on tetracyclines 
• Norway uses relatively large amounts of fluoroquinolones (15%) in the fish-breeding sector, 
which is more than the amount administered to humans in the Netherlands. 
• All countries use roughly the same amount of trim /sulfa combinations (approx. 8%). 
The above comparison has been made for all years from 2001 to 2006 inclusive, but holds for the 
years 1999, 2000 and probably 2007, as well. 
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3.3 Usage in the Netherlands in 2007 
 
The information from the sentinel farms can be used to estimate the average antibiotic use in daily 
dosages per animal year per sector in the Netherlands. This figure indicates the daily dosages the 
average dairy cow, pig or broiler is administered per year. The average use, accompanied by 95% 
confidence intervals, is shown in Figure 3.8. 
 
Figure 3.8 Average number of daily dosages per animal year in 2007, with 95% confidence intervals 
(total group) 
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These intervals indicate that with 95% certainty, the average antibiotic use in each sector in the 
Netherlands, expressed in terms of the number of daily dosages per animal year, will lie within the 
upper and lower limits indicated by the four vertical lines shown in Figure 3.8. The actual average use 
in the sectors in the Netherlands will be at most 15% (fattening pigs) to 22% (sows/piglets and 
broilers) higher or lower than the average determined at the sentinel farms. 
 
 
3.4 Trends in antibiotic usage in the Netherlands 
 
An insight into the variation in antibiotic use in the years 2006 and 2007 was obtained by analysing 
the figures of the 123 farms which took part in both years, i.e. the comparison group. Table 3.2 lists 
the figures for this group of farms as compared to the farms in the total sample for 2007. 
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Table 3.2 Differences in the average number of daily dosages per animal year between the comparison 
group and the total group. 
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2007 total group 36 42 52 29 159 
Number of farms 06-07 comparison 
group 35 30 31 27 123 
2007 total group 5.7 22.4 16.4 32.9 n/a Number of daily 
dosages 06-07 comparison group 
5.4 22.4 17.0 30.2 n/a 
 
 
 
Figure 3.9 shows the antibiotic use in the four sectors examined in this study expressed as daily 
dosages per animal year per average animal present. This figure reveals a tendency to increase in the 
antibiotic use in daily dosages administered to fattening pigs (+13.3%) and broilers (+18.9%). The 
daily dosages administered to sows/piglets decreased (-15.4%) and administered to dairy cattle 
remained virtually unchanged (-0.7%).  
 
 
Figure 3.9 Trends in antibiotic usage 2006-2007 in daily dosages per animal year at farms in the 
comparison group 2006 – 2007 
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 The number of farms in the comparison group differs from the total group, and this is the 
reason for the differences between figures 3.8 (and 3.10) and 3.9. The number of pig farms followed in 
2007 increased substantially as compared to 2006 (+33 farms). However, notwithstanding the 
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difference in the number of farms, the difference in the average number of daily dosages per animal 
year between these groups is small. See Table 3.2. 
 This data does not permit a conclusion that the use in specific sectors in the Netherlands has 
increased or declined in consecutive years. None of the differences between consecutive years were 
significant. This is primarily due to the observed differences in use between the farms (large variation) 
in combination with a somewhat too-small number of farms in the sample 
 
Figure 3.10 shows the trends in all farms in the sentinel farms from 2004 to 2007. If this study had 
been restricted to farms that have taken part in each of these years then the figures of only 77 farms 
would have been used. See also Annex 3. 
 
Figure 3.10 Trends in antibiotic usage from 2004 to 2007 inclusive, expressed as daily dosages per animal 
year (total group) 
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Figure 3.10 shows that the daily dosages administered at dairy farms are fairly constant; this is also the 
case at sow/piglet farms. The fattening pig and broiler farms exhibit increasing use; in both groups the 
use in 2007 is statistically significantly higher than the use in 2004. 
 The background data with details about the use in daily dosages per administration method is 
included in annexes 1a, 1b, 1c and 1d, and the background data with details about the use in grams of 
active ingredients is included in annexes 2a to 2d. 
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4. Dairy cattle 
 
Antibiotic use remained virtually unchanged at the dairy farms. However, there were some shifts in 
the use of the various groups of antibiotics. The farms have used slightly more tetracyclines and less 
penicillins. See Figure 4.1. 
 
Figure 4.1 Antibiotic use on dairy cattle in daily dosages per animal year (comparison group) 
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The percentage of the total antibiotic use for intramammary administration decreased from 64% in 
2006 to 53% in 2007. Oral and parenteral administration has increased. The oral administration of 
doxycycline in particular, has increased (0.03 – 0.33). Figure 4.2 shows  the various groups used for 
intramammary administration of antibiotics to dairy cows in 2006 and 2007. This reveals that there 
was a substantial increase in the use of amoxicillin clavulanic acid in 2007 as compared to 2006, as 
well as an increase in the use of cefquinome. The use of cloxacillin showed a substantial decrease. 
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Figure 4.2 Intramammary antibiotic use at active ingredient level on dairy cattle [dd/ay] (comparison 
group) 
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A relationship exists between the antibiotic use in 2006 and that in 2007 (p = 0.00…; correlation 
coefficient = 0.678) and that in general a farm’s antibiotic use in one year is a predictor of the 
antibiotic use in a following year. With other words farms with a high use in one year will often have a 
high use in the next year, whilst the use at farms with a low use in one year will often remain low. 
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5.  Fattening pigs 
 
The number of daily dosages in the comparison group 2006-2007 in this sample increased at the 
fattening pig farms from 15.0 to 17.0 (+13%). This increase is not statistically significant. Therefore it 
is not possible to conclude that there is an increase in antibiotic use at a national level on the basis of 
this data. See Figure 5.1. 
 
Figure 5.1  Antibiotic use on fattening pigs by active ingredient, in daily dosage per animal year 
(comparison group) 
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Shifts have taken place in this sector. Tetracyclines are most commonly administered to fattening pigs: 
it is striking to note that the use of tetracyclines has declined sharply, certainly in view of the 
percentage of the total use, from 76% to 59% - and this in comparison with the increase observed from 
2005 to 2006, which actually grew from 72% to 78%9. The other antibiotics reveal an increase of 3 
daily dosages, which is almost entirely due to the increase in the use of colistin sulphate that was 
virtually unused in 2006. See also Annex 1b. The use of macrolides also increased (+1), due to tylosin. 
The use of trim /sulfa combinations decreased slightly (-0.6). 
 
 
An analysis was carried out to review whether farms with a larger number of fattening pigs have a 
higher antibiotic use: this can be due to a higher disease pressure, but also to the shorter amount of 
time available for the care and inspection of each animal. The analysis revealed that in general farms 
with a larger number of fattening pigs have a slightly higher antibiotic use (p= 0.04; correlation 
coefficient = 0.324). No correlation was found between the time devoted to the animals and the 
number of daily dosages. There was a correlation between the time devoted to each animal and the 
size of the farm (p= 0.00; correlation coefficient = -0.656). However, it is not clear whether the higher 
antibiotic use was due solely to the size of the farm, or was also due to the shorter amount of time 
devoted to each animal. 
                                                     
9 The difference between this figure (78%) for 2006 and the aforementioned 76% for 2006 is due to the fact that 
different groups of farms were examined in the two instances. The comparisons review farms followed in the 
two years. Consequently, for the comparison of 2005 and 2006 the group of farms used for 2006 was slightly 
different from that used for the comparison of 2006 and 2007.  
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An analysis was carried out to review whether farms with modern stalls have a lower 
antibiotic use. With fattening pigs the converse was, on the basis of this sample, visible: farms with 
partially modernised stalls have a significantly lower antibiotic use (17 daily dosages) than farms with 
modern stalls (27 daily dosages)10 (p= 0.04; n=32). This relationship is not influenced by farm size. 
 A study was carried out to examine whether fattening pig farms with a high antibiotic use in one 
year also had a high antibiotic use in the next year, and vice versa. Analysis revealed a strong 
relationship between the use in 2006 and the use in 2007  (p = 0.00; correlation coefficient = 0.619). 
Consequently, it can be concluded that in general a fattening pig farm’s antibiotic use in one year is a 
good predictor of the antibiotic use in a following year. This implies that farms with a high use in one 
year will often have a high use in the next year, whilst the use at farms with a low use in one year will 
often remain low. 
 
The following variables did not yield any significantly different results for antibiotic use: 
• Routinely, occasionally or never preventive treatments; 
• The presence or absence of a farm treatment plan; 
• The comprehensiveness of the farm treatment plan; 
• The presence of employees; 
• The use of basic feed; 
• The fattening pig farmer’s assessment of the health of the animals on his farm in 2007; 
• The presence or absence of a standard preventive antibiotic treatment of piglets for fattening 
• The extent to which slaughter anomalies are observed (impaired lungs/livers). 
 
                                                     
10 There were too few farms with old or super-modern stalls, and for this reason they were excluded from the 
analysis. 
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6. Sows and piglets 
 
The number of daily dosages decreased at the sow farms in the comparison group 2006-2007 in this 
sample from 26.5 to 22.5 (-15%). This is not a statistically significant decrease, and therefore it is not 
possible to conclude that there is a decrease in antibiotic use at a national level on the basis of this 
data. See Figure 6.1. 
 
Figure 6.1 Antibiotic use on sows/piglets in daily dosages per animal year (comparison group) 
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The decrease in the number of daily dosages was primarily due to the reduced use of tetracycline (–2.7 
dd/ay). The use of most other antibiotic groups decreased to an extent such that the decrease in the 
proportion of the group in the total use was the same as the decrease in the total use. This is shown in 
Figure 6.2. Only the groups ‘other antibiotics’11 and ‘antibiotic combinations’12 exhibited a slight 
increase. 
 
                                                     
11 Lincomycine and colistin sulphate 
12 Dihydrostreptomycin-benzylpenicillin, Lincomycin-spectinomycin and Neomycin-benzylpenicillin. See 
Annex 1c for the exact figures. 
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Figure 6.2  Antibiotic use on sows/piglets according to active ingredient, in percentage of daily dosages 
per animal year (comparison group)  
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An analysis was carried out to review whether farms with a larger number of sows have a higher 
antibiotic use: this can be due to a higher disease incidence, but also to the shorter amount of time 
available for the care and inspection of each animal. The analysis showed that in general farms with a 
larger number of sows have a higher antibiotic use (p= 0.00; r2 = 0.35). Figure 6.3 shows that the 
antibiotic use at farms with 250 to 600 sows, is more than double the use at a farm with less than 250 
sows. There is a statistically significant difference between the average numbers of daily dosages of all 
three groups in Figure 6.3. 
 
 
Figure 6.3  Farm size (number of sows) related to the antibiotic use on sows/piglets (dd/ay) 
 
0
5
10
15
20
25
30
35
40
45
less than 250 sows 250 - 600 sows 600 and more sows
dd
/a
y number of farms: 15average number of
sows: 383
daily dosis: 25
standarddeviation: 16
number of farms: 10
average number of 
sows: 163
daily dosis: 12
standarddeviation: 9
number of farms: 13
average number of
sows: 763
daily dosis: 40
standarddeviation: 13
 
MARAN-2007 
 
 
 
 34 
 
The figures obtained from this sample reveal that farms with more sows have a higher antibiotic use 
per animal year. In addition, the figures also reveal that the time devoted to each sow decreases with 
the number of sows. However, there is no correlation between the spending of time and the antibiotic 
use . It would appear that there is another cause for the higher use of antibiotics at larger farms.  
A difference has been found between the groups of sow farms with and without employees. 
Farms with employees have a higher antibiotic use (34 daily dosages per animal year) than farms 
without employees (18 dd/ay; p=0.00; sed = 4.6). The farmers were also asked whether the employees 
had completed a relevant course or had sufficient work experience. Only three farmers replied in the 
negative to this question. 
It is expected that sow farms with different antibiotic policies will also exhibit differences in 
the quantities of antibiotics they use. Farms that occasionally made preventive use of antibiotics have 
the lowest use (15.8 dd/ay), farms that routinely employ preventative treatments have the highest use 
(33.6 dd/ay) and farms that never give preventive treatments lie in between the two (22.8 dd/ay). The 
highest and the lowest are statistically significant different (p = 0.00; sed = 4.1). This could be due to 
the fact that farms which occasionally make preventive use of antibiotics do so very deliberately on 
the recommendation of their veterinarian in response to a (past) problem. It is conceivable that farms 
which never use preventive treatments often respond to problems just too late and then need to 
introduce curative treatments that involve large amounts of antibiotics. 
It is expected that sow farmers are able to make an accurate assessment of the health of their 
animals and that the use of antibiotics is a good indicator for this health status. Farmers stating that the 
health of their animals is poor do indeed have a high antibiotic use and vice versa (p=0.00; correlation 
coefficient = 0.474). The average daily dosage at the group with animals in moderate health was 36.7, 
while the average daily dose at the group who assessed the health of their animals as good was 20.6. 
None of the sow farmers assessed the health of their animals as poor.  
 Further analyses showed that sow farms which had a high antibiotic use in 2006 also had a high 
antibiotic use in 2007, and vice versa (p = 0.00; correlation coefficient = 0.716). Consequently, it can 
be concluded that in general a sow farm’s antibiotic use in one year is a good predictor of the 
antibiotic use in a following year. This implies that farms with a high use in one year will often have a 
high use in the next year, whilst the use at farms with a low use in one year will often remain low. 
 
The following analyses did not reveal any relationships with the antibiotic use: 
• The presence or absence of a farm treatment plan; 
• The comprehensiveness of the farm treatment plan; 
• The modernity of the stalls; 
• The use of basic feed; 
• The destination of the piglets (own farm, steady customers, other customers), and 
• The number of piglets born live per sow. 
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7. Broilers 
 
The number of daily dosages at the broiler farms in the comparison group 2006-2007 in this sample 
increased by 4.8: from 25.4 to 30.2 daily dosages (+19%). This increase is not statistically significant, 
and therefore it is not possible to conclude that there is an increase in antibiotic use at a national level 
on the basis of this data. See Figure 7.1. 
 
Figure 7.1 Antibiotic use on broilers in daily dosages per animal year (comparison group) 
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The increase is largely due to the increase in the use of penicillins (+3.9) and, to a lesser extent, to the 
increase in the use of aminoglycosides (+1.5), tetracyclines (+1.4) and macrolides (+0.5). The use of 
fluoroquinolones (-1.8) and trim /sulfa combinations (-0.6) declined. The comparison of 2006 against 
2005 had revealed an increase in the use of fluoroquinolones. The changes in the proportions of the 
various groups of antibiotics reflect the increases and decreases mentioned before. The proportions of 
the other groups were relatively unchanged. 
 In addition, it was remarkable to note that of the sample farms we analysed the broiler farms, in 
particular, made use of fluoroquinolones and aminoglycosides. 
 
There are major differences between the antibiotic uses at the various farms: The 25% farms with the 
lowest antibiotic use administer an average of 8.7 daily dosages, the middle group (50%) administers 
an average of 30.9 daily dosages, and the major users (25%) administer an average of 67.8 daily 
dosages per animal year. This last 25% of the farms account for 49% of the total antibiotic use. 
An analysis was carried out to examine whether farms using basic feed also had a different 
level of antibiotic use. The analysis showed that the antibiotic use at farms using basic feed was lower 
than  farms that did not use basic feed (p=0.05; correlation coefficient = 0.371). The farms that did not 
use basic feed used feed with, for example, omega fatty acids, and a higher energy content. GMO-free 
feed, or feed in which the farmer could vary the percentage of wheat. An explanation for this could be 
that farms which supply special feed do so because of health problems. 
An analysis was performed to examine whether there is a relationship between the size of 
broiler farms and antibiotic use. However, this was not the case. 
An analysis was also performed to examine the relationship between the broiler farmer’s 
assessment of the health of the animals and antibiotic use. The average number of daily dosages per 
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animal year at the farms of broiler farmers who assessed the health of their animals as good was 24; 
the average number of daily dosages per animal year at the farms of broiler farmers who assessed the 
health of their animals as moderate was 37; the average number of daily dosages per animal year at the 
farms of broiler farmers who assessed the health of their animals as poor was 51. However, as a result 
of the large dispersion in use and the small number of farms in the sample (n=27) the differences were 
not significant. 
 An analysis was performed to examine whether broiler farms with a high antibiotic use in one 
year also had a high antibiotic use in the next year, and vice versa. Further analysis showed a 
correlation between the use in 2006 and the use in 2007 (p = 0.01; correlation coefficient = 0.50). 
Consequently, it can be concluded that in general a broiler farm’s antibiotic use in one year is a good 
predictor of the antibiotic use in a following year. This implies that farms with a high use in one year 
will often have a high use in the next year, whilst the use at farms with a low use in one year will often 
remain low. 
 The antibiotic use, expressed in daily dosages, is directly correlated with the health costs per 
broiler (p = 0.01; correlation coefficient = 0.467). As such this is not a surprise, since antibiotics 
account for 29% of the animal health costs of broilers (Bondt et al., 2007). 
The following analyses did not reveal any relationships with the antibiotic use: 
The size of the farm; 
Employees at the farm (yes/no); 
The modernity of the poultry houses; 
The use of preventive treatment (routinely, occasionally, never); 
The poultry farmer’s assessment of the health of the animals; 
The number of bacteriological flock problems; 
The number of problems other than bacteriological flock problems. 
 
8. Discussion 
 
Reliability of the results and sample size 
The results in this study are based on data from sample farms in the Farm Accountancy Data Network. 
These results can be used to calculate the average use per average animal present on an average farm. 
The average value for the different sectors in the Netherlands has been calculated with a 95% 
confidence interval, i.e. on the basis of this sample it can be stated with 95% reliability that the 
average value for the Netherlands will be between certain lower and upper limits13. 
 The number of farms in the sample depends on the required degree of certainty for the 
demonstration of possible differences in the use (increased or decreased use) in different years. The 
size of the sample is determined by establishing which increase or decrease in antibiotic use is deemed 
relevant and consequently needs to be detected as a statistically significant change. Table 8.1 lists the 
number of farms in the various sectors required to establish a difference in antibiotic use of 10, 15 and 
20% with a 95% confidence interval (α =0.05). This is based on the dispersion currently exhibited by 
the sample. The dispersion exerts a great influence on the number of farms required in the sample: it 
should be noted that comparison group of farms and therefore also the dispersion in the figures used 
for the comparison of 2005 and 2006 differs from the comparison group and dispersion for the 
comparison of 2006 and 2007. Rows in which ‘smaller than’ is stated alongside a given figure indicate 
that the current sample size is already sufficient to demonstrate the difference. For example ‘smaller 
than 31’ stated in the fattening pig column (for a difference of 15%) indicates that the current study 
would have established that a 15% increase or decrease in antibiotic use was significant. The figures 
for comparing 2007 with 2006 revealed an increase of 13% (from 15 to 17 daily dosages, Figure 3.9): 
however, this difference is just short of significant. A sample of 49 farms would have been required to 
demonstrate a difference of 10% in fattening pig antibiotic use, based on the dispersion exhibited by 
the comparison group for 2006/2007. 
 
                                                     
13 The confidence intervals were minimised by using data from the Agricultural Census, whereby the estimate 
takes into account the farm size using weighting factors. 
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Table 8.1 Optimum sample size for the demonstration of the specified % differences in antibiotic use 
between different years (α =5%) 
 
% difference Basic S14  Dairy cattle Sows Fattening 
pigs 
Broilers 
05-06 46 43 89 84 10% 
06-07 62 105 49 63 
05-06 smaller than 
34 
31 59 57 15% 
06-07 44 60 smaller than 
31 
42 
05-06 smaller than 
34 
smaller than 
27 
44 45 20% 
06-07 smaller than 
35 
39 smaller than 
31 
33 
 
Table 8.1 shows that the current sample is too small to demonstrate a 10% increase or decrease of the 
use of antibiotics. For that reason the monitoring for 2008 provides for a substantial expansion of the 
number of farms in the dairy and pig sectors. This expansion is also desirable in the broiler sector. A 
larger sample size will improve the accuracy of the estimation of the actual national use and, in so 
doing, lay firmer foundations for further studies into the background reasons for the major differences 
in antibiotic use revealed by the data. Supplementary information could be obtained by organising a 
workshop with participants from the sample: it is expected that this will provide an improved insight 
into the reasons for the major differences in use. 
 It is not currently possible to employ the usage figures from the monitoring in the Data Network 
to calculate antibiotic use at a national level, primarily because veal farms have yet to be included in 
the sample. The veal sector has now begun to implement the Rational Antibiotic Use Master Plan, and 
within this context antibiotic use is being monitored from 2007 onwards. It is expected that the first 
results will be announced in the annual MARAN report published at the beginning of 2010. The 
availability of this data should provide an opportunity for a comparison with the (national) FIDIN 
data. 
 One of the current characteristics of the method used to calculate the daily dosages is the use of 
average animal weights. This assumes that the probability that an animal will be treated with 
antibiotics is independent of the age of the animal. However, this is not the case: younger animals 
have more frequent health problems than older animals, while animals no longer receive antibiotics in 
the last period before slaughter to ensure that the meat is free of antibiotic residues. An improved 
estimation of the treatment duration would be obtained by replacing the average weight expressed in 
terms of the average weight during the animals’ presence on the farm by the best possible estimate of 
the average weight on treatment. This could possibly be achieved by collecting usage figures at herd 
level and assuming that the date of purchase of a preparation is also the date of treatment. The age 
(and related weight) of the animals treated could be estimated at this treatment date. This more 
accurate method of calculation is already being used in the monitoring of antibiotic use in the veal 
sector. Therefore we emphasize that restraint is needed in comparing the use of antibiotics (number of 
dd/ay) between different sectors. 
 On closed farms, the weights of the animal present are calculated on the basis of the factors 
including the numbers of fattening pigs and piglets and a standard weight per animal. The accuracy of 
this estimation can be improved if information is available about the weights at which piglets on 
individual farms move on to fattening. The weaned piglets, in particular, are treated at sow farms: once 
again, the appropriate designation of the preparation to the animal group and age/weight would 
provide an improved view into the antibiotic use and actual differences between farms. 
 
                                                     
14 S indicates the estimate of the required sample size (σ). This column specifies the data set used to estimate σ. 
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Comparison of countries 
Compared to other countries of which figures of veterinary antibiotic use are available, the use of 
antibiotics per animal in the Netherlands is high. It is not clear whether or not this higher usage is 
caused by specific sectors or that the usage is higher in all sectors of animal production. Unfortunately, 
the figures of the other countries can’t be specified into use per animal production sector. 
 
Use of antibiotics: a matter of health but also of management 
There are big differences in the usage of antibiotics between farms. At broiler farms for example the 
25% major users account for 49% of the total antibiotic use. 
 The analysis of the figures of all animal species shows that there is a positive correlation 
between the use of antibiotics in one year and the previous year. This could mean that the animal 
health situation at those farms is structurally bad, or it could be caused by the management of the 
farmer. Indications for the impact of animal health management mainly emerge at the sow farms. 
Further analyses at those sow farms indicates the following: 
a) farms with more sows generally have a higher use of antibiotics; however, the variation in use 
between farms also increases with increasing farm size; 
b) farms that occasionally used antibiotics preventively on average have the lowest use, farms 
that routinely employ preventative treatments have the highest use and farms that never give 
preventive treatments lie in between the two; When the decision to use preventive use 
antibiotics preventively is a deliberate choice based on medical grounds, this appears to result 
in less total antibiotic use at these farms; 
c) the assessment of sow farmers on the health of their animals is consistent with their level of 
antibiotic usage; the better the estimated health status of the farm, the lower the usage of 
antibiotics. 
 
 
9. Conclusions 
 
The results from the monitoring give a broad and detailed view of the usage of various antibiotics at 
dairy, pig and broiler farms and the trends in their use. 
 The analysis of the FIDIN figures shows that the total therapeutic veterinary antibiotic use 
including antimicrobial growth promoters (AMGPs) increased by over 3% in the years from 1999 to 
2007. During this same period, the growth promoters have been banned, first partly and as from 2006 
entirely and the therapeutic veterinary antibiotic use increased by 83%, an average increase of 7.9% 
per annum. The therapeutic usage increased by 8.9% in 2007 as compared to 2006. The therapeutic 
antibiotic use per kg live weight in 2007 was twice that in 1999. Part of this increase may be 
accounted for by a substitution of growth promoters.  
In comparison with other countries for which veterinary antibiotic use figures are available the 
antibiotic usage per animal is highest in the Netherlands. However, it is not yet clear whether this is 
applicable to all or only some sectors. Antibiotic usage is increasing in the Netherlands, Denmark and 
Germany, while the use is stable in five other countries examined in this study. 
The antibiotic usage in 2007 at the 159 sentinel farms from the Farm Accountancy Data Network 
is as follows: dairy cattle 5.7 daily dosages per animal year (+ 1.015); sows/piglets 22.4 daily dosages 
per animal year (+ 5.0); fattening pigs 16.4 daily dosages per animal year (+ 2.5); broilers 32.9 daily 
dosages per animal year (+ 7.3). 
The figures on the antibiotic usage in the Netherlands expressed in terms of daily dosages per 
animal as based on all farms from the samples for 2004 to 2007 inclusive reveal that antibiotic usage 
has remained fairly stable for dairy cattle and sows/piglets. The antibiotic usage in fattening pigs and, 
broilers in particular, shows a clear increase. The increase in fattening pigs is statistically significant 
and numbers 3.5 daily dosages per animal year (95% confidence interval: 2.0 to 11.5 daily dosages per 
animal year). The increase in broilers is also statistically significant and numbers 13.8 daily dosages 
                                                     
15 The figures between brackets indicate the bandwidth. Consequently, the actual average antibiotic use per 
sector in the Netherlands will, with 95% confidence, lie between the specified upper and lower limits: for 
example, with dairy cattle between 4.7 and 6.7 daily dosages per animal year. 
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per animal year (95% confidence: 4.1 to 27.0 daily dosages per animal year). These confidence limits 
were calculated on unweighted data. 
 The antibiotic usage in dairy cows has remained relatively unchanged at 5.4 daily dosages per 
animal year. The proportion of antibiotics administered via the udder (intramammary) fell from 3.5 
daily dosages per animal year in 2006 to 2.9 in 2007, whereby the use of cloxacillin decreased and the 
use of amoxicillin clavulanic acid increased. 
 Antibiotic usage in fattening pig increased from 15 to 17 daily dosages per animal year. The use 
of tetracyclines has decreased (–1.3 dd/ay) and the use of other antibiotics (colistin sulphate; +3 dd/ay) 
and macrolides (+1 dd/ay) increased.  
The antibiotic usage in sows/piglets in 2007 was comparable to that in 2006, both in terms of 
the total use and the use of the various groups of antibiotics. The comparison of 2006 and 2007 shows 
a decrease from 26.5 to 22.4 daily dosages administered to sows/piglets per animal year. Further 
analysis of the sow farms revealed that: a) in general, antibiotic use is higher at farms with more sows; 
b) farms that occasionally use antibiotics preventively have the lowest average antibiotic use, while 
farms that routinely give preventive treatments have the highest average use and the use at farms that 
never give preventive treatments lies in between the two; c) the sow holders’ assessment of the health 
of their animals is related to their use of antibiotics: antibiotic use decreased in proportion to the 
farmers’ assessment of the appropriate health of their animals. 
 The total antibiotic usage in broilers increased considerably from 25.4 dd/ay in 2006 to 30.2 in 
2007 (comparison group 2006/2007), mainly due to the increased use of penicillins (+3.9 dd/ay; 
amoxicillin and phenoxymethylpenicillin). Fluoroquinolones and amino glycosides are primarily used 
in the broiler sector, although the use of fluoroquinolones decreased (-1.8 dd/ay). Antibiotic use varies 
greatly between farms: for example 25% of the broiler farms account for 49% of the total antibiotic 
usage.  
 Farms in all sectors that used a large amount of antibiotics in one year mostly also used large 
amounts of antibiotics in the previous year. Consequently, antibiotic use at farms is relatively stable. 
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II Resistance data 
 
In this chapter susceptibility test results are presented as determined in 2006/2007 for the food-borne 
pathogens Salmonella spp., Campylobacter spp. and Escherichia coli O157, the food-borne 
commensal organisms E. coli, Enterococcus faecium and E. faecalis. 
 
 
Food-borne pathogens 
 
 
Salmonella  
In this chapter resistance percentages are presented on salmonella’s isolated from humans with clinical 
infections, food-animals and their products, as potential sources for distribution to humans via the food 
chain, and animal feeds as potential source for food-animals and their products.  
 
Highlights 
In 2006/2007 S. Typhimurium and S. Enteritidis were the most prevalent serovars in humans, third was the 
antigenic variant S. enterica subspecies enterica 1,4,5,12:i:-, a so called monophasic variant of S. Typhimurium 
which is emerging internationally since 2004.  Pigs and cattle were the most important animal sources of S. 
Typhimurium. Layers (eggs) and foreign travel were the most important sources for S. Enteritidis. In broilers S. 
Java was isolated most frequently. In broilers S. Enteritidis and S. Typhimurium constitute only a small fraction 
of all salmonella’s. 
In 2006/2007 81 cefotaxime resistant, ESBL suspected strains were found, which was substantially more than in 
2004/2005 (n = 21). These isolates belonged predominantly to the serovar S. Java (63%) of which only 1 strain 
was isolated from a human source, the others all from poultry sources. Resistance to cefotaxime is increasing at 
an alarming rate. The isolates from humans originate partly from exotic sources, but also from poultry. In 
animals poultry is up to now the only reservoir for ESBL-producing salmonella’s.  
 
A total of 16.861 Salmonella isolates were tested for antimicrobial susceptibility between 1999-2007. 
Human isolates (N=9155) concerned a selection from first isolates sent to the Dutch National Institute 
of Public Health (RIVM) by the regional public health laboratories. All strains were the first isolates 
recovered from patients with salmonellosis. The majority of the isolates from pigs (N=1124) and 
cattle, including calves (N=600) were sent to the RIVM by the Animal Health Service from a diversity 
of surveillance programs and clinical Salmonella infections. Those from chickens (broilers, including 
poultry products, N=1149; layers, reproduction animals and eggs, N=827) concerned mainly 
nonclinical Salmonella infections derived from a diversity of monitoring programs on the farm, 
slaughterhouses and at retail. The majority of isolates from layers in 2005 concerned those from the 
Dutch component of the EU-baseline study. Isolates from a diversity of other sources have been 
analysed as well (animal feed and human food products; other animals from animal husbandry and 
pets, samples from the environment, etc.). 
In 2006/2007, S. Typhimurium and S. Enteritidis were the most prevalent serovars isolated from 
humans in The Netherlands (table 9). Third was the antigenic variant S. enterica subspecies enterica 
1,4,5,12:i:-, a so called monophasic variant of S. Typhimurium which is emerging internationally since 
2004 (Mossong J, et al. Outbreaks of monophasic Salmonella enterica serovar 4,[5],12:i:- in 
Luxembourg, 2006. Euro Surveill 2007;12(6)) 
Like in 2004/2005 in pigs S. Typhimurium was by far the most prevalent serovar and in cattle S. 
Dublin. In poultry a difference existed in prevalence of serovars between broilers and layers. In 
isolates from broilers S. Paratyphi B var. Java (S. Java) and S. Infantis predominated and in layers S. 
Enteritidis and S. Senftenberg. 
Travel contributed from 0% to almost 40% of the cases of human salmonellosis depending on the 
sero/phagetype. Of the two most frequently isolated human serovars, travel contributed substantially 
more to the incidence of S. Enteritidis than S. Typhimurium. Travel contributed to 46% of the S. 
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Kentucky cases in humans, the serovar most commonly harbouring a high level of resistance to 
ciprofloxacin. Travel is, however, strongly underreported, by about a factor of two. 
 
Table 9. Most prevalent Salmonella sero-, and phagetypes isolated in 2004/2005 and 2006/2007 from 
humans, pigs, poultry, broilers and layers16 and the % travel related infections in 2004 – 2005. 
 
   Humans Pigs  Cattle Poultry Broilers Layers 
  04/05 06/07 04/05 06/07 04/05 06/07 04/05 06/07 04/05 06/07 04/05 06/07 
    N N N N N N N N N N N N 
Total number sent to RIVM 3384 3320 599 581 284 312 1204 1034 549 464 457 163 
Sero/phagetype  Travel  % of the total sent to RIVM 
Typhimurium 4% 33.9 33.7 54.8 44.2 14.8 26 6.5 4.8 6.2 5.4 6.1 6.7 
DT104 3% 11.8 4.8 16.5 9.6 4.6 4.5 2.7 1.7 2.2 1.7 3.1 2.5 
ft507 2% 6.5 8 14.5 9.3 4.2 8.7 1.2 1 2 1.3 0.4   
ft510 8% 1.4 1.3 1.2 2.4 0.7 0.6             
ft508 2% 1.2 0.3 1.7 0.7     0.3   0.5   0.2   
ft561 (DT7) 0%   7.2   1.2   2.9             
ft296 4%   1   0.2   0.3   0.1   0.2     
Enteritidis 13% 40.2 35.5   3.1 0.4 2.9 17.5 6.8 6.9 3 33.3 19 
Pt21 16% 7.2 4.7       0.3 2.6 0.9 3.1 0 3.1 4.9 
Pt8 9% 4.3 2.7   0.5 0.4 0.6 1.7 0.4 0.5 0.2 2.4 0.6 
Pt4 8% 12.3 14.3   0.5   1 6.3 2.9 1.6 0.9 12.9 6.7 
Pt1 24% 4.2 3   0.2     1.1 0.8 0.5 0.9 1.5 0.6 
Pt6 10% 3.7 3.8   0.2     1.2 0.1     2.8 0.6 
Pt6a 26% 1.3 1   0.2     0.2 0.4     0.4 0.6 
Pt14b 17% 1.2 0.8   0.2     0.3 0.1 0.2 0.2 0.7   
Pt3 22% 0.3 0.8                     
Dublin  0% 0.4 0.5 0.2 0.2 53.5 56.4 0.2           
Paratyphi B var 
Java 5% 0.1 0.5 0.3 0.2     18.3 33.8 30.6 32.8 2 1.2 
Infantis 15% 1.4 1 1.5 4.3 0.4 1 9.5 13.1 13.8 16.2 3.9 4.3 
Senftenberg 24% 0.3 0.6 0.3 0.9     9.2 5.7 2.6 2.4 18.6 27 
Mbandaka 23% 0.3 0.3 0.2 0.7 2.1 0.3 3 2.2 3.5 3.7 2 1.8 
Virchow 40% 1.1 1.6   0.5 0.7   5.4 7 2.9 7.8 7 4.3 
Derby  13% 0.8 0.5 12.9 10.5 1.4   1.1 0.3 1.6 0.6 0.7   
Livingstone 4% 0.3 0.2 2 2.8     1.6 1.6 1.3 2.4 2.2 1.2 
S1,4,5,12:i:- 2% 0.9 4.7 0.8 9.1 1.4 5.8 0.2 1.1 0.4 1.9     
Brandenburg  3% 1.3 0.5 2.8 4 1.8   0.3   0.2   0.7   
Heidelberg  13% 0.7 0.5   0.2     0.2 2.4   1.1   5.5 
Gallinarum 0%   0.1         0.7 2.2     1.8 13.5 
Hadar 31% 0.9 0.8         1.5 2.5 2 2.8 0.7   
Indiana  10% 0.2 0.2         1.1 2 0.9 2.4 0.2   
Agona 26% 0.4 0.5 0.5 1.2     2.7 1.5 1.5 1.9 4.2 0.6 
London  4% 0.6 0.2 0.8 3.4 0.4 0.3 0.6 0.7 1.1 1.3 0 0 
Thompson 12% 0.1 0.2   0.5 0.7   0.2 1.1 0.2 0.4 0.4 4.9 
Kentucky  36% 1.1 1.1     0.4   1.7 0.5 1.1 0.4 3.1 1.8 
Anatum 25% 0.4 0.3 5.2 0.3 5.3   0.7 1.4 1.3 1.9     
Saintpaul 32% 0.8 0.6   0.2   0.3 0.3 2.2 0.5 2.8   0.6 
Montevideo  17% 0.3 0.4   1 0.4 1.3 0.9 0.2 0.7   1.1   
Goldcoast 4% 0.5 0.4 0.3 1.4 1.4 1.6 0.2 0.1 0.2 0.2 0.2   
Panama  4% 0.5 0.4 3.2 1.4   0.6 0.2   0.2     0 
Bovismorbificans 10% 0.4 0.3 0.7 1.4 0.4 0.3 0.2 0.3 0.5 0.2   1.2 
Newport  21% 0.7 1.1 1 0.2 0.4   0.2   0.2       
Corvallis  28% 0.9 0.7         1.2 0.3 1.8       
Stanley  28% 0.5 0.5         0.1 0.3   0.4 0.2   
(Para)Typhi (A B 
C) 33% 2 1.9                     
Other   8.1 10.2 12.5 8.4 14.4 3.2 14.4 6.1 17.9 8 11.8 6.1 
 
Typing results of the Dutch Salmonella Reference Laboratory (RIVM, Bilthoven). Isolates are from 
different sources and programs. Poultry: all chicken categories together; Broilers: including chicken 
products; Layers: including reproduction animals and eggs.  
 
 
                                                     
16 Source: Report on trends and sources of zoonotic agents in the EU, 2007, The Netherlands 
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Table 10. MIC distribution (in %) and resistance percentages (R%) for all salmonella’s (N = 4642) tested 
for antibiotic susceptibility in 2006/2007. 
Salmonella
N = 4642 0.015 0.03 0.06 0.13 0.3 0.5 1 2 4 8 16 32 64 128 256 512 1024 2048
Ampicillin 15.2 57.6 6 0.6 0.1 0.1 2.2 18.2 20.6
Cefotaxime 5.2 83.7 7.9 1.4 0.1 0.1 0.3 0.2 0.9 1.7
Ceftazidime 11.7 65.9 19 1.6 0.2 0.2 0.1 0.2 1 1.5
Gentamicin 31.8 56 10.1 0.6 0.4 0.5 0.3 0.3 1.5
Neomycin 89 8.5 0.6 0.2 0.5 0.5 0.7 1.9
Tetracycline 0.1 20.3 53.9 5.3 0.5 0.1 3.7 3.3 12.8 20
Sulphamethox. 43.7 34 0.7 0.1 0.1 21.4 21.6
Trimethoprim 84.8 1.9 0.2 2.1 11.1 13.2
Ciprofloxacin 0.5 8.5 77.7 2 6.2 2.9 1.5 0.3 0.1 0.1 0.2 13.3
Nalidixic acid 20 61.8 5.3 1 0.1 0.1 2.2 9.6 12
Chloramphenicol 0.1 4.4 72.8 15.7 0.4 1.2 5.4 7
Florfenicol 0.5 38.2 53 3.3 1.3 2.7 0.4 0.5 4.9
Streptomycin 8.2 20.1 21.9 23.4 10.2 4.1 3.9 8.2 16.2
Kanamycin 87.4 7.4 1.3 0.2 0.2 3.5 5.2
Colistin 100 0
MIC (%) distribution mg/L
R%
 
The white areas indicate the dilution range tested for each antimicrobial agent. Values above this range indicate 
MIC values > the highest concentration in the range. Values at the lowest concentration tested indicate MIC-
values ≤ the lowest concentration in the range. The vertical bars indicate the epidemiological cut-off values we 
used the calculate the resistance percentages, the dashed bars indicate clinical breakpoints. 
 
Table 10 presents MIC-distributions and resistance percentages of all salmonella’s tested for 
susceptibility in 2006/2007. Highest levels of resistance were observed for ampicillin, tetracycline, 
sulphamethoxazole, streptomycin and to a lesser extend chloramphenicol, ciprofloxacin, nalidixic acid 
and trimethoprim. 
In 2006/2007 81 cefotaxime resistant, ESBL suspected strains were found, which was substantially 
more than in 2004/2005 (n = 21). The isolates belonged predominantly to the serovar S. Java (63%, N 
= 51) of which only 1 strain was isolated from a human source and the other 50 all from poultry 
sources. Other ESBL-suspected serovars were Agona, Braenderup, Concord, Cubana, Enteritidis Pt1, 
Pt4, Pt6a, Indiana, Infantis, Saintpaul, Senftenberg, Typhimurium Ft 508, Ft80 and Virchow. Of all 
these ESBL suspected salmonella’s 19.7% (N = 16) were isolated from humans and the rest almost all 
from poultry sources. Thirty six of these isolates (44%) were resistant to nalidixic acid and also 
showed increased MICs for ciprofloxacin (MIC 0.25 – 2 mg/L). Four isolates (3 Concord and 1 
Senftenberg) showed a phenotype typical for the presence of plasmid mediated quinolone resistance 
(MIC ciprofloxacin 0.5 – 1 mg/L and nalidixic acid 8 – 16 mg/L). The presence of qnr-genes was 
confirmed by pcr.  
Resistance to cefotaxime is increasing at an alarming rate. The isolates from humans originate partly 
from exotic sources (eg. Africa), but also from poultry. In animals poultry is up to now the only 
reservoir for ESBL-producing salmonella’s.  
 
Using the epidemiological cut off value of 0.06 mg/L, 618 isolates were detected that demonstrated a 
non-wild type phenotype for ciprofloxacin. Of these, 32 (0.7%) sowed MICs larger that the clinical 
breakpoint (1 mg/L). The serovars of these ciprofloxacin resistant isolates were predominantly S. 
Kentucky (50%) and S. Java (25%). Since 2002 annually high-level ciprofloxacin resistant S. 
Kentucky’s were isolated from human patients. These strains are related to travel to North African 
countries and genetically closely related because they all harbour a class 1 integron with gene cassettes 
aacC-A5 and aadA7 encoding for aminoglycoside resistance, moreover these isolates mostly harbour 
an incomplete Salmonella genomic island 1, failing the multi-drug resistance region resulting in the 
typical ACSSuT phenotype. 
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Table 11. Resistance (%) of the thirteen most prevalent Salmonella serovars isolated in The Netherlands 
in 2006/2007. 
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9)
 
H
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 (6
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Ampicillin 45.8 5.2 58.6 1.6 0.5 20.6 36.4 11 1.3 82.9 10.0 5.8 33.3 
Cefotaxime 0.2 0.5 24.3 0 0.5 5.2 3 1.2 0 0 0 0 0 
Ceftazidime 0 0 21.4 0 0.5 3.9 3 1.2 0 0 0 0 0 
Gentamicin 0 0 2.4 1.1 1.1 1.3 4 1.2 0 2.6 0 1.4 1.5 
Neomycin 1.6 0 5.6 0.5 0.6 3.0 22.7 0 0 3.8 4.5 1.7 0 
Tetracycline 48 1.6 24.3 2.1 1.1 6.5 28.3 4.9 1.3 82.9 31.4 2.9 89.4 
Sulphamethox. 46.5 1.4 56.2 7 2.2 19.4 45.5 13.4 2.6 85.5 24.3 7.2 22.7 
Trimethoprim 15.5 1 93.8 1.6 2.2 16.1 45.5 9.8 1.3 11.8 20 7.2 21.2 
Ciprofloxacin 3.7 13.5 53.3 3.7 3.8 10.3 77.8 6.1 7.7 2.6 2.9 1.4 81.8 
Nalidixic acid 2.8 12.9 47.1 3.2 2.7 9.0 77.8 4.9 6.4 2.6 2.9 1.4 81.8 
Chloramphenicol 21.4 0 2.4 5.9 0.5 3.2 7.1 4.9 3.8 7.9 4.3 4.3 0 
Florfenicol 19.3 0 0 0 0 1.3 0 1.2 1.3 0 2.9 0 0 
Streptomycin 40.9 0 38.8 20 0 13.6 18.2 0 8.3 75.0 0 0 66.7 
Kanamycin 6.1 1 10.2 0 0 0 9.1 0 8.3 8.3 0 0 33.3 
Colistin 0 0 0 0 0 0 0 0 0 0 0 0 0 
  
 
In table 11 resistance percentages are presented for the twelve most prevalent serovars isolated in The 
Netherlands in 2006/20075. The highest resistance levels are observed in S. Typhimurium, S. Java, the 
monophasic S. enterica subspecies enterica 1,4,[5],12:i:-, S. Hadar  and S. Virchow.  
 
S. Enteritidis 
In table 12 resistance percentages for S. Enteritidis and it most prevalent phage types are presented. In 
The Netherlands, human infections caused by S. Enteritidis are predominantly related to the 
consumption of raw shell eggs. In Dutch broilers and broiler products the prevalence of S. Enteritidis 
is lower (Tables 9 and 15). The difference in phage type distribution and resistance profile of strains 
from human infections and Dutch poultry indicates that other sources of infection exist. In 2006/2007 
from human infections, 122 ciprofloxacin non wild type susceptible strains were isolated, 
predominantly Pt1 (48%) and to a lesser extend Pt4 (16%). In Dutch layers in 2005 for the first time 
ciprofloxacin non-wild type strains were found (37%). Of the isolates 66% was Pt 4 and 2% Pt1. In 
2006/2007 from Dutch layers only 2 ciprofloxacin reduced susceptible S. Enteritidis isolates were 
detected (Fig. 10).  
The sudden high level of resistance in S. Enteritidis Pt4 from layers in 2005 was a very striking 
observation. Quinolone resistance is not likely to be selected through usage in layers because in these 
animals the use of fluoroquinolones or flumequine is not licensed. Therefore, the most likely 
explanation for this phenomenon was incidental introduction of quinolone resistant S. Enteritidis Pt4 
by importation of contaminated eggs or breeding animals, which was repaired in 2006/2007. 
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Table 12. Resistance (%) of S. Enteritidis and phagetypes 4, 21, 6, 1 and 8 isolated from different sources 
in 2006/2007. 
  S. Enteritidis Most prevalent phage types 
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Ampicillin 5.4 4 4 2 2 5.7 5.2 1.1 
Cefotaxime 0.4 0 4 0 0 0 2 0 
Ceftazidime 0.3 0 4 0 0 0 2 0 
Gentamicin 0 0 0 0 0 0 0 0 
Neomycin 0.1 0 0 0 0 0 0 0.0 
Tetracycline 1.7 0 0 0 1 1 3 0 
Sulphamethoxazole 1.5 0 0 1 1 0.8 5.2 0 
Trimethoprim 1 0 4 0.7 1 0.8 2.1 0.0 
Ciprofloxacin 12.9 7.4 42 6 10 3.3 64.9 3.4 
Nalidixic acid 12.3 7.4 42.3 5.3 10.1 2 62.9 3 
Chloramphenicol 0.4 0 0 0.2 0.0 0 3.1 0 
Florfenicol 0.2 0 0 0 0 0 1 0 
Streptomycin 0 - - 0 0 0 0 0 
Kanamycin 0.8 - - 0 0 0 7.1 0 
Colistin 0 - - 0 0 0 0 0 
  
 
Resistance to the quinolones (ciprofloxacin and nalidixic acid) is stable in the last three years in 
isolates from humans (Fig. 10). The increase in cipro/Nal resistance % in other poultry sources in 
2006/2007 is affected by the small numbers tested. These strains were mainly isolated from poultry 
meat. 
It can be concluded that quinolone resistant strains of S. Enteritidis isolated from humans primarily 
originate from other sources than Dutch layers, like imported eggs, travel related infections and only 
to a lesser extend consumption of poultry meat products.  
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Figure 8. Trends in resistance (%) of S. Enteritidis isolated from humans, layers and other poultry sources 
from 1999 - 2007  
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S. Typhimurium 
In 2006/2007 the most predominant phage types of S. Typhimurium in the collection of strains 
received from RIVM Bilthoven were: FT 506 (≈ DT104), FT 507 and FT 560 (table 13).  
 
Although in S. Typhimurium resistance commonly present, resistance to quinolones occurs less 
frequently and ESBL suspected strains are rare, in comparison to other serovars.  The most likely 
reason is that S. Typhimurium is more prevalent in pigs and cattle, where ESBLs are less common in 
the commensal gut flora and quinolones are used less frequently. 
 
In 2006/2007 39 non ciprofloxacin wild type susceptible to ciprofloxacin S. Typhimurium isolates 
were found (MIC above the epidemiologic cut-off value), predominantly as human clinical isolates (69 
%). Nineteen of these isolates were DT104 (38%). Although  none of these isolates was high-level 
ciprofloxacin resistant, the reduced susceptibility to ciprofloxacin indicates a poor response to therapy 
with fluoroquinolones in case of invasive infections. This is an expert rule for the interpretation of 
MIC data on ciprofloxacin for Salmonella  (www.eucast.org). 
 
Resistance levels and multiple resistances are substantially higher in S. Typhimurium than in S. 
Enteritidis (Table 11, figures 8 and 10). Of the strains, 40% (humans),57%(pigs), 48% (poultry) and 
39% (cattle) were resistant to three or more antibiotic classes (Fig. 9).  
 
Resistance in S. Typhimurium shows a tendency to increase in strains from pigs (Fig. 12). 
The relatively small number of the isolates per year and the differences in proportion of multi drug 
resistant phage types per category and per year affect the trend analysis.  
 
 
Table 13.  Resistance percentages of S. Typhimurium and phage types DT104, Ft 507, and FT560 isolated 
from different sources in 2006/2007. 
  S. Typhimurium Phage types 
  H
um
an
 (7
28
) 
C
at
tle
 (5
9)
 
Pi
gs
 (1
59
) 
Po
ul
tr
y 
(3
5)
 
D
T1
04
 (2
26
) 
Ft
 5
07
 (2
87
) 
FT
 5
60
 (1
87
) 
Ampicillin 42.9 55.9 57.2 57.1 83.6 60.6 3.7 
Cefotaxime 0.3 0.0 0.0 0.0 0.0 0.0 0.0 
Ceftazidime 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Gentamicin 0.5 0.0 0.0 0.0 0.4 0.0 0.0 
Neomycin 1.6 0.0 0.7 11.4 0.0 4.3 0.0 
Tetracycline 44.1 45.8 69.2 60.0 81.9 63.1 3.7 
Sulphamethoxazole 43.1 42.4 64.2 57.1 91.6 55.4 5.3 
Trimethoprim 13.2 11.9 28.9 14.3 8.8 24.7 4.8 
Ciprofloxacin 3.7 1.7 2.5 2.9 8.8 3.1 2.1 
Nalidixic acid 3.0 1.7 1.9 2.9 8.8 2.4 0.0 
Chloramphenicol 18.5 23.7 30.8 25.7 77.4 4.5 0.0 
Florfenicol 16.5 22.0 28.3 25.7 77.0 1.0 0.0 
Streptomycin 43.5 - 37.5 - 90.0 44.8 - 
Kanamycin 4.3 - 0 - 0 10.3 - 
Colistin 0 - 0 - 0 0 - 
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Figure 9. Percentages of S. Typhimurium and S. Enteritidis strains fully susceptible, resistant to one to 
nine different antibiotic classes in human and animal sources in The Netherlands in 2006/2007. 
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Multi drug resistance is more common in Typhimurium compared to Enteritidis, which is 
predominantly caused by the frequent occurrence of multiresistant phage types like DT104 (fig. 11). In 
Enteritidis resistance is mostly limited ton one or two antibiotic classes. In Pt1 the highest incidence of 
multiresistance is observed. This phage type is related to the Iberian peninsula, which may explain the 
higher resistance percentages. 
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Figure 10. Trends in resistance (%) of S. Typhimurium isolated from humans and food-animals from 
1999 - 2007
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S. Paratyphi B var. Java (S. Java) 
The prevalence data from the Dutch salmonella reference laboratory (RIVM) in the 2006/2007 show 
that S. Java in 2006/2007 was still the most predominant serovar in broiler production. This is 
confirmed by the isolation rate of 63% of this serovar from poultry products in 2007.  
In 2006/2007 12 S. Java were isolated from a human infections. The majority were fully susceptible to 
all antibiotics in the panel and therefore not related to the clone spreading in Dutch poultry. However, 
one isolate was ESBL positive and also high level resistant to fluoroquinolones (Cipro MIC 2 mg/L). 
From poultry 129 strains were isolated of which 98% harboured the phenotype typical for the clone. 
 
Non wild type susceptibility to ciprofloxacin in S. Java isolated from poultry increased to 58% (N = 
76). In 2006/2007 for the first time 6 isolates were found with high level resistance to ciprofloxacin.  
 
Resistance to cefotaxime (ESBL-producers) shows a clear increase in 2006/2007. This is related to the 
increase in ESBLs in commensal E. coli from broilers, by horizontal transfer of plasmid mediated 
beta-lactamases. Third-generation cephalosporins are not used in broiler production, but the use of 
ceftiofur in combination with Marek vaccine or with in ovo vaccination is a common procedure in the 
poultry reproduction and breeding sectors. It is likely that this has contributed to selection and vertical 
transmission of ESBLs in the poultry production pyramid. 
 
Resistance to tetracycline shows a similar tendency to increase as observed for cefotaxime. This 
indicates acquisition of tet-genes in the Java clone in The Netherlands. 
In 2006/2007 we included streptomycin in the panel of antibiotics. Virtually all poultry isolates were 
resistant, which is related to the aadA1-gene in the class-2 integron typical for the clone. 
 
 
Figure 11. Trends in resistance (%)  of S. Paratyphi B var. Java isolated from poultry from 1999 – 2007 
and humans (Grey-white dashed bars indicate all humans S. Java isolates from 1999 – 2007 (N = 36))  
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Salmonella in raw meat products of food-animals at retail 
Table 14. Resistance (%) of Salmonella enterica isolated from raw meat from poultry, and other raw meat 
sources in 2006/2007. 
 
Poultry 
S. Java 
N = 46 
Poultry  
other serovars 
N = 96 
Other  
Raw meat sources 
N = 35 
Ampicillin 61 42 34 
Cefotaxime 9 3 
Ceftazidime 10 4 
Gentamicin 0 4 
Tetracycline 22 28 
Sulfamethoxazole 61 47 60 
Trimethoprim 98 41 
Ciprofloxacin 63 44 
Nalidixic acid 61 43 11 
Chloramphenicol 2 6 
Florfenicol 0 3 
Streptomycin 26 29 
Kanamycin 10 14 
Colistin 0 0 
0 
0 
3 
43 
20 
9 
29 
11 
30 
7 
0 
  
In 20056/2007, as in previous years, in raw meat products originating from poultry S. Java was still by 
far the most prevalent serovar isolated. Almost all S. Java’s were resistant to trimethoprim, typical for 
the clone. Resistance levels for the quinolones were similar as observed in isolates from broilers. 
Resistance to cefotaxime was less predominant than in isolates from live animals.  
Resistance trends are presented for poultry products only, because in beef and pork the numbers of 
isolates examined are too small to provide an accurate estimate (Fig. 12). The variable contribution of 
S. Java to the annual resistance percentages over all serotypes hampers the interpretation of the 
observed trend in the resistance. 
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Figure 12. Trends in resistance (%) of Salmonella enterica isolated from poultry products in the 
Netherlands from 2001 – 2007. 
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Table 15. Distribution of Salmonella serovars, in poultry meat at retail (Surveillance data of Food and 
Consumer Product Safety Authority (VWA-KvW)) from 1997 tot 2007 
 
  1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 
N 1314 1077 859 1454 1578 1600 1510 1482 1474 1410 1395 
Salmonella spp. 
positive (%) 29.1 20.2 17.6 21 16.3 13.4 11.3 7.4 9.4 8.4 8.2 
  Main serovars as a fraction of all isolates (%) 
Paratyphi B var. 
Java 15.0 11.4 13.9 33.1 43.2 53.5 45.6 58.2 46.8 38.5 63.2 
Enteritidis 20.2 12.8 26.4 6.6 8.2 2.3 8.8 5.5 7.2 6.6 1.8 
Hadar 10.1 6.1 4.5 3.3 4.2 0.9 1.8 - 1.4 5.7 - 
Indiana 6.1 8.3 9.3 10.2 11.6 6.5 6.4 1.8 2.2 4.1 5.3 
Infantis 9.2 5.0 3.6 6.6 7.0 7.9 11.7 - 11.5 13.9 10.5 
Virchow 4.6 2.8 2.6 10.2 3.5 5.6 5.8 4.5 8.6 11.5 3.5 
Typhimurium 
(DT104) 7.8 
3.6 
(1.8 
1.3 
(0.7) 
0.1 
(0.1) 
7.4 
(7) 
7.4 
(2.8) 
5.8 
(5.3) 3.6 
5 
(2.2) 1.6 0.9 
Corvallis         4.3 1.6 - 
Other  types  27.0 53.6 39.7 30.0 22.3 23.3 19.9 26.4 18.0 16.5 14.8 
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Salmonella in animal feeds, turkeys, horses, ducks, pigeon and reptiles 
Table 16 presents the most prevalent serovars found in animal feeds from 2001 – 2007 per single and 
or compound feed type. Moreover R% of Salmonella strains isolated from incidental animal sources 
are presented. The serotypes Senftenberg, Agona, Lexington, Mbandaka and Rissen are most 
frequently isolated from animal feeds. Resistance in these serovars is very uncommon, except 
tetracycline resistance.  
In salmonella’s isolated from turkeys, horses and ducks, more resistance was observed than in strains 
from pigeons or reptiles. Nalidixic acid and ciprofloxacin resistance was highest in turkeys and ducks, 
animals with a substantial consumption of quinolones (only fluoroquinolones are licensed for use in 
Turkeys).  
 
Table 16. The most prevalent serovars isolated from animal feed and resistance (R%) of isolates of 
Salmonella enterica per single and or compound feed type,  in 2001 – 2007. Moreover R% of Salmonella 
strains isolated from incidental animal sources over 2001 – 2007 are presented. 
 
Serovar N 
  
Fi
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 m
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Fe
ed
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0 
Fe
ed
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00
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20
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, N
=1
41
4 
Tu
rk
ey
 (9
4)
 
Ho
rse
 (4
5)
 
Du
ck
 (1
1)
 
Pi
ge
on
 (4
5)
 
Re
pt
ilia
n/
Am
fib
ian
 (6
9)
 
Senftenberg 255  Antibiotics %-resistant isolates 2001-2007 %R %-resistant 2001-2007 
Agona 211 ampicillin 0 1.5 0.5 0.9 1.8 1.6 0.6 1.0 44.7 20.0 9.1 11.1 1.4 
Mbandaka 183 cefotaxime 0 0 0.2 0 0 0.8 0.4 0.1 2.1 0 0 0 0 
Lexington 169 ceftazidime 0 0 0.3 0 0 0 0.2 0 2.9 0 0 0 -- 
Rissen 132 imipenem 0 0 0 0 0 0   0 0 0 0 0 0 
Cubana 125 gentamicin 0 0 0 0 0.3 0 0.0 0.1 13.8 0 0 0 0 
Livingstone 93 neomycin 0 0 0.2 0 0.6 0 0.9 0 14.9 0 0 0 0 
Tennessee 85 tetracycline 0 1.5 0.8 0.3 1.8 5.5 0.6 1.4 42.6 17.8 9.1 6.7 2.9 
Anatum 77 trim/sulpha 0 0 0.5 0 0.8 0   0.4 0.0 33.3 -- 0.0 0.0 
Havana 64 sulphamethoxazole 0 0 0.5 2.1 2.4 4.8 0.9 1.7 38.0 11.1 0 9.1 -- 
Kentucky 56 trimethoprim 0 1.5 0.4 0.9 0.6 2.3 0.6 0.7 12.8 17.8 0 0 0 
Oranienburg 41 ciprofloxacin 1.8 1.5 0.2 0 0.9 3.1 1.1 0.4 46.8 2.2 18.2 0 0 
Montevideo 37 nalidixic acid 0 1.5 0.1 0 0.9 2.3 0.9 0.3 40.4 2.2 18.2 0 0 
Infantis 36 chloramphenicol 0 1.5 0.6 0.9 2.7 3.1 1.5 1.1 6.4 15.6 0 11.1 1.4 
Minnesota 34 florfenicol 0 0 0.5 0.9 0.9 0 0.6 0.6 4.3 6.7 0 11.1 1.4 
Cerro 32 streptomycin -- -- 4.2 -- 10.0 -- 5.6 -- 66.7 -- -- -- -- 
Yoruba 29 kanamycin -- -- 8.3 -- 20.0 -- 11.1 -- 83.3 -- -- -- -- 
17 main serotypes 1659 (83%)                             
All serotypes 1988               
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Campylobacter spp. 
 
Highlights 
In C. jejuni  resistance levels for ciprofloxacin and nalidixic acid were substantially higher than in previous 
years, in particular in broilers. At the same time in human isolates a substantial increase in resistance to 
fluoroquinolones was observed. In 2007 for the first time an erythromycin resistant C. jejuni strain was isolated 
from a cow. Erythromycin resistance is however a regular finding in humans to some extent travel related or 
related to consumption of contaminated imported products, or due to human therapeutic use of macrolides 
In C. coli resistance to macrolides occurred frequently. In 2006/2007 for the first time next to erythromycin, the 
related antibiotics clarithromycin and tulathromycin were included in the tests. The resistance levels were 
slightly different from erythromycin, which is probably due to the cut-off values used.  
 
Table 17. MIC distribution (in %) for all C.  jejuni (N = 182, of which 60 from broilers, 53 from dairy 
cows, 1 from pigs and 68 from veal calves) and C. coli (N = 320, of which 143 from pigs, 32 from broilers, 
10 from cattle and 135 from veal calves) isolated from poultry, pig and cattle faeces in The Netherlands in 
2006/2007. 
C. jejuni MIC (%) distribution 
(N = 182) 0.125 0.25 0.5 1 2 4 8 16 32 64 128 256 512 1024 2048 R% 
Ampicillin     0.5 3.3 4.9 50.5 18.1 2.2 3.3 17.0           20.3 
Gentamicin   91.2 8.2 0.5                       0.0 
Neomycin     69.2 22.0       2.2 4.4 1.6 0.5         8.8 
Strepomycin       95.1 1.6   0.5 0.5 1.6     0.5       3.3 
Tetracycline     47.3 1.1 2.7 1.1   0.5 1.6 12.6 33.0         48.9 
Trim/sulphamethoxazole       6.2 46.2 38.5 4.6   3.1 1.5           4.6 
Sulphamethoxazole             10.4 8.2 18.1 41.8 13.7 3.8 2.2 1.6   3.8 
Ciprofloxacin 46.2 12.1 4.4     1.1 7.7 17.6 11.0             37.4 
Nalidixic acid       0.5 14.3 38.5 7.7 1.6   0.5 8.8 28.0       37.4 
Erythomycin     11.5 33.0 38.5 14.8 1.6       0.5         2.2 
Clarithromycin     13.7 26.5 44.4 14.5 0.9                 0.0 
Tulathromycin     65.8 32.5 1.7                     0.0 
Chloramphenicol         30.8 54.9 8.8 5.5               0.0 
C. coli MIC (%) distribution 
(N = 320) 0.125 0.25 0.5 1 2 4 8 16 32 64 128 256 512 1024 2048 R% 
Ampicillin     1.6 5.3 8.1 26.6 28.8 19.4 2.2 8.1           29.7 
Gentamicin   59.7 30.9 6.9   0.3       2.2           2.5 
Neomycin     48.1 34.1 0.9 0.6 1.6 0.3 2.2 3.8 8.4         16.9 
Strepomycin       29.4 5.9 0.9 3.4 15.3 21.6 12.2 2.8 8.4       63.8 
Tetracycline     10.0 2.8 0.6   0.3   0.6 9.1 76.6         86.6 
Trim/sulphamethoxazole   0.8 3.4 21.0 29.4 6.7   5.9 22.7 10.1           38.7 
Sulphamethoxazole             12.5 12.5 18.4 7.8 0.9 2.8 23.8 15.3 5.9 45.0 
Ciprofloxacin 40.0 14.1 2.5 0.3 0.3 1.6 9.1 17.8 14.4             43.1 
Nalidixic acid         2.2 28.1 23.1 3.4 0.6 5.0 19.1 18.4       43.1 
Erythomycin     4.7 10.9 17.8 34.7 11.9 1.3 1.6 0.3 16.9         18.8 
Clarithromycin     8.0 13.9 21.4 30.3 8.5 1.5 0.5   15.9         17.9 
Tulathromycin     35.8 35.4 7.5 3.3 0.5 0.5 0.9 4.2 11.8         17.0 
Chloramphenicol         5.5 34.0 51.8 7.8 0.6 0.3           1.0 
 
The white areas indicate the dilution range tested for each antimicrobial agent. Values above this range indicate 
MIC values > the highest concentration in the range. Values at the lowest concentration tested indicate MIC-
values ≤ the lowest concentration in the range. Vertical bars indicate the epidemiological cut-off values, used as 
breakpoints. 
 
Table 17 presents the MIC-distributions and resistance percentages for all Campylobacter jejuni and 
C. coli strains isolated in 2006/2007. In C. jejuni highest resistance levels are observed for tetracycline 
and the quinolones. In 2007 for the first time an erythromycin resistant C. jejuni strain was isolated 
from a cow. C. coli  showed much more resistance and at higher levels than C. jejuni. 
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In C. jejuni from poultry the resistance levels in isolates from broiler faeces and from poultry raw meat 
products sampled by the Dutch Food Safety Authority at retail are very similar except for 
sulphamethoxazole, for which the levels were much higher in isolates from products (table 18). 
This was expected for isolates from broiler faeces and poultry raw meat products because they should 
represent the same bacterial populations. In C. jejuni  resistance levels for ciprofloxacin and nalidixic 
acid were substantially higher that in previous years. This may be caused by a true increase of 
resistance or by selection bias. In 2006/2007 the samples from which campylobacter was isolated were 
partly taken as part of the national control program and partly as part of the EU-baseline study in 
poultry. In isolates from cattle the resistance levels reflect the use patterns of antibiotics. Tetracycline 
and to a lesser extend quinolone resistance is highest in veal calves. 
 
In C. coli resistance to macrolides occurred frequently. In 2006/2007 for the first time next to 
erythromycin, the related products clarithromycin and tulathromycin were included in the tests. The 
resistance levels were slightly different from erythromycin, which is probably due to the cut-off values 
used.  
 
Table 18. Resistance percentages of C. jejuni and C. coli isolated from broilers, raw meat products from 
poultry in 2006/2007 
 
 C. jejuni from broilers resistance levels of ampicillin, tetracycline and the quinolones have 
 
e 18 
 
 
 
 
 
In
increased since 2000. In C. coli from pigs the resistance levels are stable except resistance to 
erythromycin, which increased again after a decrease in the past years.  This may be related to
increased therapeutic usage of macrolides (tylosin, mycotil) (fig 13). The resistance data in tabl
reflect the use patterns of the antibiotics in different animal species. The quinolone resistance levels 
are highest in veal calves and broilers, the animals in which this drug class is predominantly used. 
 
 
 
 
 
 
Broilers Poultry products Pigs Veal calves Dairy cows 
 
C. jejuni C. coli C. jejuni C. coli C. coli C. jejuni C. coli C. jejuni C. coli 
N 98 32 156 106 143 68 135 53 10 
Ampicillin 53.1 40.6 43.0 26.2 16.8 13.2 38.5 0 60 
Gentamicin 1.0 0 0.6 0 0 0 5.9 0 0 
Neomycin 4.1 3.1 7.4 2.9 4.9 14.7 34.1 3.8 0 
Streptomycin 3.1 0 1.3 21.4 75.5 5.9 68.9 1.9 30 
Tetracycline 52.0 53.1 42.3 59.2 86.7 80.9 98.5 7.5 30 
Trim/sulphamethoxazole 13.3 6.3 - - 55.0 3.4 34.4 0 25 
Sulphamethoxazole 3.1 6.3 31.5 12.6 55.9 1.5 43.7 5.7 30 
Ciprofloxacin 63.3 75.0 43.6 67.0 9.8 39.7 72.6 13.2 20 
Nalidixic acid 62.2 78.1 42.3 66.0 9.8 39.7 71.9 13.2 20 
Erythromycin 3.1 9.4 0.7 7.8 21 2.9 19.3 1.9 10 
Clarithromycin 0 14.3 0.7 7.8 15.5 0 18.3 0 0 
Tulathromycin 0 14.3 0.7 7.8 18.4 0 19.7 0 0 
Chloramphenicol 0 0 0 0 0 0 2.2 0 0 
 
MARAN-2007 
 
 
 
 56 
C. jejuni
0
10
20
30
40
50
60
70
A
m
pi
ci
lli
n
G
en
ta
m
ic
in
N
eo
m
yc
in
St
re
pt
om
yc
in
Te
tra
cy
cl
in
e
Tr
im
/s
up
lh
a
S
ul
ph
am
et
ho
xa
zo
le
Ci
pr
of
lo
xa
ci
n
N
al
id
ix
ic
 a
ci
d
Er
yt
hr
om
yc
in
C
hl
or
am
ph
en
ic
ol
R
es
is
ta
nc
e 
%
2000 (117)
2001 (149)
2002 (44)
2003 (48) 
2004 (57)
2005 (78)
2006/2007 (98)
C. coli
0
10
20
30
40
50
60
70
80
90
100
Am
pi
ci
lli
n
G
en
ta
m
ic
in
Ne
om
yc
in
S
tre
pt
om
yc
in
Te
tra
cy
cl
in
e
Tr
im
/s
up
lh
a
S
ul
ph
am
et
ho
xa
zo
le
C
ip
ro
flo
xa
ci
n
N
al
id
ix
ic
 a
ci
d
E
ry
th
ro
m
yc
in
C
hl
or
am
ph
en
ic
ol
R
es
is
ta
nc
e 
%
2000 (127)
2001 (173
2002 (64)
2003 (193)
2004 (198)
2005 (153)
2006/2007 (143)
Poultry 01- 07 (111)
Figure 13. Trends in resistance (%) of C. jejuni  isolated from broilers and C. coli isolated from 
slaughter pigs  and broilers (grey striped bars), from 2000 - 2007 in The Netherlands 
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Figure 14. Trends in resistance (%) of Campylobacter spp. isolated from humans isolated between 1992 
and 2007 at the regional Public Health Laboratories (PHLS) of Arnhem and Heerlen covering 990.000 
inhabitants. The dotted line represents data from the national surveillance in 1992 – 2007, the continuous 
line represents national surveillance data; annually the average number of strains tested was 
approximately 2400, ranging from 1900 – 2900.  
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In Campylobacter spp. isolated from humans, resistance to fluoroquinolones has again increased., like 
in broilers, in particular between 2005 and 2006.  Resistance to erythromycin remains rare (fig. 14).  
Table 19 shows that as was found in previous years, in travel-related infections fluoroquinolone 
resistance occurred more frequently than in isolates from domestically acquired infections, for 
tetracycline this difference was observed for C. jejuni only.  
 
 
 
Table 19. Domestically acquired and travel related resistance in C. jejuni and C. coli isolated from humans 
 
from 2002 - 2007 from all 16 PHLS covering > 50% of the Dutch population. 
 C. jejuni strains isolated from Dutch poultry until 2005 not one high level erythromycin resistant In
strain has been detected. Therefore human infections with C. jejuni strains resistant to erythromycin 
may be travel related or related to consumption of contaminated imported products, or due to human 
therapeutic use of macrolides.  
 
 2002-2005 2006-2007 
 Domestically acquired Travel related Domestically acquired Travel related 
 C. jejuni C. coli C. jejuni C. coli C. jejuni C. coli C. jejuni C. coli 
 N R% N R% N R% N R% N R% N R% N R% N R% 
Fluoroquinolone 6831 32,7 389 36 601 53,4 57 49,1 4763 43,7 327 42,5 269 63,6 32 68,8 
Tetracycline 5075 18,5 355 22,5 430 26,7 49 20,4 3262 21,5 257 26,5 154 29,2 31 19,4 
Erythromycin 5765 1,2 374 2,9 511 1,6 53 0 3784 1,8 282 5 212 3,8 29 10,3 
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Shigella toxin producing E. coli O157 
 
Highlights 
Resistance in E. coli O157 was traditionally rarely present.  In human isolates resistance levels were low. In  
isolates from calves however, resistance was quite commonly present, with levels varying from 0.7 – 20.7 %. In 
calves one ESBL suspected isolate was detected.  
No clear trends in resistance can be observed. The levels vary from year to year. 
 
Table 20. MIC distribution (in %) for E. coli O157 isolated in The Netherlands in 2006/2007 from human 
(N = 137) and cattle faeces (N = 142) 
N = 137
0.015 0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 128 256 512 1024 2048
Ampicillin 34.3 62.0 2.2 1.5 3.6
Cefotaxime 56.9 43.1 0
Ceftazidime 22.6 73.0 4.4 0
Gentamicin 20.4 64.2 13.1 2.2 0
Neomycin 91.8 4.1 2.0 2.0 2.0
Tetracycline 0.7 92.7 2.9 0.7 2.9 3.6
Sulphamethoxazole 92.7 7.3 7.3
Trimethoprim 97.8 1.5 0.7 2.2
Ciprofloxacin 6.6 57.7 35.0 0.7 0.7
Nalidixic acid 21.2 76.6 2.2 0
Chloramphenicol 16.1 80.3 2.9 0.7 0.7
Florfenicol 4.4 83.2 10.9 1.5 1.5
Streptomycin 2.3 80.7 10.2 1.1 2.3 3.4 6.8
Kanamycin 93.2 4.5 1.1 1.1 2.2
Colistin 100 0
N = 142
0.015 0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 128 256 512 1024 2048
Ampicillin 23.2 59.2 0.7 12.7 4.2 16.9
Cefotaxime 50.7 48.6 0.7 0.7
Ceftazidime 23.9 73.9 1.4 0.7 0.7
Gentamicin 6.3 71.8 18.3 1.4 0.7 0.7 0.7 2.1
Neomycin 81.8 9.1 1.8 3.6 3.6 7.3
Tetracycline 0.0 76.1 14.1 2.1 7.7 9.9
Sulphamethoxazole 80.3 19.7 19.7
Trimethoprim 88.7 2.1 5.6 3.5 9.2
Ciprofloxacin 7.0 53.5 38.7 0.7 0.7
Nalidixic acid 28.2 70.4 1.4 0
Chloramphenicol 4.2 75.4 12.7 0.7 4.2 2.8 7.7
Florfenicol 8.5 81.7 8.5 0.7 0.7 1.4
Streptomycin 49.4 29.9 5.7 4.6 10.3 20.7
Kanamycin 85.1 6.9 1.1 6.9 8.0
Colistin 99 1.1 1.1
MIC (%) distribution mg/L
R%
MIC (%) distribution mg/L
R%
 
The white areas indicate the dilution range tested for each antimicrobial agent. Values above this range indicate 
MIC values > the highest concentration in the range. Values at the lowest concentration tested indicate MIC-
values ≤ the lowest concentration in the range. Vertical bars indicate the cut-off values used as breakpoints. 
Dashed bars indicate the clinical breakpoints. 
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Figure 15.  Trends in resistance percentages of E. coli O157 (STEC) isolated in The Netherlands from 
1998 - 2007 
Human STEC
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In 2006/2007, 279 isolates of notifiable Shi-toxin producing E. coli O157 (STEC) were sent to RIVM 
for routine typing. 137 specimens were taken from human and 142 from cattle faeces in an attempt to 
trace a human clinical infection (table 20).  
Resistance in E. coli O157 was traditionally rarely present and limited to isolates from sporadic cases. 
In cattle isolates however, resistance was quite commonly present, with levels varying from 0.7 – 20.7 
%. This includes one isolate demonstrating an ESBL-phenotype based on MICs for cefotaxime of 1 
mg/L and ceftazidime 4 mg/L (table 20). The cattle isolates originated predominantly from calves (N = 
117), which may explain the relatively high resistance levels. 
In 2006/2007 resistance levels were higher than in previous years for most antibiotics tested. This 
could indicate a trend, but could also be due to annual variations. The most striking differences were 
observed for ampicillin and sulphamethoxazole. Streptomycin was tested for the first year (fig. 15). In 
general the resistance levels were higher in isolates from animals that from humans. 
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Commensal indicator organisms 
 
The level of antimicrobial resistance in randomly sampled commensal organisms of the intestinal tract 
directly reflects the selection pressure as a result of the use of antibiotics as therapeutics in animals, 
especially over time. For this purpose, E. coli and Enterococcus faecium and E. faecalis, as indicator 
organisms for the Gram-negative and Gram-positive flora, are monitored. Isolation of bacteria from 
the intestine of randomly picked animals at slaughter aims to detect the development of resistance at 
the bacterial population level in food animals.  
In 2005 we started to monitor resistance in isolates from both dairy cattle and veal calves. For this 
purpose we used the samples that were taken at farms to determine the prevalence of Salmonella, E. 
coli O157 and Campylobacter.  
Resistance percentages in tables 21, 23 and 24 indicate the level of resistance in all E. coli, E. faecium 
and E. faecalis strains of slaughter pigs, broilers, dairy cows and veal calves, respectively. Because of 
the sampling strategy, this method is inherently insensitive for detecting resistance.  The method is 
insensitive because only one randomly selected isolate per epidemiological unit (herd or flock) is 
selected. The total sample of selected isolates is intended to represent the E. coli, or Enterococcus 
species population of each animal species of the entire Netherlands. One percent resistance in eg. E. 
coli indicates that in all animals 1% of the E. coli bacteria are resistant. Because each animal harbours 
app. 106 cfu/g faeces E. coli in its gut, 1% would be app. 104cfu/g faeces. This means that when no 
resistance is detected, this does not exclude the possibility that with selective enrichment resistance 
could be detected.  
 
Escherichia coli 
 
Highlights 
Overall, the resistance levels of food-borne commensal E. coli were highest in broilers and poultry raw meat 
products, followed by veal calves, slaughter pigs and dairy cattle, in which resistance is rare. In broilers and 
slaughter pigs, for most antibiotics the resistance levels show a tendency to increase. This increase is also 
obvious for multi-drug resistance. 
In broilers and poultry raw meat products resistance to cefotaxime indicative of extended spectrum beta-
lactamases (ESBLs), has increased from 9.7% in 2004 to almost 17% in 2006/2007. 
 
Traditionally in E. coli isolated from food-producing animals resistance to ampicillin, tetracycline, 
sulphamethoxazole and trimethoprim is very commonly present. In 2006/2007 for the first year 
streptomycin was included, which resulted in high resistance levels in all animals studied. (table 21). 
Overall, the resistance levels were highest in broilers, followed by veal calves, slaughter pigs and dairy 
cattle, in which resistance is rare.  
In broilers resistance to ciprofloxacin and nalidixic acid are stable at app. 50%.  However, high level 
ciprofloxacin resistance occurred in 6.5% of the isolates, which is substantially more than in 2006 
(2.6%)  
In broilers and slaughter pigs in particular, for most antibiotics the resistance levels show a tendency 
to increase, while in cattle the levels seem more stable (fig 17). This increase is also obvious for multi-
drug resistance, although the situation seems to stabilize somewhat in 2006/2007 at a high level except 
in dairy cattle where multi-drug resistance is rare. 
In broilers resistance to cefotaxime (and ceftazidime that was only tested in 2007), indicative of the 
presence of extended spectrum beta-lactamases (ESBLs), has increased from 9.7% in 2004 to almost 
17% in 2006/2007. The synchronous increase in cefotaxime resistance in Salmonella from poultry 
indicates transfer of plasmid mediated ESBLs between these species. 
The observed increase in chloramphenicol resistance demonstrates the complexity of the current 
resistance situation in broiler (fig 17). Chloramphenicol has been banned and not been used in almost 
20 years and still resistance increases. This is the result of integrons and plasmids on which 
chloramphenicol-resistance genes (catA) are linked to a.o. beta-lactamases, tetracycline- and 
sulphonamide resistance genes.  
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Table 21. MIC distributions (in %) for E. coli isolated as indicator organism from intestines of slaughter 
pigs (N = 248),  broiler chickens (N = 197), veal calves (N = 327) and dairy cattle (N = 280)  in The 
Netherlands in 2006/2007. 
0.015 0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 128 256 512 1024 2048
Ampicillin 3.6 30.6 29.4 0.4 0.4 11.3 24.2 35.9
Cefotaxime 26.6 72.2 0.4 0.4 0.4 0.8
Ceftazidime 49.6 48.0 1.6 0.8 0.8
Gentamicin 6.0 52.0 31.5 6.0 2.8 0.4 0.8 0.4 4.4
Neomycin 61.7 24.6 9.6 1 1.2 1.8 0.6 3.6
Tetracycline 6.5 13.7 7.3 0.8 2.0 3.6 25.4 40.7 71.8
Sulphamethoxazole 45.2 0.4 2.0 52.4 54.4
Trimethoprim 47.6 2.4 0.4 16.1 33.5 49.6
Ciprofloxacin 17.7 13.3 66.5 0.8 1.2 0.4 2.4
Nalidixic acid 54.8 41.9 1.2 0.4 1.6 2.0
Chloramphenicol 10.5 71.4 6.5 3.2 3.6 2.8 2.0 11.7
Florfenicol 0.4 22.6 68.5 8.1 0.4 0.4
Streptomycin 17.3 25.9 4.9 7.4 6.2 7.4 30.9 51.9
Kanamycin 60.5 25.9 8.6 1.2 3.7 13.6
Colistin 100 0.0
0.015 0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 128 256 512 1024 2048
Ampicillin 0.5 3.6 17.3 13.2 1.0 13.7 50.8 64.5
Cefotaxime 15.2 68.0 0.5 0.5 7.1 2.5 6.1 16.8
Ceftazidime 42.1 40.1 1.5 4.1 3.6 0.5 2.5 5.1 0.5 16.2
Gentamicin 4.1 48.2 35.5 5.6 1.5 2.0 2.5 0.5 6.6
Neomycin 59.7 21.4 2.6 2.6 7.1 3.9 2.6 16.2
Tetracycline 12.7 21.3 12.7 19.8 33.5 53.3
Sulphamethoxazole 31.0 3.0 66.0 69.0
Trimethoprim 37.6 2.5 1.0 11.2 47.7 58.9
Ciprofloxacin 3.0 8.1 39.1 5.1 27.4 8.6 2.0 0.5 2.0 1.0 3.0 49.7
Nalidixic acid 29.9 18.8 1.0 0.5 2.5 8.1 20.8 18.3 49.7
Chloramphenicol 21.3 68.5 9.1 0.5 0.5 1.0
Florfenicol 6.1 66.0 9.6 3.0 2.5 2.0 10.7 18.3
Streptomycin 7.0 23.3 18.6 4.7 4.7 4.7 37.2 51.2
Kanamycin 62.8 25.6 4.7 7.0 11.6
Colistin 100 0.0
0.015 0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 128 256 512 1024 2048
Ampicillin 0.9 19.3 28.7 3.7 0.3 0.6 9.8 36.7 47.4
Cefotaxime 17.4 74.6 4.6 1.5 0.9 0.3 0.3 0.3 3.4
Ceftazidime 40.7 50.5 6.1 1.2 0.6 0.9 2.8
Gentamicin 4.9 46.2 34.3 5.8 0.9 0.6 2.8 1.8 2.8 8.9
Neomycin 56.0 15.9 3.2 1 2.4 6.0 8.3 7.1 23.8
Tetracycline 3.1 18.0 7.6 0.3 0.9 15.3 54.7 70.9
Sulphamethoxazole 47.2 1.5 51.2 52.8
Trimethoprim 56.3 0.9 0.3 10.4 32.1 42.8
Ciprofloxacin 9.2 9.8 63.6 0.9 3.7 3.7 1.2 0.9 0.6 3.7 2.8 17.4
Nalidixic acid 42.8 38.2 1.5 0.3 1.2 5.2 10.7 17.1
Chloramphenicol 5.8 55.4 11.0 2.1 3.1 7.3 15.3 27.8
Florfenicol 0.9 11.3 63.0 15.0 2.1 0.6 1.5 5.5 9.8
Streptomycin 1.3 18.7 22.7 5.3 5.3 6.7 8.0 32.0 52.0
Kanamycin 60.0 16.0 1.3 22.7 24.0
Colistin 100 0.0
0.015 0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 128 256 512 1024 2048
Ampicillin 3.2 28.9 58.6 5.4 0.4 2.1 1.4 3.9
Cefotaxime 21.1 77.1 1.4 0.4 0.4
Ceftazidime 51.8 45.4 2.5 0.4 0.4
Gentamicin 5.0 66.1 24.6 3.9 0.0 0.0 0.4 0.4
Neomycin 77.0 18.3 3.3 0 0.5 0.5 0.9
Tetracycline 10.7 59.3 24.6 0.4 0.4 1.4 3.2 5.0
Sulphamethoxazole 95.0 0.4 4.6 5.0
Trimethoprim 93.6 1.8 0.4 0.4 1.8 2.1 4.3
Ciprofloxacin 9.6 13.9 76.1 0.4 0.4
Nalidixic acid 62.9 35.4 1.1 0.4 0.4 0.7
Chloramphenicol 3.2 80.7 14.6 0.4 0.4 0.7 1.4
Florfenicol 0.4 12.1 81.4 5.4 0.4 0.4 0.7
Streptomycin 31.3 52.2 4.5 1.5 1.5 3.0 6.0 11.9
Kanamycin 80.6 14.9 4.5 4.5
Colistin 100 0.0
Slaughter pigs
N = 248
Broilers
N = 197
Veal calves
N = 327
Dairy cattle
N = 280
MIC (%) distribution mg/L
R%
MIC (%) distribution mg/L
R%
MIC (%) distribution mg/L
R%
MIC (%) distribution mg/L
R%
 
The white areas indicate the dilution range tested for each antimicrobial agent. Values above this range indicate 
MIC values > the highest concentration in the range. Values at the lowest concentration tested indicate MIC-
values ≤ the lowest concentration in the range. Vertical bars indicate the epidemiological cut-off values used as 
breakpoints. The dashed bars indicate the clinical breakpoints. 
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The evolution of multi-drug resistance in food-producing animals as presented in Figure 16 is a 
worrisome situation. It demonstrates that in these animals an environment is created where multi 
resistant strains of all kind of species of microorganisms can survive and multiply. Examples of 
clinical relevance are ESBL-, and integron positive Enterobacteriaceae and MRSA, all organisms that 
are currently very commonly and increasingly present. 
 
 
 
 
 
 
Figure 16. Trends in percentages of E. coli strains fully susceptible, resistant to one to a maximum of 
nine antimicrobial classes in broiler chickens, slaughter pigs and veal calves in The Netherlands from 
1998 - 2007. 
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Figure 17. Trends in resistance (in%) of E. coli isolated from slaughter pigs and broilers in The Netherlands from 
1998 - 2007
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E. coli in raw meat products of food-animals 
 
Table 22. Resistance (in %) of E. coli isolated from raw meat products at retail in the Netherlands in 
2006/2007.  
 
Poultry meat Biol poultry Pork Veal Beef Lamb  
N = 230 N = 31 N = 56 N = 16 N = 113 N = 10 
Ampicllin 64.8 38.7 33.9 30.9 19.2 30 
Cefotaxime 15.2 6.4 1.7 18.7 0.9 
Ceftazidime 9.6 0 0 9.1 0 
Gentamicin 7.4 3.2 1.7 6.3 0 
Tetracycline 53.9 51.6 41.1 62.5 14.1 40 
Sulphamethoxazole 66.1 35.4 48.2 68.8 45.1 70 
Trimethoprim 44.3 32.3 26.8 43.8 7.9 
Ciprofloxacin 33.9 12.9 3.6 12.5 3.6 
Nalidixic acid 33.5 19.3 7.1 25.0 3.5 
Chloramphenicol 14.3 12.9 10.7 12.5 7.1 
Florfenicol 1.7 3.2 0 6.3 0 
Streptomycin 33.9 21.4 24.3 27.3 10.8 37.5 
Kanamycin 12.6 0 2.7 9.1 3.1 25 
Colistin 1.3 0 0 0 0 
10 
0 
10 
30 
10 
10 
0 
0 
0 
  
Resistance percentages of E. coli strains isolated from poultry products sampled at retail in the 
Netherlands were similar to those isolated as indicator organisms from faeces of Dutch broilers 
(Tables 21 and 22). However, like in 2005 resistance to the quinolones was substantially lower in 
poultry raw meat products. Resistance in isolates from biological poultry were always less resistant 
than those from conventional animals. 
 
The numbers of strains isolated from veal are too small to conclude on differences with isolates from 
veal calf faeces. Resistance levels in isolates from beef are lower than those from veal (Table 22). 
 
Figure 21 shows trends in resistances in the different meat products. The resistance percentages show 
a general tendency to increase, similar as observed in isolates from faeces 
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Poultry meat products
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Figure 18. Trends in resistance (in%) of E. coli isolated from raw poutry meat products, beef, veal, sheep 
and pork,  in The Netherlands from 1998 - 2007
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Enterococcus faecium, Enterococcus faecalis 
 
Highlights 
 Highest resistance levels were observed for tetracycline and erythromycin in both bacterial species. In 
broiler chickens the resistance levels show a tendency to decrease, while in the other animals the levels seem to 
be stable. Resistance to vancomycin remains present but is rare. Multi drug resistance is very common in veal 
calves, pigs and broilers, but not in dairy cows  
 
The quantitative information on the MIC-distributions are summarized for all E. faecalis and E. 
faecium strains isolated from faecal samples from food-producing animals in 2006/2007 in Table 23. 
In Table 24 the calculated resistance percentages are presented for each bacterial species and specified 
by the different animal sources. 
 
In table 23, if available, both the epidemiological cut-off values and clinical EUCAST breakpoints are 
presented. The MIC distributions show that using the cut-off values has no effect on the level of 
resistance percentages in the enterococci. 
 
Highest resistance levels were observed for tetracycline and erythromycin in both species and 
flavomycin (intrinsic resistance in E. feacalis) and quinu/dalfopristin in E. faecalis. (Tables 23 and 24, 
Fig. 22). The accuracy of the resistance percentages for quinu/dalfopristin are difficult to assess. The 
frequency distribution of the MICs for the streptogramins is complex and generally multimodal. The 
cut-off value for E. faecium has been defined by EUCAST at 1 mg/L, which seems very low and may 
overestimate the acquired resistance levels. For E. feacalis for quinu/dalfopristin no cut-off has been 
established yet. EFSA proposed to use 32 mg/L for this species, which seems appropriate. 
 
Amoxicillin resistance was only observed at relatively low levels in E. faecium isolated from all 
animal species.  
 
In 2006/2007 high level ciprofloxacin resistant E. faecalis isolates were observed (MIC ≥ 16 mg/L). 
These strains were isolated from veal calves and broilers, the animal species in which quinolones are 
predominantly used.  In E. faecium also ciprofloxacin resistance occurred in these animal species, but 
the MICs were lower compared to E. faecalis. 
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Table 23. MIC distributions (In %) for E. faecalis (N = 228) and E. faecium (N = 464) isolated in food 
producing animals in The Netherlands in 2006/2007. 
. 
MIC (%) distribution mg/L E. faecalis 
(N = 228) 0.25 0.5 1 2 4 8 16 32 64 128 256 512 1024 2048 
R% 
Amoxicillin   99.6 0.4           0.0 
Linezolid   1.3 94.3 4.4          0.0 
Tetracyline  21.9 8.8   0.4  9.2 25.0 34.6     69.3 
Erythromycin   28.5 14.9 12.3 2.2 0.4 1.3 0.4 0.4 39.5    44.3 
Vancomycin  3.5 61.0 35.1 0.4          0.0 
Ciprofloxacin  19.7 64.5 13.6 0.4 0.4  0.9 0.4      1.8 
Flavomycin     94.7 3.5 0.4  0.4    0.9  1.3 
Salinomycin  3.5 64.0 18.0 10.5 3.5 0.4        3.9 
Quinu/dalfopristin  0.9  1.3 3.5 34.2 54.8 4.8 0.4      0.4 
Genta > 500          93.9 0.4  0.4 5.3 5.7 
Strep > 2000            61.8 1.3 36.8 36.8 
Chloramphenicol      67.5 18.0  11.0 3.5     14.5 
MIC (%) distribution mg/L E. faecium 
(N = 464) 0.25 0.5 1 2 4 8 16 32 64 128 256 512 1024 2048 
R% 
Amoxicillin   69.8 17.2 7.5 0.6 2.2 1.7 0.9      5.4 
Linezolid   1.1 61.4 37.5          0.0 
Tetracyline  46.8 1.1 0.2   0.2 1.3 12.5 37.9     51.9 
Erythromycin   22.2 21.3 15.7 6.5 0.9 0.4   33.0 0.0   40.7 
Vancomycin  71.8 16.8 10.6      0.9     0.9 
Ciprofloxacin  7.3 28.4 29.1 29.1 5.8 0.2        6.0 
Flavomycin     0.2     0.4 1.3 7.5 90.5  99.8 
Salinomycin   23.5 61.4 2.2 11.9 1.1        12.9 
Quinu/dalfopristin  20.5 10.3 26.5 36.6 4.1 1.1 0.9       69.2 
Genta > 500          98.5 0.2  0.2 1.1 1.3 
Strep > 2000            74.6 1.5 23.9 23.9 
Chloramphenicol    0.2 1.3 76.3 15.7 5.8 0.6      0.6 
  
The white areas indicate the dilution range tested for each antimicrobial agent. Values above this range indicate 
MIC values > the highest concentration in the range. Values at the lowest concentration tested indicate MIC-
values ≤ the lowest concentration in the range. Vertical bars indicate the epidemiological cut-off values used as 
breakpoints. The dashed bars indicate clinical breakpoints. 
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Table 24. Resistance percentages (%) of E. faecalis and E.  faecium isolated from faeces from dairy cows, 
veal calves, slaughter pigs and broilers in The Netherlands in 2006/2007. 
Amoxicillin 0 0 0 0
Linezolid 0 0 0 0
Tetracyline 31.4 62.3 89.3 79.4
Erythromycin 11.4 47.8 51.8 51.5
Vancomycin 0 0 0 0
Ciprofloxacin 0 2.9 0 2.9
Bacitracin 8.6 21.7 14.3 23.5
Flavomycin 0 2.9 0 1.5
Salinomycin 0 0 0 13.2
Quinu/dalfopristin 0 1.4 0 0
Genta > 500 0 8.7 10.7 1.5
Strep > 2000 14.3 46.4 44.6 4.2
Chloramphenicol 5.7 31.9 16.1 0
Amoxicillin 0 11.7 3.1 2.0
Linezolid 0 0 0 0
Tetracycline 6.5 66.7 85.6 46.9
Erythromycin 12.2 61.7 34.0 49.0
Vancomycin 0 1.1 2.1 0
Ciprofloxacin 10.6 6.1 0 8.2
Bacitracin 43.1 34.4 17.5 63.3
Flavomycin 100 100 99 100
Salinomycin 0 1.7 30.9 46.9
Quinu/dalfopristin 54.5 70.6 88.7 63.3
Genta > 500 0 2.8 0 2.0
Strep > 2000 2.4 45.0 9.3 15.0
Chloramphenicol 0 1.7 0 0
E. faecalis
Broiler chickens 
(68)
E. faecium
Broiler chickens 
(49)
Dairy cows
(35)
Veal calves
(69)
Slaughter pigs
(56)
Dairy cows
(123)
Veal calves
(180)
Slaughter pigs
(97)
 
 
Table 24 shows the resistance percentages for E. faecalis and E. faecium in isolates from different 
animal sources. Obviously resistance was more common in intensively reared food producing animals 
(veal calves, pigs and broilers) than in dairy cows reflecting the differences in husbandry and 
antibiotic use practices. Resistance to tetracycline and erythromycin is very common in these food 
producing animals. Salinomycin resistance is typically observed in pigs and broilers where ionophores 
are used as coccidiostatic agent in the feed.  
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Figure 19. Trends in resistance percentages of E. faecium and E. faecalis isolated from slaughter pigs, 
broilers and veal calves in The Netherlands from 1996 – 2007 
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Figure 20.  Percentages of E .faecalis and E. faecium strains fully susceptible, resistant to one to a 
maximum of nine antimicrobial classes in dairy cows, slaughter pigs, broiler chickens and veal calves in 
The Netherlands 2006 - 2007. 
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Figure 19 shows the variation in resistance levels over time. In broiler chickens the resistance levels 
show a tendency to decrease, while in the other animals the levels seem to be stable. Multi drug 
resistance is very common in veal calves, pigs and broilers, but not in dairy cows (Fig. 20). 
 
 
E. faecium and E. faecalis in raw meat products of food-animals 
In comparison with isolation rates from faecal samples, E. faecalis was more frequently isolated than 
E. faecium, which may indicates that survival rates of these species on meat products are not identical. 
Except E. faecalis from broilers and beef, the numbers of isolates were too small to draw firm 
conclusions on both the occurrence and trends in resistance (Table 25, Fig. 24). 
Nevertheless, resistance percentages in E. faecalis and E. faecium were very similar to those found in 
isolates from food animal faeces. 
Vancomycin resistance was found in isolates from veal calves,  slaughter pigs, poultry products and 
veal. One E. faecalis isolate from poultry raw meat was classified as vancomycin resistant (MIC 8 
mg/L). This is a very rare finding and the presence of a vanA or B-gene needs to be confirmed. 
Figure 24 shows the trend from 2003 to 2007 in isolates from raw meat products. Accurate trends 
cannot be observed and trend analysis is complicated by the relatively small numbers of strains per 
year. Obviously resistance is more common in E. faecium compared to E. faecalis except in poultry 
products.  
 
Table 25. Resistance % of E. faecalis and E. faecium isolated from raw meat products from poultry, beef,  
pork, lamb and veal in the Netherlands in 2006/2007 
E. faecalis Poultry  N =173 
Beef  
N = 77 
Pork 
N = 42 
Lamb  
N = 12 
Veal  
N = 25 
Amoxicillin 0.6 0 0 0 4.0 
Linezolid 0 0 0 0 0 
Tetracycline 76.3 27.3 38.1 41.7 79.2 
Erythromycin 42.2 9.1 11.9 8.3 32.0 
Vancomycin 1.2 0 0 0 8.0 
Ciprofloxacin 4.0 2.6 0 0 2.0 
Flavophospholipol 9.2 2.6 7.1 8.3 16.0 
Salinomycin 5.2 0 0 0 0 
Quinu/dalfopristin 1.2 0 0 0 0 
Genta > 500 5.8 0 0 8.3 8.0 
Strep > 2000 24.9 8.1 7.1 25.0 36.0 
Chloramphenicol 3.5 3.9 2.4 0 24.0 
E. faecium Poultry  N = 53 
Beef  
N = 30 
Pork 
N = 11 
Lamb  
N = 4 
Veal  
N = 9 
Amoxicillin 7.5 3.3 0 0 0 
Linezolid 3.8 0 0 0 0 
Tetracycline 52.8 13.3 9.1 0 44.
Erythromycin 34.0 6.7 18.2 0 11.1 
Vancomycin 5.7 0 0 0 0 
Ciprofloxacin 7.5 0 0 0 0 
Salinomycin 24.5 0 0 0 0 
Quinu/dalfopristin 54.7 40.0 45.5 75.0 55.6 
Genta > 500 0 0 0 0 0 
Strep > 2000 9.6 3.3 0 0 0 
Chloramphenicol 0 3.3 0 0 0 
4 
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 Figure 21. Trends in resistance percentages in E. faecalis and E. faecium isolated from raw meat products 
from poultry, beef and pork in The Netherlands from 2003 to 2007 
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Animal pathogens 
 
Bovine respiratory disease pathogens Pasteurella multocida and 
Mannheimia haemolytica 
 
In collaboration with the Animal Health Service in Deventer, the Netherlands, annually strains isolated 
from diagnostic specimens mostly taken at autopsy from cattle suffering from respiratory diseases, are 
tested for susceptibility by broth microdilution. This has been done since 1996. The number of strains 
isolated per year is limited, therefore every two years resistance data on respiratory disease pathogens 
from cattle are reported.  
Although the resistance data may reflect a worst-case scenario of resistance in these pathogens, it still 
presents very important information on which resistance determinants occur and to what extend. 
 
Highlights  
Generally the resistance levels were higher in M. haemolytica. Tetracycline resistance occurred most frequently 
in both species, although substantially more frequently in M. haemolytica, in which species also resistance to 
amoxicillin, flumequine and chloramphenicol occurred frequently. Resistance to aminoglycosides was present in 
single isolates in P. multocida only. Single isolates resistant to tilmicosin and florfenicol were detected. For 
florfenicol this was the first time a resistant PMU is reported in The Netherlands. 
 
In Table 26 the MIC distributions are presented for both Pasteurella multocida (PMU) and 
Mannheimia haemolytica (MHA). In Figure 22 the trends in resistance percentages are presented from 
1996 to 2005. 
 
The resistance profiles of PMU and MHA were not identical. Generally the resistance levels were 
higher in MHA. Tetracycline resistance occurred most frequently in both species, although 
substantially more frequently in MHA. In MHA also resistance to amoxicillin, flumequine and 
chloramphenicol occurred frequently. Resistance to aminoglycosides is present in single isolates in 
PMU only. 
The resistance percentages for the quinolones are misleading. Based on the R breakpoint ≥ 2 mg/L, 
0% PMU and 2.3% MHA were classified as resistant to enrofloxacin. However, for both genera 
substantial populations (app. 10% for PMU and 25% for MHA) show reduced susceptibility to 
enrofloxacin (MICs  > 0.125 mg/L), demonstrating that acquired resistance to quinolones is commonly 
present. 
Resistance to ceftiofur and tulathromycin was not detected. Single isolates resistant to tilmicosin and 
florfenicol were detected. For florfenicol this was the first time a resistant PMU is reported in The 
Netherlands. 
 
Figure 22 shows that the resistance percentages vary substantially over the years. In PMU resistance 
shows a tendency to decrease, while in MHA the levels seem more stable. 
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Table 26. MIC-distributions (in %) for bovine respiratory disease pathogens P. multocida and M. 
haemolytica isolate from Dutch cattle by the Animal Health Service in Deventer in 2006 and 2007. 
 
0.015 0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 128 256
Amoxicillin 92.7 2.4 4.9 4.9
Ceftiofur 92.7 7.3 0.0
Tetracycline 43.9 9.8 22.0 2.4 7.3 4.9 4.9 4.9 14.6
Neomycin 12.2 36.6 24.4 19.5 2.4 2.4 2.4 4.9
Gentamicin 2.4 31.7 48.8 12.2 4.9 4.9
Spectinomycin 2.4 36.6 48.8 4.9 7.3 7.3
Trim/sulpha 80.5 4.9 4.9 4.9 2.4 2.4 2.4
Enrofloxacin 87.8 2.4 2.4 4.9 2.4 0.0
Flumequine 87.8 2.4 2.4 2.4 2.4 2.4 7.3
Tilmicosin 2.4 2.4 26.8 22.0 36.6 7.3 2.4 2.4
Tulathromycin 5.0 20.0 70.0 5.0 0.0
Chloramphenicol 33.3 47.6 4.8 4.8 9.5 0.0
Florfenicol 4.9 85.4 7.3 2.4 2.4
0.015 0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 128 256
Amoxicillin 84.1 15.9 15.9
Ceftiofur 97.7 2.3 0.0
Tetracycline 27.3 27.3 2.3 18.2 20.5 4.5 43.2
Neomycin 2.3 52.3 45.5 0.0
Gentamicin 2.3 4.5 90.9 2.3 0.0
Spectinomycin 11.4 86.4 2.3 0.0
Trim/sulpha 75.0 2.3 4.5 15.9 2.3 2.3
Enrofloxacin 63.6 9.1 2.3 2.3 18.2 2.3 2.3 2.3
Flumequine 63.6 11.4 11.4 6.8 2.3 2.3 2.3 13.6
Tilmicosin 2.3 4.5 20.5 47.7 20.5 2.3 2.3 4.5
Tulathromycin 4.2 4.2 4.2 75.0 12.5 0.0
Chloramphenicol 10.0 65.0 20.0 5.0 25.0
Florfenicol 6.8 81.8 9.1 2.3 0.0
M. haemolytica
(44)
MIC (%) distribution mg/L
R%
P. multocida
(41)
MIC (%) distribution mg/L
R%
 
 
The white areas indicate the dilution range tested for each antimicrobial agent. Values above this range indicate 
MIC values > the highest concentration in the range. Values at the lowest concentration tested indicate MIC-
values ≤ the lowest concentration in the range. The vertical bars indicate the breakpoints. 
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Figure 22.  Trends in resistance (in %) of P. multocida and M. haemolytica isolated from 1996 – 2007 in 
the Netherlands. 
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Bovine mastitis pathogens E. coli, coliform bacteria, S. aureus, coagulase-negative 
staphylococci, S. uberis and S. dysgalactiae. 
 
Highlights 
The resistance levels for E. coli strains isolated from milk samples from cows suffering from mastitis were low 
except for ampicillin. In 2006/2007 the first ESBL-producing E. coli’s were isolated from mastitis.  
The coliform bacteria showed a high level of resistance to ampicillin and to the combination with clavulanic 
acid. All isolates were susceptible to cefoperazone and cefquinome.  
The S. aureus isolates tested were susceptible to most antibiotics. 9.2% were penicillin resistant. In 2006/2007 
one S. aureus was identified to be MRSA. The strain belonged to the animal associated clonal complex 398. The 
coagulase negative staphylococci were more resistant than S. aureus. 56% were resistant to penicillin and 1.5% 
to oxacillin (mecA-positive).  
 
 
Table 28. MIC-distributions (in %) for E. coli and coliform bacteria isolated from mastitis milk samples 
from Dutch cattle by the Animal Health Service in Deventer in 2006-2007. 
0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128
Ampicillin 6.9 33.3 39.7 6.9 13.2 13.2
Amox-clavulanic acid 2.9 31.9 48.5 12.7 2.5 1.0 0.5 1.5
Cefquinome 87.7 9.8 1.5 0.5 0.5 0.5
Cefoperazone 1.5 15.2 59.8 10.3 3.9 2.9 2.5 2.0 1.0 1.0 1.0
Cefuroxime 4.9 67.6 23.5 3.4 0.5 0.5
Tetracycline 12.7 53.4 19.1 1.0 0.5 1.5 11.8 13.7
Gentamicin 0.5 23.5 64.7 11.3 0.0
Kanamycin 4.4 65.7 19.6 2.9 2.9 4.4 4.4
Neomycin 0.5 34.3 50.0 7.8 0.5 6.9 6.9
Streptomycin 18.6 58.3 5.4 0.5 3.4 13.7 17.2
Enrofloxacin 83.3 14.7 0.5 1.0 0.5 0.5
Trim/Sulpha 86.8 2.9 1.0 9.3 9.3
0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128
Ampicillin 1.0 3.9 2.0 1.0 5.4 18.6 68.1 86.8
Amox-clavulanic acid 18.1 52.0 7.4 1.5 1.0 5.4 12.7 2.0 20.1
Cefquinome 81.9 14.7 2.5 0.5 0.5 0.0
Cefoperazone 7.4 45.1 16.2 6.9 12.7 7.4 2.9 1.5 0.0
Cefuroxime 3.9 48.0 22.5 8.8 8.3 8.3 8.3
Tetracycline 2.0 43.1 34.8 5.9 1.0 1.0 2.5 9.8 13.2
Gentamicin 11.8 72.5 15.2 0.5 0.5
Kanamycin 2.5 65.2 18.6 5.4 2.9 2.9 1.0 1.5 2.5
Neomycin 19.6 67.6 7.8 3.4 0.5 1.0 1.0
Streptomycin 16.7 58.3 12.7 2.5 2.9 1.5 5.4 6.9
Enrofloxacin 58.3 35.3 2.9 2.5 0.5 0.5 0.0
Trim/Sulpha 84.8 10.8 0.5 1.0 2.9 2.9
Coliform
(204)
MIC (%) distribution mg/L
R%
E. coli
(204)
MIC (%) distribution mg/L
R%
 
The white areas indicate the dilution range tested for each antimicrobial agent. Values above this range indicate 
MIC values > the highest concentration in the range. Values at the lowest concentration tested indicate MIC-
values ≤ the lowest concentration in the range. The vertical bars indicate the breakpoints. 
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In E. coli strains isolated from milk samples from cows suffering from mastitis the resistance levels 
were low to moderate. Only resistance to ampicillin, streptomycin, and tetracycline was present in 
percentages higher than 10%. One isolate was highly resistant to amoxicillin/clavulanic acid and to 
cefquinome indicating the presence of an ampC type Extended Spectrum Beta/Lactamase (ESBL) or a 
mutation in the promoter region of the chromosomal ampC-gene. A second isolate showed clear 
reduced susceptibility to cefquinome (MIC 4 mg/|L) indicating the presence of an ESBL as well. 
These isolates were also resistant to cefoperazone and cefuroxime. Resistance to the fluoroquinolone 
enrofloxacin is rare. 
In coliform bacteria from mastitis cases (Klebsiella, Enterobacter), resistance to ampicillin was very 
common based on chromosomal beta-lactamases. Also resistance to amoxicillin-clavulanic acid is so 
often present that empiric treatment with this combination should be discouraged in cases of severe 
and acute mastitis without a culture result. 
All isolates were susceptible to the third generation cephalosporins, cefoperazone and cefquinome and 
the fluoroquinolone, enrofloxacin. 
 
Fig. 23 demonstrates that both in E. coli and in coliform mastitis pathogens the resistance levels 
remain stable over the years. 
 
 
Figure 23.  Trends in resistance percentages for E. coli and coliform bacteria isolated from clinical 
mastitis cases in dairy cattle in the Netherlands from 2002 – 2007. 
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Table 29. MIC-distributions (in %) of S. aureus and coagulase-negative staphylococci (CNS) isolated from 
clinical mastitis cases in dairy cattle by the Animal Health Service in Deventer in 2006/2007. 
 
0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128
Penicillin 89.8 1.0 5.6 1.0 1.0 1.5 9.2
Oxacillin 1.5 16.8 39.8 39.8 1.0 0.5 0.5 0.5#
Amox-clavulanic acid 44.9 40.3 8.2 5.6 0.5 0.5 0.5#
Cephalothin 1.0 26.0 58.7 12.8 0.5 0.5 0.5 0.5#
Tetracycline 11.7 80.1 5.1 3.1 3.1
Kanamycin 0.5 1.5 24.0 56.1 17.9 0.0
Neomycin 1.0 5.6 50.0 40.3 3.1 0.0
Streptomycin 1.0 14.8 61.2 19.4 0.5 3.1 3.6
Erythromycin 25.0 69.4 4.1 1.5 1.5
Clindamycin 2.1 32.3 61.5 2.1 1.0 1.0 1.0
Pirlimycin 3.6 36.4 47.7 8.7 2.1 0.5 1.0 3.6
Trim/sulpha 96.9 3.1 0.0
0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128
Penicillin 64.3 2.5 3.5 7.5 9.0 2.5 4.0 1.0 5.5 56*
Oxacillin 9.5 29.6 35.2 16.1 6.5 1.5 1.5 1.5#
Amox-clavulanic acid 55.3 28.6 10.6 4.5 0.5 0.5 1.5#
Cephalothin 3.0 31.3 46.0 14.1 4.5 0.5 0.5 1.5#
Tetracycline 3.0 46.7 35.2 1.5 2.5 0.5 10.6 11.1
Kanamycin 20.6 34.7 30.2 10.1 2.5 0.5 0.5 1.0 1.5
Neomycin 49.7 24.1 16.6 5.5 2.0 0.5 0.0 1.0 0.5 0.5
Streptomycin 2.5 7.5 24.6 37.2 17.6 3.5 0.5 2.0 4.5 7.0
Erythromycin 2.0 39.2 50.8 3.0 1.0 1.5 2.5 4.0
Clindamycin 5.0 33.2 42.7 10.1 5.5 1.5 0.5 1.0 0.5 2.0
Pirlimycin 2.0 23.6 40.7 16.6 4.0 6.0 5.5 1.0 0.5 13.1
Trim/sulpha 71.9 12.6 13.1 0.5 1.0 1.0 2.0
CNS (199) MIC (%) distribution mg/L R%
S. aureus 
(196)
MIC (%) distribution mg/L R%
 
 
The white areas indicate the dilution range tested for each antimicrobial agent. Values above this range indicate 
MIC values > the highest concentration in the range. Values at the lowest concentration tested indicate MIC-
values ≤ the lowest concentration in the range. The vertical bars indicate the breakpoints. 
* All isolates with penicillin MIC ≤ 0.06 mg/L positive for penicillinase production were classified resistant to 
penicillin. 
 # All isolates with oxacillin MIC > 4 mg/L were mecA-positive. These isolates were also classified R for amox-
clavulanic acid and cephalothin. 
 
In spite of the intensive use of antibiotics in the control of bovine mastitis in the Netherlands, the S. 
aureus isolates tested were susceptible to most antibiotics. In 2006/007 9.2% of the isolates were 
penicillinase producers and one oxacillin-resistant isolate was detected. This isolate was confirmed to 
be MRSA by molecular techniques and belonged to the currently widespread occurring clonal 
complex 389, which are very common in pigs and veal calves in The Netherlands. It remained a single 
observation indicating that in dairy cattle this MRSA-clone is rare.  
 
The coagulase negative staphylococci were more resistant than S. aureus. Penicillin resistance based 
on MICs and cefinase test was similar as in previous years. Three oxacillin resistant mecA-positive 
isolates were found that were also classified resistant to amoxicillin-clavulanic acid and cephalothin.  
 
Resistance to pirlimycin was commonly presents (13.1%) and substantially higher that the related but 
more potent clindamycin (2%). 
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Although the numbers of strains included were relative large, the trends in resistance in fig. 24 may be 
affected by selection bias and not reflect true trends. Resistance to the lincosamides seems to have 
decreased after 2004. However in that year we changed from using lincomycin or clindamycin in our 
test panel, which will have affected the results. 
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Figure 24.  Trends in resistance percentages for S. aureus and coagulase negative staphylococci isolated from 
mastitis milk in the Netherlands from 2002 - 2007.
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Table 30. MIC-distributions (in %) of S. uberis and S. dysgalactiae isolated from mastitis milk samples 
from Dutch cattle by the Animal Health Service in 2006/2007. 
 
 
0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 256
Penicillin 27.7 9.4 3.0 13.9 33.7 5.4 0.5 5.0 1.5 1.5
Cephalothin 0.5 11.4 24.3 7.4 34.7 13.9 1.5 0.5 5.0 1.0 5.9
Erythromycin 2.5 32.2 39.6 1.5 1.0 5.4 2.5 1.0 0.5 13.9 23.3
Clindamycin 11.4 36.1 6.9 0.5 0.5 0.5 1.5 22.3 3.5 2.5 2.5 11.9 42.6
Lincomycin 2.0 27.2 1.0 1.5 4.0 16.8 2.5 1.0 2.0 2.0 40.1 45.0
Pirlimycin 0.5 3.5 46.0 3.5 2.0 1.0 9.4 14.4 6.9 0.5 1.5 10.9 34.2
Trim/sulpha 1.0 6.9 55.9 27.7 5.9 0.5 0.5 1.5 1.5
Tetracycline 0.5 19.8 35.6 2.5 2.0 26.7 7.4 5.4 41.6
0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 256
Penicillin 98.0 1.0 0.5 0.5 0.0
Cephalothin 57.7 41.3 1.0 0.0
Erythromycin 2.0 42.8 47.3 0.5 1.0 6.5 8.0
Clindamycin 0.5 1.0 58.2 25.4 1.0 6.5 1.5 0.5 5.5 7.5
Lincomycin 39.8 23.9 3.0 10.4 7.5 1.5 0.5 13.4 22.9
Pirlimycin 0.5 1.5 52.7 28.4 3.0 0.5 2.0 3.5 2.5 0.5 0.5 4.5 11.4
Trim/sulpha 2.5 46.8 48.8 1.5 0.5 0.0
Tetracycline 0.5 0.5 1.0 9.0 14.9 2.5 1.0 18.9 48.8 3.0 74.1
S. uberis 
(202)
MIC % distribution (µg/ml)
R%
S. dysgalactiae 
(201)
MIC % distribution (µg/ml)
R%
 
 
The white areas indicate the dilution range tested for each antimicrobial agent. Values above this range indicate 
MIC values > the highest concentration in the range. Values at the lowest concentration tested indicate MIC-
values ≤ the lowest concentration in the range. The vertical bars indicate the breakpoints. 
 
In 2006/2007 almost all isolates of S. uberis and all S. dysgalactiae were susceptible to penicillin and 
therefore also to all other beta-lactams (Table 30). The S. uberis isolates resistant to cephalothin were 
most likely misidentified enterococci. S. uberis shows a bimodal distribution of the penicillin MICs 
indicating that subpopulation of strains with MICs ≥ 0.125 mg/L with acquired resistance occurred. 
This indicates the presence of altered penicillin binding proteins as resistance mechanism as described 
for S. pneumoniae. 
Resistance to erythromycin and the lincosamides (lincomycin and pirlimycin) occurred most 
frequently in S. uberis. Resistance to tetracycline was most common in S. dysgalactiae.  
In 2006/2007 for the first year clindamycin was included in the tests. The fact that the resistance levels 
were not identical to those for linco- and pirlimycin was most likely related to inadequate breakpoints 
for the drugs, underestimating the resistant populations for all three lincosamides. 
 
Resistance to erythromycin and the lincosamides show an increase in 2006/2007 in S. uberis. 
Resistance to the other antibiotics was stable. 
MARAN-2007 
 
 
 
 83 
S. uberis
0
10
20
30
40
50
60
70
80
Pe
ni
ci
llin
C
ep
ha
lo
th
in
E
ry
th
ro
m
yc
in
C
lin
da
m
yc
in
Li
nc
om
yc
in
Pi
rli
m
yc
in
Tr
im
/s
ul
ph
a
Te
tra
cy
cl
in
e
2002 (N = 103)
2003 (N = 83)
2004 (N = 99)
2005 (N = 95)
06/07 (N = 202)
S. dysgalactiae
0
10
20
30
40
50
60
70
80
Pe
ni
ci
llin
C
ep
ha
lo
th
in
E
ry
th
ro
m
yc
in
Li
nc
om
yc
in
Pi
rli
m
yc
in
Tr
im
/s
ul
ph
a
Te
tra
cy
cl
in
e
2002 (N = 107)
2003 (N = 94)
2004 (N = 90)
2005 (N = 62)
06/07 (N = 201)
 
Figure 25.  Trends in resistance percentages for S. uberis and S. dysgalactiae isolated from mastitis milk in The 
Netherlands from 2002 - 2005. 
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III  Appendices 
 
Appendix I.  Resistance determinants in MRSA strains isolated in 
2006/20077 from pigs, veal calves, and food products in The Netherlands17 
 
After the discovery of the high prevalence of MRSA in pig and later also in veal calf farming and in 
persons at risks like veterinarians and farmers, a large research program started in The Netherlands. As 
part of this research program intensive prevalence studies were conducted in different animal species 
and all isolates were sent to the National Institute for Public Health and the Environment (RIVM-
Bilthoven) for molecular typing and to the Central Veterinary Institute (CVI-Lelystad) for 
susceptibility testing. The purpose of these studies were to identify the genetic characteristics of these 
MRSA’s and to determine if next to the mecA-gene cluster additional resistance genes would be 
acquired as a result of different antibiotic use practices in food producing animals. 
The present study describes the Minimum Inhibitory Concentrations (MICs) of MRSA’s isolated from 
pigs, veal calves and animal food products in the Netherlands in 2007. Moreover it describes the 
resistance associated genes present is a subset of 60 of the MRSA’s. 
In 2007 508 MRSA strains were sent to CVI-Lelystad for susceptibility testing. These strains 
were isolated from pigs (piglets, sows and slaughter pigs, N = 295), from veal calves (N = 52) and 
from food products (N = 161). Susceptibility was tested by broth microdilution according to CLSI 
guidelines using a custom format Sensititre panel. 
Sixty-four isolates from pigs (N = 22), veal calves (N = 21) and food products (N = 22) were 
genetically characterized using the MRSA micro-array of Clondiag Chip Technologies. The isolates 
were also tested for vancomycin susceptibility using screen plates according to CLSI M31-A2. 
Figure 26. Resistance percentages of 527 MRSA’s isolated from pigs (N = 314), veal calves (N = 52) and 
meat products (N = 161) isolated in the Netherlands in 2006 and 2007. 
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17 Dik Mevius, Cindy Dierikx, Denice Verheijen, Kees Veldman, Ben Wit, Peter van der Wolf, Haitske 
Graveland, Xander Huijsdens, Arjen van der Giessen. On behalf of the Dutch working group SOM. Resistance 
and virulence determinants in MRSA strains isolated in 2007 from pigs, veal calves, and food products in The 
Netherlands. ASM Conference on Antimicrobial Resistance in Bacteria of Animal origin, June 2008, 
Copenhagen 
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All isolates from pigs and veal calves belonged to CC398, while the isolates from meat products were 
more variable. Next to methicillin resistance, almost all isolates were resistant to tetracycline. This 
occurred predominantly in isolates from meat products not belonging to CC398. Resistance to 
clindamycin, erythromycin, gentamicin, neomycin and ciprofloxacin was observed in frequencies 
varying from 10 - 70% of the isolates. Resistance genes detected were mecA, tetM, aadD, ermC, aacA-
aphD, tetK, blaZ, vgaA, sat, aphA3, vga in order of most frequent occurrence.  
It can be concluded that animal associated MRSA harbours a variety of additional resistance 
determinants.  
 
 
Figure 27. Resistance genes detected by MRSA array in 62 MRSA isolates from veal calves, pigs and meat 
products in The Netherlands in 2006 and 2007. 
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Appendix II. ESBLs and qnr-genes in Salmonella Paratyphi B var Java 
isolated from Dutch poultry18 
 
Salmonella Paratyphi B var. Java is the most predominant serovar isolated from broiler chickens in 
The Netherlands since approximately 1998. The clone harbours a 2300 bp class 2 integron in the 
chromosome with dfrA1, sat1, aadA1/C gene cassettes. S. Java is well adapted to poultry colonizing 
chickens and the housing facilities very readily, but is not specifically pathogenic and rarely causes 
food borne infections in humans. As a result of the use of quinolones in poultry an increase in low-
level resistance to ciprofloxacin and full resistance to nalidixic acid was observed starting in 1999 (fig 
28). This was caused by single point mutations in the gyrA gene. Since 2003 a rapid increase in 
cefotaxime resistance was observed in both E. coli and in S. Java from Dutch broilers (fig 28). This is 
indicative of the presence of extended spectrum beta-lactamases (ESBLs) in both bacterial species and 
of horizontal transmission of the genes in poultry. Molecular characterization of cefotaxime resistant 
isolates of S. Java isolates from 2006 showed that different ESBL genes were present (fig 29) and 
most of them were also found in E. coli  This makes horizontal transmission of these genes even more 
likely to exist. The beta-lactamases deteced in S. java were blaTEM-20, 52 , blaCTX-M-1, 2  
 
 
Figure 28. Dynamics in resistance percentages of ciprofloxacin, nalidixic acid and cefotaxime for S Java 
isolates from Dutch poultry from 1999 – 2008. 
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18 Cindy Dierikx, Kees Veldman, Muna Anjum, Muriel Mafura, Marga Japing, Ruud Baaiman , Wilfrid van Pelt, 
Henny Maas and  Dik Mevius. Extended Spectrum ß-lactamases and qnr-genes in Salmonella Paratyphi B var 
Java isolated from Dutch Poultry. ASM Conference on Antimicrobial Resistance in zoonotic bacteria and food-
borne pathogens, 15 – 18 June 2008, Copenhagen, Abstract B89, page 64 - 65. 
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At the end of 2007 and the beginning of 2008 S. Java isolates were observed with low-level resistance 
to ciprofloxacin but without high level resistance to nalidixic acid. This phenotype has been described 
to be typical for plasmid mediated quinolone resistance genes (qnr) in Salmonella  enterica. Moreover 
one isolate was observed in January 2008 that was both cefotaxime resistant and also showed the qnr-
phenotype. This indicates the presence of plasmid mediated ESBLs and quinolone resistance genes in 
one isolate. 
Molecular identification identified the presence of both blaCTX-M-9 and qnrA1 on a large plasmid in one 
S. Java isolate and qnrB5 in two other S. Java isolates.  
 
This indicates that ESBLs are well established in the GI-tract of broiler chickens and that transmission 
has occurred between E. coli  and Salmonella. The detection of mobile quinolone resistance genes, 
partly linked to and ESBL is a worrisome development given the high selection pressure in poultry 
production. 
 
 
 
Figure 29. Genes and plasmids detected in S. Java isolates 
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Appendix III.  Materials and Methods 
 
Salmonella enterica 
A total of 16.861 isolates were tested for antimicrobial susceptibility between 1999-2007 (table 31). 
Human isolates (N=9155) concerned a selection from first isolates sent to the Dutch National Institute 
of Public Health (RIVM) by the regional public health laboratories. All strains were the first isolates 
recovered from patients with salmonellosis. The majority of the isolates from pigs (N=1124) and 
cattle, including calves (N=600) were sent to the RIVM by the Animal Health Service from a diversity 
of surveillance programs and clinical Salmonella infections. Those from chickens (broilers, including 
poultry products, N=1149; layers, reproduction animals and eggs, N=827) concerned mainly 
nonclinical Salmonella infections derived from a diversity of monitoring programs on the farm, 
slaughterhouses and at retail.. The majority of isolates from layers in 2005 concerned those from the 
Dutch component of the EU-baseline study. Isolates from a diversity of other sources have been 
analysed as well (animal fodder and human food products; other animals from animal husbandry and 
pets, samples from the environment, etc.). 
 
Table 31. Number of Salmonella isolates tested for susceptibility from 1999 – 2007 in the Netherlands. 
 Total 1999 2000 2001 2002 2003 2004 2005 2006 2007
Human 9155 674 349 1055 862 1338 1339 1176 1273 1089  
Pig 1124 31 195 114 168 127 119 120 115 135  
Cattle 600 18 28 56 33 23 106 90 159 87    
Chicken (misc.) 850 0 10 174 172 160 29 30 116 159   
Broilers (faeces/meat) 1149 68 110 143 212 206 110 82 164 54  
Layers/Repro/Eggs 827 93 86 62 56 88 91 232 75 44    
Other sources 3156 0 9 309 330 446 473 603 535 451  
Total 16861 884 787 1913 1833 2388 2267 2333 2437 2019
 
  
 
  
 
Representativeness of percentages of resistance for humans or animals over all types 
In principal, if isolates are selected randomly from a source the percentage of resistant strains within a 
source can be computed straightforwardly. Standard statistical considerations would apply to indicate 
significant differences between years and between animal and human sources. Table 32 shows that 
quite substantial numbers are needed to indicate significant differences in resistance percentages less 
than 10%. However, resistance strongly depends on Salmonella type and many different types are 
involved; a cocktail of types that differs between sources and that may differ between years. 
Moreover, low numbers tested and incidentally missed, or selected types with rare antibiograms, may 
influence the resulting resistance percentages. Finally the source definition in itself may be biased, as 
the reason for sending-in isolates, especially from cattle and pigs, is often unknown. This explains 
many of the irregularities between years. 
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Table 32. Power analysis to show the sample sizes needed to indicate significant differences in resistance 
percentages between groups (for example between years or between human and animal sources). 
Level of significance = 0,05 and Power = 0,7 
R-group 1 R-group 2 Difference N1=N2 
40% 30% 10% 287 
30% 20% 10% 251 
20% 10% 10% 211 
70% 50% 20% 111 
60% 40% 20% 95 
50% 30% 20% 84 
40% 20% 20% 70 
30% 10% 20% 59 
60% 30% 30% 23 
  
E. coli, E. faecium, E. faecalis and Campylobacter spp. isolated from slaughter pigs and broilers 
E. coli and E. faecium, E. faecalis and Campylobacter spp. were isolated from faecal samples taken 
from healthy animals at slaughter by the Food and Consumer Product Safety Authority as part of the 
national control programs. Samples were taken at slaughterhouses or at farms. For isolation of the 
above mentioned organisms one faecal sample was taken for each epidemiological unit (farm, flock or 
group of animals) aseptically, or the caeca collected (broilers). At the laboratory the samples were 
directly 1:10 diluted in buffered peptone solution with 20% glycerol and stored at –20°C. E. coli, E. 
faecium, E. faecalis and Campylobacter spp. were isolated directly after arrival of the samples at CVI-
Lelystad or the Food and Consumer Product Safety Authority in Zutphen. For E. coli MacConkey agar 
and for the enterococci Slanetz and Bartley agar was inoculated with cotton swabs (E. coli), or a50 µl 
of a serial dilution (enterococci). A colony with typical morphology was subcultured to obtain a pure 
culture and stored at –80°C in buffered peptone water with 20% glycerol. E. coli was identified 
biochemically. The final identification of the enterococci was done with Polymerase Chain Reaction 
(PCR) as described by Dutka Malen in 1995.  
For isolation of Campylobacter CCDA-agar with 32 µg/ml cefoperazone and 10 µg/ml amphotericin B 
to inhibit growth of Gram-negative bacteria and fungi, was directly inoculated with a cotton swab. All 
campylobacters were typed with PCR to the species level. Only C. jejuni and C. coli were tested for 
their susceptibility. All other spp. were excluded from the programme. 
 
 
E. coli, E. faecium and E. faecalis isolated from raw meat products of food-animals 
For isolation of all bacterial species raw meat products were rinsed with Buffered Peptone Water 
(BPW). For E. coli 10 ml BPW rinse was enriched in 90 MacConkey-, or Laurylsulphate broth. After 
overnight aerobic incubation at 44°C the broth was subcultured on Coli-ID agar (24 h at 44°C). For 
enterococci 10 ml BPW rinse was enriched in 90 ml Azide Dextrose broth. After overnight aerobic 
incubation at 44°C, the broth was subcultured on Slanetz and Bartley agar for 48 hrs at 44°C. 
Identification was done biochemically. 
 
Shigella toxin producing E. coli O157 (STEC) 
For STEC both human and animal strains were combined. All sorbitol negative human strains from all 
medical microbiological laboratories in the Netherlands were sent to RIVM for serovar O157 
confirmation and further typing. The animal strains were partly isolated in the monitoring programme 
of farm-animals of VWA/RIVM. These samples were taken at farms from faeces of healthy animals. 
One isolate per farm was included. Isolates from non-human sources included strains isolated from 
samples taken in an attempt to trace a human infection. 
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Bovine mastitis pathogens E. coli, coliform bacteria, S. aureus, coagulase-negative 
staphylococci, S. uberis and S. dysgalactiae. 
Annually at the Animal Health Service large numbers of milk samples from clinical cases of bovine 
mastitis are sent in for bacteriological examination. From the isolates a selection of approximately 100 
strains of E. coli, coliform bacteria, S. aureus, coagulase-negative staphylococci, S. uberis and S. 
dysgalactiae were sent to CVI-Lelystad for MIC-determinations. Inclusion criteria for the strains 
were: a maximum of one isolate per species per farm, only pure cultures were included after direct 
inoculations from the milk samples on agar plates, except for S. aureus for which species also pure 
cultures after broth enrichment were included. 
 
Susceptibility tests 
Susceptibility was tested quantitatively with the broth micro dilution test with cation-adjusted Mueller 
Hinton broth according to ISO standard 20776-1-2006 or CLSI guidelines M31-A3 for Campylobacter 
spp.. For broth microdilution, microtitre trays were used with dehydrated dilution ranges of custom 
made panels of antibiotics. Trek Diagnostic Systems, in the UK, manufactured these microtitre trays. 
ATCC strains E. coli 25922 and E. faecalis 29212 were used daily to monitor the quality of the results. 
For quality control of the results of campylobacters, C. jejuni ATCC 33560 was used as control strain.  
The MICs were defined as the lowest concentration without visible growth. Strains with MIC’s higher 
than the MIC-breakpoints were considered resistant. Percentages of resistance were calculated. For 
Salmonella, the indicator organisms E. coli and enterococci and Campylobacter spp. EUCAST 
epidemiological cut-off values were used as prescribed by EFSA19 20 (table 34). For the animal 
pathogens clinical breakpoints were used (CLSI M31-A3, M100-S17) as listed in table 34. 
 
Data interpretation needs to take into account that for some antibiotics the cut-off values are 
substantially lower than the previously used clinical breakpoints, which may have affected the level of 
the resistance percentages. These percentages indicate the acquisition of resistance in intrinsically 
susceptible bacteria population as an effect of determinants like antibiotic usage. They cannot directly 
be translated in therapeutic failure, when antibiotics would be used to treat infection with those 
organisms. 
 
                                                     
19Report from the Task Force of Zoonoses Data Collection including a proposal for a harmonized monitoring 
scheme of antimicrobial resistance in Salmonella in fowl (Gallus gallus), turkeys, and pigs and Campylobacter 
jejuni and C. coli in broilers, the EFSA Journal (2007), 96,1-46.  
 
20 Report from the Task Force on Zoonoses Data Collection including guidance for harmonized monitoring and 
reporting of antimicrobial resistance in commensal Escherichia coli and Enterococcus spp. from food animals 1. 
The EFSA Journal (2008) 141: 1-44 
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Table 33. Epidemiological cut-off values (mg/L) used for the classification of Salmonella, E. coli (indicator 
organism), Campylobacter spp. and enterococci. Isolates with MIC-values higher than those presented in 
this table are considered resistant.  
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Amoxicillin 4 8 16 8 - -
Cefotaxime 0.5 0.25 - - - -
Ceftazidime 2 0.5 - - - -
Streptomycin - 16 2 4 2000 2000
Gentamicin 2 2 1 2 500 500
Kanmycin 8 8 - - - -
Neomycin 4 8 1 2 - -
Tetracycline 8 8 2 2 2 2
Sulphamethoxazole 256* 256* 256 32 - -
Trimethoprim 2 2 - - - -
Trim/sulphamethoxazole 2/38 2/38 16/304 4/76 - -
Nalidixic acid 16 16 16 32 - -
Ciprofloxacin 0.06 0.06 1 1 4 4
Chloramphenicol 16 16 16 16 32 32
Florfenicol 16 16 - - - -
Vancomycin - - - - 4 4
Flavomycin - - - - - 16
Quinu/dalfopristin - - - - 1 32
Erythromycin - - 4 16 4 4
Clarithromycin - - 8 32 - -
Tulathromycin - - 16 16 - -
Linezolid - - - - 4* 4*
Colistin 8 8 - - - -
Salinomycin - - - - 4 4  
* CLSI breakpoint 
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 Table 34. MIC-breakpoints (mg/L) used for the classification of E. coli and coliform bacteria (mastitis), P. 
multocida, M. haemolytica, S. aureus, coagulase negative staphylococci (CNS) and streptococci. Isolates 
with MIC-values higher than those presented in this table are considered resistant.  
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 c
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Penicillin - - - 0.125 0.125 2
Oxacillin - 2 * -
Ampicillin 16 16 16 - - -
Amox-clavulanic acid 16 - - 4 4 4
Cephalothin - - - 16 16 16
Cefuroxime 16 - - - - -
Cefquinome 4 - - - - -
Ceftiofur - 4 4 - - -
Cefoperazone 32 - - - - -
Streptomycin 32 - - 16 16 -
Spectonomycin - 64 64 - - -
Gentamicin 8 4 4 - - -
Neomycin 16 16 16 16 16 -
Kanamycin 32 - - 16 16
Tetracycline 8 8 8 8 8 8
Trim/sulphamethoxazole 2/38 2/38 2/38 2/38 2/38 2/38
Flumequine - 4 4 - - -
Enrofloxacin 2 1 1 - - -
Chloramphenicol - 16 16 - - -
Florfenicol - 4 4 - - -
Erythromycin - - - 4 4 0.5
Pirlimycin - - - 2 2 2
Clindamycin - - - 2 2 -  
 
* Only mecA positive isolates were classified resistant, this equals MIC ≥ 4 mg/L 
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Appendix IV.  Annexes to Chapter 1 Usage of antibiotics in animal 
husbandry in the Netherlands 
 
 
Annex 1a  Average number of daily dosages dairy cows per animal year 
 
 
ANIMAL SPECIES MELKVEE DAIRY CATTLE
2006 2007
NUMBER OF FARMS 35 35
TOTAL daily dosages per animal year 5.5 5.4
mam. oral other mam. oral other
group sum 3.48 0.08 1.86 2.86 0.42 2.1
Cephalosporines Cefquinome 0.18 0 0.03 0.27 0 0.02
Ceftiofur 0 0 0.45 0 0 0.55
Cefapirin 0 0 0.02 0 0 0.0
Cefoperazone 0.03 0 0 0.07 0 0
Cefalexin 0.14 0 0 0.05 0
0.35 0 0.5 0.39 0 0.6
Penicillin Benzylpenicillin 0 0 0.36 0 0 0.3
Ampicillin 0 0 0.03 0 0 0.09
Amoxicillin 0 0 0 0 0 0
Cloxacillin 1.15 0 0 0.34 0 0
Fenoxymethylpenicillin 0 0 0 0 0 0
1.15 0 0.39 0.34 0 0.39
Macrolides Erythromycin 0 0 0 0 0 0
Tylosin 0 0 0.13 0 0 0.1
Tilmicosin 0 0 0 0 0 0
Tulathromycin 0 0 0.01 0 0 0.03
0 0 0.14 0 0 0.19
Quinolones Danofloxacin 0 0 0 0 0 0
Enrofloxacin 0 0 0.04 0 0 0.06
Flumequine 0 0 0 0 0 0
Difloxacin 0 0 0 0 0 0
Marbofloxacin 0 0 0 0 0 0
0 0 0.04 0 0 0.06
Sulfanomides and trimethoprim Trimethoprim-sulfachloorpyridazin 0 0 0 0 0 0
Trimethoprim-sulfadiazin 0 0.02 0.06 0 0.01 0.06
Trimethoprim-sulfadoxin 0 0 0.1 0 0 0.11
Trimethoprim-sulfamethoxazole 0 0 0 0 0 0
Sulfadimidine 0 0 0 0 0 0
Sulfaclozine Na 0 0 0 0 0 0
Sulfaquinoxalin 0 0 0 0 0 0
0 0.02 0.16 0 0.01 0.17
Tetracyclines Tetracycline 0 0 0.02 0 0 0.01
Chloortetracycline 0 0 0 0 0 0
Doxycycline 0 0.03 0 0 0.33 0
Oxytetracycline 0 0 0.4 0 0.01 0.45
0 0.03 0.42 0 0.34 0.46
Aminoglycocides Gentamicin 0 0 0.01 0 0 0.01
Neomycin 0 0 0 0 0 0
0 0 0.01 0 0 0.01
Combinations Amoxicillin-clavulanic acid 0.76 0 0 1.11 0 0
Amoxicillin-colistin 0 0 0 0 0 0
Ampicillin-colistin 0 0 0 0 0 0
Ampicillin-cloxacillin 0.25 0 0 0.2 0 0
Dihydrostreptomycin-benzylpenicillin 0 0 0.06 0 0 0.07
Dihydrostreptomycin-benzylpenicillin-nafcilline 0.53 0 0 0.44 0 0.01
Lincomycin-neomycin 0.14 0 0 0.16 0 0
Lincomycin-spectinomycin 0 0 0 0 0.02 0
Neomycin-benzylpenicillin 0.3 0 0.13 0.22 0 0.14
Dihydrostreptomycin 0 0 0 0 0 0
1.98 0 0.19 2.13 0.02 0.2
Others Florfenicol 0 0 0.01 0 0 0.03
Lincomycin 0 0 0 0 0.02 0
Colistin 0 0.03 0 0 0.03 0
Tiamulin 0 0 0 0 0 0
Pirlimycin 0 0 0 0 0 0
0 0.03 0.01 0 0.05 0.03
3
3
0
6
2
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Annex 1b Average number of daily dosages fattening pigs per animal year 
 
 
 
ANIMAL SPECIES VLEESVARKENS FATTENING PIGS
2006 2007
NUMBER OF FARMS 31 31
TOTAL daily dosages per animal year 15.0 17.0
mam. oral other mam. oral other
group sum 0 14.33 0.65 0 15.92 1.01
Cephalosporines Cefquinome 0 0 0 0 0 0
Ceftiofur 0 0 0.02 0 0 0
Cefapirin 0 0 0 0 0 0
Cefoperazone 0 0 0 0 0 0
Cefalexin 0 0 0 0 0 0
0 0 0.02 0 0 0
Penicillin Benzylpenicillin 0 0 0.21 0 0 0.27
Ampicillin 0 0 0.08 0 0 0.11
Amoxicillin 0 0.03 0 0 0.02 0
Cloxacillin 0 0 0 0 0 0
Fenoxymethylpenicillin 0 0 0 0 0 0
0 0.03 0.29 0 0.02 0.38
Macrolides Erythromycin 0 0 0 0 0 0
Tylosin 0 1.23 0.04 0 2.02 0.09
Tilmicosin 0 0 0 0 0.13 0
Tulathromycin 0 0 0 0 0 0.02
0 1.23 0.04 0 2.15 0.11
Quinolones Danofloxacin 0 0 0 0 0 0
Enrofloxacin 0 0 0.01 0 0 0.01
Flumequine 0 0 0 0 0 0
Difloxacin 0 0 0 0 0 0
Marbofloxacin 0 0 0 0 0 0
0 0 0.01 0 0 0.01
Sulfanomides and trimethoprim Trimethoprim-sulfachloorpyridazin 0 0 0 0 0 0
Trimethoprim-sulfadiazin 0 1.2 0 0 0.78 0
Trimethoprim-sulfadoxin 0 0 0 0 0 0
Trimethoprim-sulfamethoxazole 0 0.43 0 0 0.28 0
Sulfadimidine 0 0 0 0 0 0
Sulfaclozine Na 0 0 0 0 0 0
Sulfaquinoxalin 0 0 0 0 0 0
0 1.63 0 0 1.06
Tetracyclines Tetracycline 0 0 0 0 0 0
Chloortetracycline 0 0 0 0 0 0
Doxycycline 0 2 0 0 3.37 0
Oxytetracycline 0 8.97 0.24 0 6.12 0.39
0 10.97 0.24 0 9.49 0.39
Aminoglycocides Gentamicin 0 0 0 0 0 0
Neomycin 0 0 0 0 0 0
0 0 0 0 0 0
Combinations Amoxicillin-clavulanic acid 0 0 0 0 0 0
Amoxicillin-colistin 0 0.29 0.02 0 0.06 0.03
Ampicillin-colistin 0 0 0 0 0 0
Ampicillin-cloxacillin 0 0 0 0 0 0
Dihydrostreptomycin-benzylpenicillin 0 0 0.02 0 0 0.06
Dihydrostreptomycin-benzylpenicillin-nafcilline 0 0 0 0 0 0
Lincomycin-neomycin 0 0 0 0 0 0
Lincomycin-spectinomycin 0 0.12 0 0 0.17 0
Neomycin-benzylpenicillin 0 0 0 0 0 0.01
Dihydrostreptomycin 0 0 0 0 0 0
0 0.41 0.04 0 0.23 0
Others Florfenicol 0 0 0.01 0 0 0.01
Lincomycin 0 0 0 0 0 0
Colistin 0 0.05 0 0 2.81 0
Tiamulin 0 0.01 0 0 0.16 0.01
Pirlimycin 0 0 0 0 0 0
0 0.06 0.01 0 2.97 0.02
0
.1
MARAN-2007 
 
 
 
 96 
Annex 1c Average number of daily dosages in sows/piglets per animal year 
 
ANIMAL SPECIES ZEUGEN /BIGGEN SOWS /PIGLETS
2006 2007
NUMBER OF FARMS 30 30
TOTAL daily dosages per animal year 26.5 22.4
mam. oral other mam. oral other
group sum 0 22.53 3.93 0 18.41 3.99
Cephalosporines Cefquinome 0 0 0.02 0 0 0.04
Ceftiofur 0 0 0.11 0 0 0.11
Cefapirin 0 0 0 0 0 0
Cefoperazone 0 0 0 0 0 0
Cefalexin 0 0 0 0 0 0
0 0 0.13 0 0 0.15
Penicillin Benzylpenicillin 0 0 0.83 0 0 0.82
Ampicillin 0 0.29 0.39 0 0.21 0.62
Amoxicillin 0 4.32 0.07 0 3.6 0.04
Cloxacillin 0 0 0 0 0 0
Fenoxymethylpenicillin 0 0 0 0 0 0
0 4.61 1.29 0 3.81 1.48
Macrolides Erythromycin 0 0 0 0 0 0
Tylosin 0 0.69 0.01 0 0.23 0.01
Tilmicosin 0 0.75 0 0 0.55 0
Tulathromycin 0 0 1.15 0 0 0.84
0 1.44 1.16 0 0.78 0.85
Quinolones Danofloxacin 0 0 0 0 0 0
Enrofloxacin 0 0 0.03 0 0 0.02
Flumequine 0 0 0 0 0 0
Difloxacin 0 0 0 0 0 0
Marbofloxacin 0 0 0.01 0 0 0.02
0 0 0.04 0 0 0.04
Sulfanomides and trimethoprim Trimethoprim-sulfachloorpyridazin 0 0 0 0 0 0
Trimethoprim-sulfadiazin 0 4.78 0.22 0 4.88 0.23
Trimethoprim-sulfadoxin 0 0 0.12 0 0 0.12
Trimethoprim-sulfamethoxazole 0 1.49 0.01 0 0.8 0
Sulfadimidine 0 0 0 0 0 0
Sulfaclozine Na 0 0 0 0 0 0
Sulfaquinoxalin 0 0 0 0 0 0
0 6.27 0.35 0 5.68 0.35
Tetracyclines Tetracycline 0 0 0 0 0 0
Chloortetracycline 0 0 0 0 0 0
Doxycycline 0 3.29 0 0 1.05 0
Oxytetracycline 0 5.35 0.25 0 4.93 0.22
0 8.64 0.25 0 5.98 0.22
Aminoglycocides Gentamicin 0 0.06 0.01 0 0.02 0
Neomycin 0 0 0 0 0 0
0 0.06 0.01 0 0.02
Combinations Amoxicillin-clavulanic acid 0 0 0 0 0 0
Amoxicillin-colistin 0 0.02 0.13 0 0.02 0.13
Ampicillin-colistin 0 0 0 0 0 0
Ampicillin-cloxacillin 0 0 0 0 0 0
Dihydrostreptomycin-benzylpenicillin 0 0 0.55 0 0 0.62
Dihydrostreptomycin-benzylpenicillin-nafcilline 0 0 0 0 0 0
Lincomycin-neomycin 0 0 0 0 0 0
Lincomycin-spectinomycin 0 0.09 0 0 0.17 0.02
Neomycin-benzylpenicillin 0 0 0.01 0 0 0.11
Dihydrostreptomycin 0 0 0 0 0 0
0 0.11 0.69 0 0.19 0.88
Others Florfenicol 0 0 0.01 0 0 0.02
Lincomycin 0 0 0 0 0.19 0
Colistin 0 1.26 0 0 1.64 0
Tiamulin 0 0.14 0 0 0.12 0
Pirlimycin 0 0 0 0 0 0
0 1.4 0.01 0 1.95 0.02
0
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Annex 1d Average number of daily dosages in broilers per animal year 
 
 
ANIMAL SPECIES VLEESKUIKENS BROILERS
2006 2007
NUMBER OF FARMS 27 27
TOTAL daily dosages per animal year 25.4 30.2
mam. oral other mam. oral other
group sum 0 25.42 0 0 30.2 0
Cephalosporines Cefquinome 0 0 0 0 0 0
Ceftiofur 0 0 0 0 0 0
Cefapirin 0 0 0 0 0 0
Cefoperazone 0 0 0 0 0 0
Cefalexin 0 0 0 0 0 0
0 0 0 0 0 0
Penicillin Benzylpenicillin 0 0 0 0 0 0
Ampicillin 0 0.25 0 0 0.38 0
Amoxicillin 0 3.42 0 0 6.74 0
Cloxacillin 0 0 0 0 0 0
Fenoxymethylpenicillin 0 0.94 0 0 1.36 0
0 4.61 0 0 8.48
Macrolides Erythromycin 0 0 0 0 0 0
Tylosin 0 1.01 0 0 1.52 0
Tilmicosin 0 0 0 0 0 0
Tulathromycin 0 0 0 0 0 0
0 1.01 0 0 1.52
Quinolones Danofloxacin 0 0 0 0 0 0
Enrofloxacin 0 0.17 0 0 0.48 0
Flumequine 0 8.81 0 0 6.71 0
Difloxacin 0 0 0 0 0 0
Marbofloxacin 0 0 0 0 0 0
0 8.98 0 0 7.19
Sulfanomides and trimethoprim Trimethoprim-sulfachloorpyridazin 0 1.95 0 0 1.55 0
Trimethoprim-sulfadiazin 0 0 0 0 0 0
Trimethoprim-sulfadoxin 0 0 0 0 0 0
Trimethoprim-sulfamethoxazole 0 1.37 0 0 1.32 0
Sulfadimidine 0 0.41 0 0 0.39 0
Sulfaclozine Na 0 0 0 0 0 0
Sulfaquinoxalin 0 0.15 0 0 0 0
0 3.88 0 0 3.26
Tetracyclines Tetracycline 0 0 0 0 0 0
Chloortetracycline 0 0 0 0 0 0
Doxycycline 0 1.91 0 0 3.88 0
Oxytetracycline 0 1.52 0 0 0.91 0
0 3.43 0 0 4.79
Aminoglycocides Gentamicin 0 0 0 0 0 0
Neomycin 0 3.19 0 0 4.67 0
0 3.19 0 0 4.67
Combinations Amoxicillin-clavulanic acid 0 0 0 0 0 0
Amoxicillin-colistin 0 0 0 0 0 0
Ampicillin-colistin 0 0 0 0 0 0
Ampicillin-cloxacillin 0 0 0 0 0 0
Dihydrostreptomycin-benzylpenicillin 0 0 0 0 0 0
Dihydrostreptomycin-benzylpenicillin-nafcilline 0 0 0 0 0 0
Lincomycin-neomycin 0 0 0 0 0 0
Lincomycin-spectinomycin 0 0.32 0 0 0.14 0
Neomycin-benzylpenicillin 0 0 0 0 0 0
Dihydrostreptomycin 0 0 0 0 0 0
0 0.32 0 0 0.14
Others Florfenicol 0 0 0 0 0 0
Lincomycin 0 0 0 0 0 0
Colistin 0 0 0 0 0.15 0
Tiamulin 0 0 0 0 0 0
Pirlimycin 0 0 0 0 0 0
0 0 0 0 0.15
0
0
0
0
0
0
0
0  
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Annex 2a Average number of grams active ingredient in dairy cows per animal year 
 
 
ANIMAL SPECIES DAIRY CATTLE
2006 2007
NUMBER OF FARMS 35 35
TOTAL daily dosages per animal year 57.8 54.9
mam. oral other mam. oral other
group sum 1.62 48.06 8.14 1.66 43.38 9.88
Cephalosporines Cefquinome 0.01 0 0.03 0.02 0 0.02
Ceftiofur 0 0 0.27 0 0 0.33
Cefapirin 0 0 0.01 0 0 0.0
Cefoperazone 0.01 0 0 0.02 0 0
Cefalexin 0.03 0 0 0.01 0 0
0.05 0 0.31 0.05 0 0.37
Penicillin Benzylpenicillin 0 0 2.1 0 0 1.71
Ampicillin 0 0 0.25 0 0 1.04
Amoxicillin 0 2.93 0.05 0 4.16 0.02
Cloxacillin 0.64 0 0 0.76 0 0
Fenoxymethylpenicillin 0 0 0 0 0 0
0.64 2.93 2.4 0.76 4.16 2.77
Macrolides Erythromycin 0 0 0.01 0 0 0
Tylosin 0 3.52 0.62 0 3.9 0.69
Tilmicosin 0 0 0.01 0 2.16 0.01
Tulathromycin 0 0 0.01 0 0 0.01
0 3.52 0.65 0 6.06 0.71
Quinolones Danofloxacin 0 0 0 0 0 0
Enrofloxacin 0 0 0.09 0 -0.04 0.14
Flumequine 0 0.54 0 0 2.79 0
Difloxacin 0 0 0 0 0 0
Marbofloxacin 0 0 0 0 0 0
0 0.54 0.09 0 2.75 0.14
Sulfanomides and trimethoprim Trimethoprim-sulfachloorpyridazin 0 0 0 0 0 0
Trimethoprim-sulfadiazin 0 7.55 0.78 0 2.55 0.8
Trimethoprim-sulfadoxin 0 0 1.06 0 0 1.06
Trimethoprim-sulfamethoxazole 0 8.73 0 0 5.57 0
Sulfadimidine 0 0 0 0 0 0
Sulfaclozine Na 0 0 0 0 0 0
Sulfaquinoxalin 0 2.42 0 0 0 0
0 18.7 1.84 0 8.12 1.86
Tetracyclines Tetracycline 0 0 0.03 0 0 0.02
Chloortetracycline 0 0 0 0 0 0
Doxycycline 0 3.89 0 0 14.31 0
Oxytetracycline 0 17.33 1.06 0 7.63 2.2
0 21.22 1.09 0 21.94 2.22
Aminoglycocides Gentamicin 0 0 0.02 0 0 0.02
Neomycin 0 0.72 0 0 0 0
0 0.72 0.02 0 0 0.0
Combinations Amoxicillin-clavulanic acid 0.19 0.01 0 0.28 0 0
Amoxicillin-colistin 0 0 0.02 0 0 0.07
Ampicillin-colistin 0.07 0 0 0.05 0 0
Ampicillin-cloxacillin 0 0 0 0 0 0
Dihydrostreptomycin-benzylpenicillin 0 0 0.52 0 0 0.58
Dihydrostreptomycin-benzylpenicillin-nafcilline 0.2 0 0.04 0.16 0 0.04
Lincomycin-neomycin 0.06 0 0 0.07 0 0
Lincomycin-spectinomycin 0 0.11 0.02 0 0.12 0.01
Neomycin-benzylpenicillin 0.41 0 0.96 0.29 0 0.9
Dihydrostreptomycin 0 0 0 0 0 0
0.93 0.12 1.56 0.85 0.12 1.6
Others Florfenicol 0 0 0.18 0 0 0.19
Lincomycin 0 0 0 0 0.04 0
Colistin 0 0.31 0 0 0.19 0
Tiamulin 0 0 0 0 0 0
Pirlimycin 0 0 0 0 0 0
0 0.31 0.18 0 0.23 0.19
2
2
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Annex 2b Average number of grams active ingredient in fattening pigs per animal year 
 
 
ANIMAL SPECIES FATTENING PIGS
2006 2007
NUMBER OF FARMS 31 31
TOTAL daily dosages per animal year 42.1 59.2
mam. oral other mam. oral other
group sum 0.00 41.30 0.79 0.00 57.98 1.17
Cephalosporines Cefquinome 0 0 0 0 0 0
Ceftiofur 0 0 0.01 0 0 0
Cefapirin 0 0 0 0 0 0
Cefoperazone 0 0 0 0 0 0
Cefalexin 0 0 0 0 0 0
0 0 0.01 0 0 0
Penicillin Benzylpenicillin 0 0 0.14 0 0 0.18
Ampicillin 0 1.47 0.15 0 0.06 0.16
Amoxicillin 0 1.26 0.03 0 2.28 0.02
Cloxacillin 0 0 0 0 0 0.02
Fenoxymethylpenicillin 0 2.5 0 0 7.57 0
0 5.23 0.32 0 9.91 0.38
Macrolides Erythromycin 0 0 0 0 0 0
Tylosin 0 5.24 0.02 0 10.25 0.07
Tilmicosin 0 0.19 0 0 0.13 0
Tulathromycin 0 0 0 0 0 0
0 5.43 0.02 0 10.38 0.07
Quinolones Danofloxacin 0 0 0 0 0 0
Enrofloxacin 0 0.35 0 0 0.53 0.
Flumequine 0 0.09 0 0 0.39 0
Difloxacin 0 0 0 0 0 0
Marbofloxacin 0 0 0 0 0 0
0 0.44 0 0 0.92 0.
Sulfanomides and trimethoprim Trimethoprim-sulfachloorpyridazin 0 0 0 0 0 0
Trimethoprim-sulfadiazin 0 2.76 0.07 0 2.08 0.06
Trimethoprim-sulfadoxin 0 0 0.01 0 0 0.01
Trimethoprim-sulfamethoxazole 0 1.11 0 0 0.73 0
Sulfadimidine 0 0 0 0 0 0
Sulfaclozine Na 0 0.21 0 0 0 0
Sulfaquinoxalin 0 0 0 0 4.14 0
0 4.08 0.08 0 6.95 0.07
Tetracyclines Tetracycline 0 0 0 0 0 0
Chloortetracycline 0 0 0 0 0 0
Doxycycline 0 5.7 0 0 12.3 0
Oxytetracycline 0 19.49 0.15 0 15.87 0.23
0 25.19 0.15 0 28.17 0.23
Aminoglycocides Gentamicin 0 0 0 0 0 0.09
Neomycin 0 0.21 0 0 0.35
0 0.21 0 0 0.35 0.
Combinations Amoxicillin-clavulanic acid 0 0 0.01 0 0 0
Amoxicillin-colistin 0 0.47 0.03 0 0.1 0.03
Ampicillin-colistin 0 0 0 0 0 0
Ampicillin-cloxacillin 0 0 0 0 0 0
Dihydrostreptomycin-benzylpenicillin 0 0 0.15 0 0 0.21
Dihydrostreptomycin-benzylpenicillin-nafcilline 0 0 0 0 0 0.01
Lincomycin-neomycin 0 0 0 0 0 0
Lincomycin-spectinomycin 0 0.02 0 0 0.06 0
Neomycin-benzylpenicillin 0 0 0.01 0 0 0.01
Dihydrostreptomycin 0 0 0 0 0 0
0 0.49 0.2 0 0.16 0.
Others Florfenicol 0 0 0.01 0 0 0.03
Lincomycin 0 0 0 0 0 0
Colistin 0 0.23 0 0 1.08
Tiamulin 0 0 0 0 0.06 0.01
Pirlimycin 0 0 0 0 0 0
0 0.23 0.01 0 1.14 0.04
03
03
0
09
26
0
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Annex 2c Average number of grams active ingredient in sows/piglets per animal year 
 
 
ANIMAL SPECIES SOWS /PIGLETS
2006 2007
NUMBER OF FARMS 30 30
TOTAL daily dosages per animal year 140.7 142.8
mam. oral other mam. oral other
group sum 0.00 129.47 10.57 0.00 131.31 11.10
Cephalosporines Cefquinome 0 0 0.01 0 0 0.02
Ceftiofur 0 0 0.16 0 0 0.15
Cefapirin 0 0 0 0 0 0
Cefoperazone 0 0 0 0 0 0
Cefalexin 0 0 0 0 0 0
0 0 0.17 0 0 0
Penicillin Benzylpenicillin 0 0 1.74 0 0 1.9
Ampicillin 0 2.04 1.96 0 1.54 2.03
Amoxicillin 0 17.71 0.53 0 14.95 0.4
Cloxacillin 0 0 0 0 0 0
Fenoxymethylpenicillin 0 0 0 0 0 0
0 19.75 4.23 0 16.49 4.33
Macrolides Erythromycin 0 0 0 0 0 0
Tylosin 0 5.39 0.02 0 5.16 0.03
Tilmicosin 0 2.81 0 0 2.24 0
Tulathromycin 0 0 0.17 0 0 0.13
0 8.2 0.19 0 7.4 0.
Quinolones Danofloxacin 0 0 0 0 0 0
Enrofloxacin 0 0 0.03 0 0 0.02
Flumequine 0 0 0 0 0 0
Difloxacin 0 0 0 0 0 0
Marbofloxacin 0 0 0 0 0 0
0 0 0.03 0 0 0
Sulfanomides and trimethoprim Trimethoprim-sulfachloorpyridazin 0 0 0 0 0 0
Trimethoprim-sulfadiazin 0 33.32 1.36 0 37.71 1.15
Trimethoprim-sulfadoxin 0 0 0.65 0 0 0.68
Trimethoprim-sulfamethoxazole 0 10.47 0.1 0 6.51 0.04
Sulfadimidine 0 0 0 0 0 0
Sulfaclozine Na 0 0 0 0 0 0
Sulfaquinoxalin 0 0 0 0 0 0
0 43.79 2.11 0 44.22 1.87
Tetracyclines Tetracycline 0 0 0 0 0 0
Chloortetracycline 0 0 0 0 0 0
Doxycycline 0 13.66 0 0 8.68 0
Oxytetracycline 0 41.72 0.73 0 50.97 0.66
0 55.38 0.73 0 59.65 0.66
Aminoglycocides Gentamicin 0 0.02 0.01 0 0.01 0
Neomycin 0 0 0 0 0 0
0 0.02 0.01 0 0.01
Combinations Amoxicillin-clavulanic acid 0 0 0 0 0 0
Amoxicillin-colistin 0 0.11 0.44 0 0.15 0.44
Ampicillin-colistin 0 0 0 0 0 0
Ampicillin-cloxacillin 0 0 0 0 0 0
Dihydrostreptomycin-benzylpenicillin 0 0 2.53 0 0 2.87
Dihydrostreptomycin-benzylpenicillin-nafcilline 0 0 0 0 0 0
Lincomycin-neomycin 0 0 0 0 0 0
Lincomycin-spectinomycin 0 0.15 0.02 0 0.24 0.08
Neomycin-benzylpenicillin 0 0 0.04 0 0 0.37
Dihydrostreptomycin 0 0 0 0 0 0
0 0.26 3.03 0 0.39 3.76
Others Florfenicol 0 0 0.07 0 0 0.11
Lincomycin 0 0.01 0 0 0.43 0
Colistin 0 1.98 0 0 2.63 0
Tiamulin 0 0.08 0 0 0.09
Pirlimycin 0 0 0 0 0 0
0 2.07 0.07 0 3.15 0.11
.17
16
.02
.04
0
0
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Annex 2d Average number of grams active ingredient broilers per animal year 
 
 
ANIMAL SPECIES BROILERS
2006 2007
NUMBER OF FARMS 27 27
TOTAL daily dosages per animal year 0.6 0.7
mam. oral other mam. oral other
group sum 0.00 0.64 0.00 0.00 0.69 0.
Cephalosporines Cefquinome 0 0 0 0 0 0
Ceftiofur 0 0 0 0 0 0
Cefapirin 0 0 0 0 0 0
Cefoperazone 0 0 0 0 0 0
Cefalexin 0 0 0 0 0 0
0 0 0 0 0 0
Penicillin Benzylpenicillin 0 0 0 0 0 0
Ampicillin 0 0.01 0 0 0.02 0
Amoxicillin 0 0.06 0 0 0.13 0
Cloxacillin 0 0 0 0 0 0
Fenoxymethylpenicillin 0 0.02 0 0 0.02 0
0 0.09 0 0 0.17
Macrolides Erythromycin 0 0 0 0 0 0
Tylosin 0 0.07 0 0 0.11 0
Tilmicosin 0 0 0 0 0 0
Tulathromycin 0 0 0 0 0 0
0 0.07 0 0 0.11
Quinolones Danofloxacin 0 0 0 0 0 0
Enrofloxacin 0 0 0 0 0 0
Flumequine 0 0.09 0 0 0.07 0
Difloxacin 0 0 0 0 0 0
Marbofloxacin 0 0 0 0 0 0
0 0.09 0 0 0.07
Sulfanomides and trimethoprim Trimethoprim-sulfachloorpyridazin 0 0.07 0 0 0.05 0
Trimethoprim-sulfadiazin 0 0 0 0 0 0
Trimethoprim-sulfadoxin 0 0 0 0 0 0
Trimethoprim-sulfamethoxazole 0 0.05 0 0 0.05 0
Sulfadimidine 0 0.08 0 0 0.05 0
Sulfaclozine Na 0 0 0 0 0 0
Sulfaquinoxalin 0 0.01 0 0 0 0
0 0.21 0 0 0.15
Tetracyclines Tetracycline 0 0 0 0 0 0
Chloortetracycline 0 0 0 0 0 0
Doxycycline 0 0.04 0 0 0.08 0
Oxytetracycline 0 0.1 0 0 0.07 0
0 0.14 0 0 0.15
Aminoglycocides Gentamicin 0 0 0 0 0 0
Neomycin 0 0.02 0 0 0.03
0 0.02 0 0 0.03
Combinations Amoxicillin-clavulanic acid 0 0 0 0 0 0
Amoxicillin-colistin 0 0 0 0 0 0
Ampicillin-colistin 0 0 0 0 0 0
Ampicillin-cloxacillin 0 0 0 0 0 0
Dihydrostreptomycin-benzylpenicillin 0 0 0 0 0 0
Dihydrostreptomycin-benzylpenicillin-nafcilline 0 0 0 0 0 0
Lincomycin-neomycin 0 0 0 0 0 0
Lincomycin-spectinomycin 0 0.02 0 0 0.01 0
Neomycin-benzylpenicillin 0 0 0 0 0 0
Dihydrostreptomycin 0 0 0 0 0 0
0 0.02 0 0 0.01
Others Florfenicol 0 0 0 0 0 0
Lincomycin 0 0 0 0 0 0
Colistin 0 0 0 0 0 0
Tiamulin 0 0 0 0 0 0
Pirlimycin 0 0 0 0 0 0
0 0 0 0 0 0
00
0
0
0
0
0
0
0
0
 
MARAN-2007 
 
 
 
 102 
Annex 3 Number of farms and number of animals in the sample 
 
 
Table B3.1 lists the number of farms taking part each year and the associated number of animals. 
 
 
 
Type of holding 2004 2005 2006 2007 
Dairy cattle 3,919 2,962 3,099 3,025 
Sows/piglets1) 17,618 16,790 13,642 19,862 
Fattening pigs 63,740 58,622 61,503 128,807 No. of animals 
Broilers2) 870 1,962 2,047 1,931 
Dairy cattle 45 36 37 36 
Sows/piglets 49 46 34 42 
Fattening pigs 39 42 33 52 
Number 
of farms 
Broilers 15 29 29 29 
1) These are all farms with sows and piglets, both specialised sow farms and closed pig farms. The 
sows and piglets on the closed farms are analysed with the sows/piglets and the fattening pigs on these 
farms with the fattening pigs. The specified numbers of animals are sows. 
2) x 1,000 
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Annex 4 Notes to the method used to calculate the mg antibiotic use / kg body weight 
 
Last year, a slightly different method was used for this calculation, and consequently the absolute 
figures cannot be compared with each other. See the following figure. 
Last year the numbers of animals were obtained from LEI /CBS, agricultural and horticultural figures. 
This information has now been sourced from Eurostat to provide for comparisons between countries. 
Cattle (exclusive of calves) and sheep have now been included in the calculations for the purposes of a 
realistic comparison with countries with relatively large numbers of cattle and sheep. 
 
Figure, Annex 4 the differences in the results calculated using method 2006 and method 2007 
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Both curves in the above figure show an increase. The red curve is considerably higher the 
calculations were based on the administration of the same quantity of antibiotics to a much smaller 
number of livestock with a lower kg body weight (i.e. exclusive of cattle and sheep). 
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